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Polysialic acid (polySia) is a carbohydrate polymer highly expressed during 
embryonic development but rarely expressed during postnatal development. 
Two polysialyltransferase (polyST) enzymes are responsible for the 
synthesis of polySia: ST8SiaII and ST8SiaIV. During oncogenesis polySia is 
re-expressed and it modulates cell-cell and cell-matrix adhesion, migration, 
invasion and metastasis. PolySia expression is strongly associated with poor 
clinical prognosis and correlates with aggressive and invasive disease in 
neuroblastoma and many other tumours. PolyST inhibition thus presents a 
novel, selective and largely unexplored therapeutic opportunity to reduce 
tumour dissemination. 
Progress towards development of polyST inhibitors has been limited by lack 
of an efficient technique for quantitative assessment of enzyme activity. We 
have validated a highly sensitive cell-based and cell-free high throughput 
HPLC-based inhibition assays. Using isogenic cell lines (C6-STX: 
polySia+/ST8SiaII+ and C6-WT: polySia-/ST8SiaII-) and naturally polySia 
expressing human neuroblastoma cells (SH-SY5Y), a set of ST8SiaII 
inhibitors designed and synthesised in house were evaluated for their ability 
to reduce polySia expression and to modulate cell migration in vitro. We 
have identified CMP-sialic acid precursors, including ICT-3176, which 
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reduced polySia expression and tumour cell migration by up to 70%. These 
effects were only found in cell lines expressing ST8SiaII and polySia.  
Furthermore, we have investigated the possible additive anti-migratory effect 
of combining polyST inhibition with the inhibition of certain signalling 
pathways that have been previously suggested to be modulated by polySia 
expression. Out of these combinations it was found that combining ST8SiaII 
and C-MET/ALK inhibition had a synergistic effect on inhibiting cancer cell 
migration. Additionally, the effect of polySia expression on cancer cell 
behaviour under hypoxic conditions was examined, where it was found that 
polySia expression enhanced cell migration and survival and inhibits cell 
adhesion.  
In summary, polyST inhibitors which dramatically decrease cell migration in 
vitro through modulation of polySia assembly were identified, using optimised 
cell-free and cell-based assays. Initial investigations into the role of polySia 
in hypoxia were also accomplished. This work paves the way for 
development of a novel therapeutic for the treatment of neuroblastoma. 
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1.1. Cancer 
 
Due to its widespread occurrence and high mortality rates, cancer has 
become a disease of huge concern and fear among the public. Despite the 
significant improvement in cancer diagnostic and treatment options, the 
mortality rate for all cancers combined is still high (Figure 1.1)1-4. Cancer 
represents a condition in which out of control cell growth occurs. This 
situation is caused by both external factors (radiation, tobacco smoking and 
chemicals) and/or internal factors (impaired immunity or inherited mutations). 
In general, cancers arise from the accumulation of genetic and epigenetic 
changes and abnormalities in cancer-associated signalling pathways, 
causing the acquisition of cancer-related phenotypes to create what is called 
‘’tumour microenvironment’’ which promotes tumour carcinogenesis 5. 
 
 
Figure 1.1 World-wide cancer statistics (A) and cancer statistics of the UK (B) (Source: CRUK).  
Six hallmarks of cancer have been identified as essential for carcinogenesis 
6. During the multistep process of human tumour pathogenesis, cells should 
acquire these hallmark capabilities to be able to grow, proliferate, invade 
other tissues and evade immune destruction. Sustaining growth signalling 
could be considered as the most fundamental trait of cancer cells, which 
(A) 
(B) 
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enables them to sustain a chronic proliferation even when they are not 
receiving messages to grow 6. To achieve that, cancer cells either produce 
growth factor ligands themselves to which they can respond, or send 
stimulatory signals to normal cells within the supporting tumour-associated 
stroma to stimulate these cells to supply cancer cells with various growth 
factors. Evasion of apoptosis is another hallmark of cancer: in normal cells, 
apoptosis is triggered in response to different physiological stresses in order 
to maintain tissue homeostasis. However, apoptosis is attenuated in tumours 
via different strategies most commonly by the loss of tumour protein p53 
(TP53) tumour suppressor function or by increasing the expression of anti-
apoptotic regulators. In order to address the need for nutrients and oxygen 
supply and evacuation of metabolic waste and carbon dioxide, cancer cells 
generate a tumour-associated neovasculature in a process known as 
angiogenesis, i.e. the ability to grow new blood vessels 6,7. During tumour 
progression, an “angiogenic switch” is relatively permanently activated in 
order to maintain the formation of new blood vessels to supply tumour cells 
with their needs 8. Unlimited replicative potential is acquired by the cancer 
cells in order to generate macroscopic tumours, which means that, in 
contrast to normal cells, tumour cells keep replicating no matter how many 
times they have already done so, which is linked to the ability of tumour cells 
to maintain telomeric DNA at lengths sufficient to avoid triggering 
senescence or apoptosis. Finally, for a tumour cell to be malignant it should 
acquire the ability to metastasise and invade surrounding tissues. Metastatic 
dissemination is the last step in tumour progression, and is considered as the 
main difference between the benign and malignant tumours (Figure 1.2) 6. 
Besides these six established hallmarks, two emerging hallmarks of cancer 
has also been reported which are: reprogramming of cellular energy 
metabolism in order to support continuous cell growth and proliferation, 
replacing oxidative phosphorylation which is the metabolic program that 
operates in most normal tissues. And second involves active evasion of 
immune system attacks 6. 
4 
 
The acquisition of different cancer hallmarks is made possible by two 
enabling characteristics: the development of genomic instability in cancer 
cells, which generates random genetic changes that control hallmark 
capabilities. And second modulation of the inflammatory state of 
premalignant lesions that is driven by cells of the immune system, some of 
which serve to promote tumour progression through various means 6.  
 
Figure 1.2 The ‘Hallmarks of Cancer’ as proposed by Hanahan and Weinberg. An illustration of 
the six hallmarks acquired by the cancer cells during tumour pathogenesis 
6
.  
Although many studies have been performed in this field, the current success 
of cancer prevention, diagnosis and treatment is relatively low 2. The events 
leading to cancer are not fully understood and as such, there is an enormous 
need for further studies and for novel ideas and theories to improve cancer 
treatment and diagnostic options. 
1.2. Metastasis   
 
Cancer is specifically characterised by the ability of tumour cells to 
metastasise from the primary tumour to other organs 9. Metastasis resistant 
to therapy is the major cause of mortality from cancer 10. It could be 
considered as one of the greatest challenges to the oncologist, due to its 
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unpredictable onset and its great impact on the prognosis of the disease; one 
localised tumour can often be easily removed by surgery, but for hundreds of 
metastases this is impossible. The majority of cancer cases may have no or 
few symptoms related to their metastasis and consequently, many patients 
show metastasis by the time of diagnosis and metastasis prevention may not 
be relevant. However, the development of anti-metastatic drugs could help in 
stopping further metastases in patients who are diagnosed in early stages, 
minimise invasion locally within the affected organ, reduce the transfer to 
further metastatic phenotype in addition to simply being used as prophylactic 
treatment for cancer patients at high risk for development of metastasis 9.  
Furthermore, in recent studies metastasis-to-metastasis spread was found to 
be common; metastasis can occur in the form of spread between distant 
sites, rather than simply as separate waves of invasion directly from the 
primary tumour. This mechanism occurs either through de novo monoclonal 
seeding of daughter metastases or through the transfer of multiple tumour 
clones between metastatic sites 11. In a study by Matthew K. et al., it was 
found that, in prostate cancer patients, a distant bone metastasis caused a 
local recurrence. It was observed that cross-metastatic site seeding is 
combined with dynamic remoulding of subclonal mixtures in response to 
therapy causing subsequent emergence of therapy-resistant disease 12. The 
development of potent anti-metastatic drugs would thus help to prevent 
cross-metastasis and consequently improve the prognosis of the disease. 
The most common sites of cancer metastasis are the lungs, bones and liver. 
However, most cancers have the ability to spread to many other parts of the 
body. Cancerous cells invade important organs and cause mortality by 
different mechanisms. Physical obstruction and malfunction of vital organs 
are some of the most common causes of mortality by cancer metastasis due 
to the serious problems they might cause, such as respiratory failure, hepatic 
failure and cardiovascular insufficiency 13. Other impairments that could be 
induced by the spread of tumour cells throughout the body are the 
competition between cancer and normal cells for nutrients and oxygen as 
well as secondary infection due to immunodeficiency 14.    
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The preference of cancer cells to spread to certain metastatic locations is 
justified in different ways such as the ‘’seed and soil‘’ hypothesis by Stephen 
Paget in 1889, which proposed that metastasis depends on cross-talk 
between selected cancer cells (the 'seeds') and specific organ 
microenvironments (the 'soil') 15, and the James Ewing theory which 
assumes that metastatic dissemination occurs by a matter of anatomy; the 
directionality of blood flow, where organs in close proximity ‘en route’ are 
likely to be main site of metastasis for a particular primary tumour. However, 
some types of metastasis cannot be explained by this hypothesis, for 
example a particular kidney cancer may always metastasise towards the 
thyroid which cannot be explained easily by anatomy 9. This field has 
developed over the past century passing by different breakthroughs. The 
conclusion of these studies so far suggests that the interactions of tumour 
cells with homeostatic factors that promote tumour cell growth, survival, 
angiogenesis, invasion and metastasis are the major regulators for 
metastatic potential and that the outcome of metastasis process depends on 
both intrinsic factors of the tumour cells and the response of the host tissue 
15. Further studies are needed to reveal the factors that contribute to the 
success of the metastatic process since at the cellular level only 1 in 10,000 
metastasising cells can potentially grow into a new metastatic deposit 9. 
Understanding the pathogenesis of metastasis at the systemic, cellular and 
molecular levels are therefore important goals of cancer research. 
 
1.2.1. Incidence of metastasis and associated risk factors  
 
Primary tumours can be classified into those with “good” or “poor” prognoses 
based on their metastatic potential. All cancers have the potential to spread, 
whether metastases develop or not depends on many factors. For example, 
a subset of breast tumours can be identified as being predisposed to 
metastasis, even when no clinical evidence for metastatic spread is apparent 
at the time of tumour resection 16. According to their abnormality under a 
microscope, cancer cells are classified into different grades. Tumour grades 
are used as an indicator to how quickly the tumour is likely to grow and 
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spread. Pathologists commonly describe tumour grade by four degrees of 
severity: Grades 1, 2, 3, and 4 (which is a general grading system while 
individual tumour types have their own grading system), When cancer cells 
resemble normal cells, it is graded as grade 1. Tumours of this type tend to 
grow and multiply relatively slowly, and are generally considered to 
exhibit non-aggressive behaviour. On the other hand, Grade 3 or Grade 4 
tumour cells do not bear any resemblance to normal cells of the same type, 
and their spread is expected to be faster than tumours with a lower grade 
(Table 1.1) 17.  
 
Table 1.1 Guidelines for grading tumours. Illustration of the general tumour grading system and 
description of each grade, reflecting the appearance of tumour cells under a microscope 
17
. 
 
Grade Meaning 
GX Grade cannot be assessed (Undetermined grade) 
G1 Well-differentiated (Low grade) 
G2 Moderately differentiated (Intermediate grade) 
G3 Poorly differentiated (High grade) 
G4 Undifferentiated (High grade) 
 
Other factors that contribute to tumour metastatic potential are the length of 
time the cancer has been present; the risk of metastasis increases the longer 
a tumour is in the body. The genetic makeup also affects the tumour 
metastatic potential; molecular analyses of cancer cells in various stages of 
progression have revealed that alterations in tumour suppressor genes and 
oncogenes accumulate during tumour progression and correlate with the 
clinical aggressiveness of cancer. As a result, it is possible to predict 
metastasis in certain types of cancer by detecting certain genetic alterations. 
A number of genes have been found to control the induction or suppression 
of metastasis in experimental models 18,19. It was discovered that genetic 
alterations are generally associated with the initiation of cell transformation in 
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normal cells, which leads to the loss of intercellular and/or extracellular 
matrix mediated cell-cell adhesion. These transformations in the genetic 
material allow tumour cells to undergo rapid multiplication and to generate 
more modifications in adhesion and motility-related molecules which permits 
their escape from the original site and consequently allow them to acquire 
invasive characteristics 20. 
 
1.2.2. Mechanisms of metastasis 
 
The multistep process of invasion and metastasis has been structured as a 
sequence of distinct phases, often termed the invasion-metastasis cascade. 
This cascade starts with the outgrowth of a metastatic lesion, which requires 
the development of a vascular network to supply tumour cells with nutrients 
for an expanding tumour mass initially supplied by simple diffusion. This 
necessitates the synthesis and secretion of angiogenic factors in order to 
establish a capillary network from the surrounding host tissue 21. Afterwards, 
the tumour cells invade the surrounding tissues and penetrate thin-walled 
venules, such as lymphatic channels, which offer very little resistance to 
penetration by tumour cells and provide the most common route for tumour 
cell entry into the circulation, where most of the tumour cells are destroyed 
by the host's immune response. Afterwards, the surviving single tumour cells 
or tumour aggregates detach from the blood vessels and become trapped in 
the capillary beds of distant organs by adhering either to capillary endothelial 
cells or to sub-endothelial basement membrane that might be exposed, 
where they extravasate and proliferate within the organ parenchyma to form 
micrometastases. Once they do, the cells can again invade the host stroma, 
penetrate blood vessels, and enter the circulation to produce secondary 
metastases (Figure 1.3)15. Generally, these steps are essential, and the 
same, for all tumours to metastasise and the metastatic process will not 
succeed if any one step fails 21,22.  
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Figure 1.3 Main steps in the metastatic process 
23
.  
Activation of epithelial to mesenchymal transition (EMT) is thought to be an 
event in malignant cancer that is responsible for promoting tumour 
metastasis and invasiveness. EMT is a biological process that allows a 
polarised epithelial cell, which normally interacts with basement membrane 
via its basal surface, to undergo multiple biochemical changes that enable it 
to assume a mesenchymal cell phenotype, which includes enhanced 
migratory capacity, invasiveness, elevated resistance to apoptosis, and 
greatly increased production of extracellular matrix (ECM) components 
(Figure 1.4) 23,24.  
Epithelial cells form polarised sheets or layers of cells that are connected 
laterally via several types of cellular junctions, including adherens junctions, 
desmosomes, and tight junctions. In contrast, mesenchymal cells embed 
themselves inside the ECM and rarely establish tight contact with 
neighbouring cells 24.  
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Figure 1.4 Schematic representation of EMT in metastatic cancer 
24
. 
Many of the hallmark EMT effector molecules are subcellular structure 
proteins that demarcate the epithelial or mesenchymal identity of a cell. 
During EMT, key molecular components of these structures are subjected to 
various levels of regulation. For example, the genes encoding various 
epithelial junction proteins, such as E-cadherin, α-catenin, and γ-catenin, are 
down-regulated at the mRNA and protein levels. Among them, E-cadherin is 
regarded as a gatekeeper of the epithelial state in various epithelial cell 
types. During EMT, cells must switch from expressing epithelial cadherin (E-
cadherin) to expressing neural cadherin (N-cadherin) for contact inhibition of 
locomotion (CIL) to occur; the process by which a cell changes its direction 
of migration upon collision with another cell 23,25.  
Activation of EMT is considered essential to allow carcinoma cells to lose 
cell–cell junctions and dissociate from each other for single-cell migration 
and invasion 24.  
Since colonisation demands tumour cells to restart proliferation upon 
extravasation into a foreign microenvironment, reversion of EMT (MET) 
occurs to provide such growth advantage 23. 
It is known that the potential of tumour cells to metastasise depends on their 
pre-programmed metastatic capacity (poor prognosis signature) and 
epigenetic factors provided by the adjacent tumour microenvironment to 
promote invasion and metastases 22. Metastasis-competent cells must 
perform a variety of tasks, which are likely to be regulated by transient or 
permanent changes in DNA, RNA or proteins. The best characterised 
alteration involved in the metastatic process is the alteration in the cell-cell 
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and cell-matrix interactions which is controlled by a number of adhesion 
molecules such as integrins, fibronectin, immunoglobulin-cell adhesion 
molecules and cadherins 5.  
Adhesion molecules play a pivotal role in the development and progression 
of cancer. Alteration of the function of these molecules in neoplastic cells 
results in the loss of intercellular adhesion, desquamation of tumour cells 
from the underlying lamina propria, allowing tumour cells to escape from their 
site of origin, degrade the extracellular matrix, acquire a more motile and 
invasive phenotype, and finally, invade and metastasise. Besides 
participating in tumour invasiveness and metastasis, adhesion molecules 
significantly contribute to a variety of functions including signal transduction, 
cell growth, differentiation, site-specific gene expression, morphogenesis, 
immunologic function, cell motility, wound healing, and inflammation 26. 
Adhesion between vertebrate cells is generally mediated by three types of 
adhesion junctions: adherens junctions (AJs), tight junctions (TJs), and 
desmosomes 27. Together they constitute the intercellular junctional complex, 
which has an important role in defining the physiological function of a cell. 
Cadherins are the principal components of AJs and desmosomes, which 
cluster at sites of cell–cell contact in most solid tissues. The cadherin 
superfamily consists of classical cadherins, which are the main mediators of 
calcium dependent cell–cell adhesion, and non-classical cadherins, which 
include desmosomal cadherins and the recently discovered large subfamily 
of protocadherins 27,28. 
1.3. Neural cell-adhesion molecule (NCAM)  
 
One of the best-studied members of the immunoglobulin cell adhesion 
molecule (Ig-CAM) family, which are crucial components of cadherin-based 
adherens junctions, is the neural cell adhesion molecule (NCAM, CD56). 
NCAM was the first cell adhesion molecule to be characterised and has been 
studied extensively. It is encoded by a single gene, located on chromosome 
11 in humans and on chromosome 9 in mice 28,29.  
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Figure 1.5 Structure of the different membrane-bound forms of the neural cell adhesion 
molecule (NCAM). The extracellular part of all NCAM isoforms consists of 5 immunoglobulin-
like and 2 fibronectin type III-like domains. The 120-kDa NCAM isoform is linked to the 
membrane through a phospholipid anchor. The 140-kDa NCAM and 180-kDa NCAM isoforms, in 
contrast, are anchored to the cell membrane and have specific intracellular domains, through 
which they can interact with the cytoskeleton or components of the postsynaptic density. Blue 
dots demarcate the attachment sites for polySia polymers on NCAM [33]. 
 
1.3.1. NCAM structure 
 
NCAM is a cell surface glycoprotein normally distributed along intracellular 
boundaries, without being associated with specific adhesive structures such 
as adherens junctions or tight junctions. NCAM consists of five 
immunoglobulin domains (Ig 1-5) and two fibronectin type III repeats (F3) 
(Figure 1.5) 30. Analyses of NCAM by electron microscopy have revealed a 
bent rod-like structure located after Ig5. The angle of the bend at the hinge-
region between N-terminal (approx. 18 nm) and C-terminal (approx. 10 nm) 
parts varies considerably (50–140°) with an average value of 98°, which 
provides sufficient internal flexibility for NCAM to fit within the cell-cell 
distance 30,31.    
Several NCAM isoforms exist, which are either linked to the plasma 
membrane by a glycosylphosphatidyl-inositol (GPI) anchor (NCAM120) or 
have trans-membrane and cytoplasmic domains (NCAM140 and NCAM180, 
the numbers refer to their relative molecular weights) (Figure 1.5). In addition 
to the three main isoforms, the molecule also exists in a secreted form 
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(soluble NCAM), produced by the expression of the so called SEC-exon that 
contains a stop codon, giving rise to a truncated form of the extracellular part 
of NCAM with a molecular weight of around 115 kDa 32.  This high structural 
diversity of NCAM is due to alternative splicing and dynamically regulated 
post-translational modifications. During development, NCAM140 and 
NCAM180 are transiently expressed in the nervous system as well as in 
several other tissues 33. Expression of these isoforms, also called 
“embryonic” isoforms, plays a pivotal role in developmental events such as 
neuronal cell migration, differentiation and proliferation. In the adult, 
however, NCAM120 is the major isoform to be expressed in the nervous 
system, in skeletal muscle cells as well as some neuroendocrine tissues 30. 
 
1.3.2. NCAM function  
 
NCAM is abundantly expressed on developing myotubes and motor axons, 
and after synapse formation becomes confined to the neuromuscular 
junctions (NMJ), where it is expressed both presynaptically and 
postsynaptically as well as on Schwann cells. Although NCAM can act as a 
homophilic adhesion molecule, the defects in synaptic maturation that we 
observed are more consistent with a role for presynaptic NCAM in helping to 
target and organize other presynaptic molecules via intracellular signalling 
cascades or direct protein–protein interactions 34.  
1.3.2.1. NCAM role in cell-cell adhesion and neuronal survival  
 
The major function of NCAM is to promote cell-cell adhesion and as a result, 
to create and maintain tissue integrity 33. NCAM mediates calcium 
independent cell-cell adhesion by means of homophilic trans-interactions. An 
anti-parallel interaction takes place between the Ig1-Ig3, Ig2-Ig2, and the Ig2-
Ig3 contacts 30, with an NCAM on one cell binding to the NCAM on an 
adjacent cell. The combination of these trans-interactions, at cell-cell contact 
with cis-homophilic binding, the parallel interaction of the NCAM molecules 
mediated by the Ig1-Ig2 contact, reflects an interaction between NCAM 
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molecules present on the same cell surface and results in the formation of 
zipper like structures (Figure 1.6) 35. This property is particularly important 
during development when single cells needs to bind to each other to form 
tissue integrity. Besides that, this property is also important in modulating 
tissue permeability rather than establishing cell polarity; tight junctions mostly 
act to control paracellular permeability in epithelial and endothelial cells, and 
to establish a boundary that restricts lipid and protein diffusion between the 
apical and basolateral membrane domains of these cells, thus establishing 
cell polarity. The adhesive properties of adherens junctions are also 
important for creating a boundary at the cell membrane that limits the free 
movement of membrane proteins and promotes the establishment of cell 
polarity. Notably, adherens junctions frequently act in concert with tight 
junctions to control cell permeability and cell polarity 28.  
 
Figure 1.6 NCAM-NCAM interactions. Parallel and anti-parallel interactions identified in the 
crystal structure of the first three N-terminal Ig modules of NCAM. The parallel interaction 
mediated by the first and second Ig modules is shown in (a), whereas the anti-parallel 
interactions are shown in (b), (c) and (d). In (b), the interaction is mediated by the second and 
third Ig modules, in (c), by the first and third Ig modules, and in (d), by two second Ig modules 
from two different NCAM molecules. In all cases the modules are observed from the same 
viewpoint 
31,35
.  
The joined forces of the first three Ig modules represent the strength of 
NCAM-mediated adhesion; the Ig1 and Ig2 modules of NCAM mediate 
both cis and trans interactions, while Ig3 is involved only in trans interactions. 
Although cis interactions between the Ig1-Ig2 modules do not mediate cell-
cell interactions themselves, some studies suggest they have a role in the 
15 
 
stability of the trans interactions. In other words, the formation of cis dimers 
may be a prerequisite for the establishment of trans interactions 35. 
Besides having a role in maintaining tissue integrity, NCAM-NCAM 
interactions mediate neural development through the activation of 
calmodulin-dependent protein kinase IIα (CAMK IIα) which activates receptor 
type Tyr-protein phosphatase-α (RPTP α) that promotes the activation of Tyr-
protein kinase FYN (FYN) resulting in the stimulation of focal adhesion 
kinase and neurite outgrowth and neuronal survival. NCAM interactions also 
stimulate the recruitment of growth associated protein 43 (GAP43) resulting 
in the formation of spectrin-GAP43-protein kinase CβII (PKCβII) signalling 
complex that promotes cytoskeletal remodelling and neurite outgrowth 35,36.  
1.4. Polysialylation of NCAM  
 
The most prominent post-translational modification of NCAM is polysialic 
acid (polySia), a homopolymer of α-2,8-linked sialic acid residues which is 
added to specific N-glycan attachment sites in the fifth immunoglobulin like 
domain of NCAM (Figure 1.5, 1.7). PolySia is abundantly expressed 
throughout embryonic development and down-regulated during maturation 
and differentiation. In the adult brain, polySia-NCAM is only expressed in 
areas that retain a high degree of plasticity such as the hippocampus and the 
olfactory bulb, albeit its expression is relatively lower than that expressed 
during embryogenesis. PolySia-NCAM also regulates synaptic plasticity, 
including such processes as learning and memory consolidation 37-39. 
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(A)
(B) 
 
 
Figure 1.7 Chemical structure of polySia (A) and sialic acid monomer (B)
38
. 
 
1.4.1. N-linked polysialylation biochemistry 
 
The assembly of an oligosaccharide on an isoprenoid lipid (dolichol) from 
nucleotide activated monosaccharides on the cytoplasmic side of the 
membrane by a set of specific glycosyltransferases and the subsequent 
translocation of the lipid-linked oligosaccharide is a unifying scheme in all 
systems 40.  
For polySia synthesis, the oligosaccharide is further extended by lumen-
oriented polysialyltransferases, which use dolichylphosphate-bound 
monosaccharides as substrates 41. 
1.4.2. Polysialyltrasferase enzymes 
 
Polysialylation of NCAM is catalysed by polysialyltransferase enzymes 
(PolySTs). PolySTs transfer Neu5Ac monomer units from the activated sugar 
donor CMP-Neu5Ac to the non-reducing end of the growing polySia polymer 
[42].  
In mammals the polySia chain is synthesised by two Golgi-resident enzymes, 
ST8SiaII (STX) and ST8SiaIV (PST), which have a strong specificity for their 
protein targets. These enzymes are found in the carbohydrate-active 
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enzymes database (CAZy) family GT-29, along with all other mammalian 
sialyltransferases 32,42.  
There are more than 20 different sialyltransferases involved in the 
biosynthesis of sialylated glycoproteins and glycolipids. To date only 15 
different human sialyltransferase cDNAs have been cloned and 
characterised. Each of the sialyltransferase genes is differentially expressed 
in a tissue-, cell type-, and stage-specific manner to regulate the sialylation 
pattern of cells. These enzymes differ in their substrate specificity, tissue 
distribution and various biochemical parameters 43. 
ST8SiaII and ST8SiaIV belong to the family of six genes encoding alpha 2,8-
sialyltransferases (Table 1.2). ST8SiaII has been described at first as the 
initiating enzyme that transfers the first sialic acid residue to the 8-hydroxyl of 
Neu5Ac residue α2,3-linked to the terminal position of N-linked glycans, 
mainly found attached to the neural cell adhesion molecule (NCAM). Both 
ST8SiaII and ST8SiaIV catalyse the transfer of sialic acid through α-2,8-
linkages onto sialic acid residues and co-operatively elongate the polySia 
chain using CMP-Sia as a donor substrate 43.  
The protein structures of ST8SiaII and ST8SiaIV each consist of a short 
cytoplasmic region connected to a transmembrane (TM) region that is joined 
to an intra-luminal region. The intra-luminal region consists of a stem region 
and a catalytic domain, and sialyl motifs L (Large), S (Small), III, and VS 
(Very Short), which are a common feature of all α-2,3-, α-2,6-, and α-2,8-
sialyltransferases. Sialyl motif L is positioned in the centre of the enzyme and 
is characterized by a 55-amino-acid region that serves as a donor substrate 
(CMP-Sia) binding site. Sialyl motif S is located at the C-terminal region of 
the enzyme and consists of 28 amino acid residues that are involved in the 
binding of both donor and acceptor substrates. Sialyl motif VS is also located 
in the C-terminal region and is reported to be involved in catalytic activity. 
Key histidine (H) and glutamic acid (E) residues in this motif are highly 
conserved between the sialyltransferases. Motif III (YHYYD) is located 
between sialyl motif S and VS and is also involved in the catalytic activity of 
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both ST8SiaII and ST8SiaIV 44. In addition, a novel polybasic 
polysialyltransferase domain (PSTD; 32 amino acids) identified next to the 
motif S in both polysialyltransferases, which is only observed in the two 
polySTs and not in other sialyltransferases, was demonstrated to be involved 
in polysialylation activity. More recently, a second conserved polybasic motif, 
named polybasic region (PBR), was identified close to sialyl motif L in 
ST8SiaII and ST8SiaIV. The PBR consists of 35 amino acids, of which seven 
are the basic amino acids arginine (R) and lysine (K), and is involved in 
NCAM-specific polysialylation, highlighting a crucial role in acceptor-
substrate recognition. These basic amino acids are considered to be 
important for IgV specific polysialylation of NCAM through binding via acidic 
patch of first FNIII domain (Figure 1.8) 44,45.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8 Schematic representation of ST8SiaII and ST8SiaIV enzymes (A).Both polySTs 
consist of a short N-terminal cytosolic part, a transmembrane domain (TMD), a stem region and 
a C-terminal catalytic domain. The large (L), short (S) and very short (VS) sialyl motifs 
conserved in all mammalian sialyltransferases are depicted as black boxes. The two polyST 
specific domains, termed polybasic region (PBR) and polyST specific domain (PSTD), are 
shown as white boxes. B) Domain structure and molecular requirements for polysialylation of 
NCAM 
46
.  
 
 
 
(A) 
(B) 
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Table 1.2 Summary of the human alpha-2,8-sialyltransferases. 
 
Sialyltransferases Structures formed Reference 
ST8Sia I 
Neu5Acα2-8 
Neu5Acα2-3Galβ1-4Glc-Cer 
47
 
ST8Sia II 
Neu5Acα2-8 
Neu5Acα2-3Galβ1-4GlcNAc 
48
 
ST8Sia III 
Neu5Acα2-8 
Neu5Acα2-3Galβ1-4GlcNAc 
49
 
ST8Sia IV 
Neu5Acα2-8 
(Neu5Acα2-8)nNeu5Acα2-
3Galβ1-R 
50
 
ST8Sia V 
Gangliosides  
GD1c, GT1a, GQ1b, GT3. 
51
 
ST8Sia VI 
Neu5Acα2-(NeuAcα2,3)6-
Gal 
52
 
 
1.4.2.1. Distinct Functions of ST8SiaII and ST8SiaIV 
 
The dynamic regulation of polysialylation during development is mainly 
accomplished by the up- and down-regulation of the polySTs. As shown in 
rodents, ST8SiaII is mainly involved in polySia biosynthesis during brain 
development, whereas ST8SiaIV seems to be the major polyST of the adult 
brain where it persists. Studies to define distinct roles for each enzyme have 
been performed in vitro using soluble forms of ST8SiaII and ST8SiaIV and in 
vivo using knock-out mouse models 46,53. 
Single knock-out mouse models lacking either ST8SiaII or ST8SiaIV allowed 
for a detailed analysis of the in vivo polysialylation capacity of the remaining 
polyST. At postnatal day one, a time point of maximal polySia expression, 
loss of ST8SiaIV is completely compensated by the remaining activity of 
ST8SiaII. Conversely, the absence of ST8SiaII causes a 40 % reduction of 
polySia. Moreover, the range of different lengths of the polySia chains 
produced by either enzyme was similar 46.  
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In total, studies showed a reduced polysialylation efficiency of ST8SiaIV in 
comparison to ST8SiaII in vivo, which might result from a less efficient 
recognition of and/or binding to NCAM by ST8SiaIV. This is consistent with 
the fact that ST8SiaII is the prevailing enzyme in the developing brain where 
utmost synthesis of polySia chains is required, whereas ST8SiaIV constitutes 
the dominant enzyme in adulthood, in which the expression of polySia NCAM 
is considerably reduced and restricted to distinct areas of the brain 54. 
The human ST8SiaII gene is located on chromosome 15 and the 
corresponding enzyme consists of six exons. Although the promoter region 
of the ST8SiaII gene has not been well examined in vitro, the schizophrenia-
associated haplotype block of ST8SiaII appears to localize in several 
putative consensus motifs and transcriptional factor binding sites, including 
those for CCAAT, MZF1, CREB, GATA, TATA, and SP1. In the mouse 
genome, ST8SiaII expression is driven by SP1-binding motifs present in a 
TATA-less GC-rich domain and by the cAMP-CREB cascade. It is also 
reported that ST8SiaII is under the control of Pax3, a member of a paired 
homeobox family of evolutionary conserved transcription factors that are 
important for brain development 55. 
1.4.3. Effect of polysialylation on NCAM-mediated cell adhesion  
 
The large size and negative charge of the polySia carbohydrate physically 
inhibits NCAM-NCAM homophilic binding and thus attenuates cell–cell 
adhesion 56. In other words, in the developing nervous system, polySia-
NCAM has been shown to promote plasticity of cell-cell interactions during 
cell migration and neurite outgrowth, changing NCAM function from a pro-
adhesive to a pro-migratory molecule, facilitating axon path-finding and 
plastic changes in the embryonic and adult nervous system, and its 
expression under different pathological conditions implies a role in neural 
regeneration and repair. 
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1.4.4. Effect of polysialylation on NCAM-dependent signalling 
implicated in the regulation of tumour cell proliferation, survival and 
differentiation 
 
Recent studies have revealed that the expression of polySia affects NCAM-
dependent signalling involved in the regulation of tumour cell proliferation, 
survival and differentiation. This function of polySia appears clearly different 
from its role as a positive regulator of chain migration and axon fasciculation 
and from the anti-adhesive properties of polySia 37. 
A study by Seidenfaden et al., showed that in both rhabdomyosarcoma and 
neuroblastoma tumours, NCAM polysialylation results in a significant 
increase in proliferative response, determined by metabolic assays, to 
different growth factors such as brain-derived neurotrophic factor (BDNF) 
nerve growth factor and fibroblast growth factor-2 (FGF-2). Degradation of 
polySia using endoneuramindase-N (an enzyme that selectively cleaves 
polySia from NCAM) led to inhibition of cell growth, while growth of the 
NCAM- and polySia-negative neuroblastoma cell lines was unaffected. 
Polysialylation of NCAM induces inhibition of mitogen-activated 
protein/extracellular signal-related kinase (MAPK) dependent survival and 
differentiation in neuroblastoma cell lines; activation of MAPK after polySia 
removal exerts a survival promoting, anti-apoptotic effect 37, which is 
consistent with the results of another study reported by K. Eggers. et al 57. 
Polysialylation of NCAM was also found to exert an inhibitory effect on 
neurite outgrowth and significantly decreased the number of neurite bearing 
cells 57, which may have implications for cancer cells. 
In conclusion, studies suggest that polySia acts as a negative regulator of 
heterophilic NCAM signals at sites of cell-cell contact, which after down 
regulation of polySia trigger the cell to cease proliferation and to differentiate. 
The dynamic regulation of polySia therefore provides the control over an 
instructive signal for tumour cell growth 37,57. 
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1.4.5. Effects of polySia on cellular interactions 
 
PolySia serves as a potent negative regulator of cell interactions via its 
unusual biophysical properties. The role of polySia as a control element of 
specific NCAM interactions has been uncovered from in vitro studies 58. As 
mentioned earlier, loss of polySia in neuroblastoma cells initiates NCAM 
trans-interactions at cell–cell contact sites, leading to reduced proliferation in 
favour of neuronal differentiation via activation of the MAPK pathway. 
Interestingly, in myoblasts and muscle-derived tumour cell lines a similar 
approach induced differentiation into a muscle-specific phenotype, indicating 
a general differentiation-promoting activity initiated by polySia-deprived 
NCAM. Another interesting outcome of the cellular studies was the 
heterophilic nature of the polySia-sensitive NCAM signals 58,59.  
Different possible modes are implicated in the action of polySia. PolySia 
might mask NCAM and consequently, removal of polySia or lack of 
polysialylation induces specific trans homophilic or heterophilic NCAM 
interactions. This may involve cis-dimerisation of non-polysialylated NCAM. 
PolySia might also behave as a negative regulator of cell surface apposition 
by attenuation of adhesive trans-interactions of NCAM and other molecules, 
e.g. cadherins. PolySia also could function as a scavenger molecule, 
facilitating interactions of soluble factors with cell surface receptors such as 
BDNF, as mentioned earlier (Section 1.4.3.). Alternatively, polySia could be 
permissive by modulating inhibitory cis NCAM-interactions. (see Figure 1.9) 
58.  
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Figure 1.9 Possible modes of polySia action. (a) PolySia masks NCAM. (b) PolySia as a 
negative regulator of cell surface apposition. (c) PolySia as a scavenger molecule facilitating 
interactions of soluble factors with cell surface receptors (d) polySia could be permissive by 
modulating inhibitory cis NCAM-interactions 
58
. 
 
1.4.6. Effect of polySia expression on cancer prognosis 
 
As an onco-developmental antigen, polySia is re-expressed during 
progression of a number of malignant human tumours, including small cell 
lung carcinoma, Wilms' tumour, neuroblastoma, breast cancer and 
rhabdomyosarcoma (Table 1.3). In these tumours, polysialylation of NCAM 
correlates with increased metastatic potential, tumour progression and poor 
prognosis (Figure 1.10-1.11) 37,60. The mechanism by which polySia-NCAM 
promotes metastasis in tumour tissues is analogous to its mechanism during 
cell migration and neurite outgrowth.  
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Besides increasing inter-membrane repulsion due to the negative charge of 
the polySia chains, it also modulates the NCAM-NCAM interactions as well 
as NCAM interactions with other molecules that promote tumour metastasis, 
which will be discussed later (Chapter 4). 
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Table 1.3 Expression of polySia-NCAM in selected types of cancer and its effect on cancer 
metastasis and prognosis. 
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Figure 1.10 PolySia-NCAM expression in glioblastoma patients correlated to A) overall survival 
and B) disease-free survival. PSA in these figures refers to polySia 
67
.  
(A) 
(B) 
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Figure 1.11 Kaplan-Meier curves of NCAM with/without polySia in SCLC patients (A). The 
probability of survival of patients with samples expressing NCAM without polySia is 
significantly higher than that of those expressing polySia, (B) Progression-free survival with 
respect to ST8SiaII status among neuroblastoma patients 
76,79 
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PolySia-NCAM is expressed by approximately two thirds of the glioblastoma 
patients at variable levels and was found to be an adverse prognosis factor 
for both overall survival and disease free survival (Figure 1.10)67. The same 
effect on prognosis was also reported in both SCLC and neuroblastoma 
patients. In a study on SCLC patients, 88% of the patients were positive for 
NCAM. Among the NCAM positive patients 60% were positive for polySia. 
The probability of survival of the NCAM subgroup without polySia was 
significantly higher than that of the NCAM with polySia expression.  
Studying ST8SiaII expression in 39 NB tumours and 8 cell lines showed that 
ST8SiaII expression was high among NB tumours of all stages, as well as 
neuroblastoma cell lines of different phenotypes. 
1.5. The role of polySia expression in neuroblastoma 
 
Neuroblastoma is the most common extracranial solid tumour of infancy. It is 
an embryonal malignancy of the sympathetic nervous system arising from 
neuroblasts (pluripotent sympathetic cells) 80. The clinical presentation varies 
depending on the location, size and functional characteristics. They are 
aggressive tumours that frequently metastasise.  
Overall prognosis for children with neuroblastoma is mixed. Five-year 
survival in children diagnosed between 2000-2007 was 91% in infants, 59% 
in children aged 1-4 years, 52% in children 5-9 years, and 56% in patients 
aged 10-14 years. Teenagers and adults with neuroblastoma have 
significantly worse outcome than younger children. Survival drops steeply 
after the first year from diagnosis, so there is a large gap between 1-year and 
3-year survival 81,82.  
Neuroblastoma prognosis significantly depends on the stage of the disease 
and Children’s Oncology Group (COG) risk groups (Table 1.4). Children in 
the low-risk group typically have a 5-year survival rate that is higher than 
95%, while in children in the intermediate-risk group, the 5-year survival rate 
is around 90% to 95%. High-risk group patients, however, have a 5-year 
survival rate of less than 50% 83,84. There is thus a desperate need for new 
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therapies to save the lives of children with these high-risk cancers. For these 
reasons, and due to the body of research associating neuroblastoma with 
polySia, neuroblastoma is a key tumour of interest at the Institute of Cancer 
Therapeutics. Human neuroblastoma cell line SH-SY5Y was used as a 
model for the experiments carried out in the studies described in this thesis.  
Table 1.4 Staging system and children’s oncology group (COG) risk groups of neuroblastoma 
83
. 
 Stage Cancer distribution 
Low risk 
1 Cancer is still in the area where it started; 
2 
A 
The cancer is still in the area where it 
started and on one side of the body, but 
not all of the visible tumour could be 
removed by surgery. 
B 
The cancer is on one side of the body and 
may or may not have been removed 
completely by surgery. 
Intermediate 
risk 
3 
The cancer has not spread to distant parts 
of the body, but cannot be removed 
completely by surgery or is still in the area 
where it started and is on one side of the 
body; It has spread to lymph nodes that 
are relatively nearby but on the other side 
of the body. Or the cancer is in the middle 
of the body and is growing toward both 
sides. 
4 
4 
The cancer has spread to distant sites 
such as distant lymph nodes, bone, liver, 
skin, bone marrow, or other organs. 
4S 
The child is younger than 1 year old. The 
cancer is on one side of the body. 
High risk 
Any child who is Stage 2A or 2B, older than age 1, whose cancer has 
extra copies of the MYCN gene 
Any child who is Stage 3, younger than age 1, whose cancer has extra 
copies of the MYCN gene 
Any child who is Stage 3, older than age 1, whose cancer has extra 
copies of the MYCN gene 
Any child who is Stage 3, older than 18 months of age, whose cancer 
has unfavorable histology 
Any child who is Stage 4, whose cancer has extra copies of the MYCN 
gene regardless of age 
Any child who is Stage 4 and older than 18 months 
Any child who is Stage 4 and between 12 and 18 months old whose 
cancer has extra copies of the MYCN gene, unfavorable histology, 
and/or normal DNA ploidy (a DNA index of 1) 
Any child who is Stage 4S (younger than age 1), whose cancer has extra 
copies of the MYCN gene. 
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1.5.1. Epidemiology and Current neuroblastoma therapy in the clinic 
 
Neuroblastoma is a complex disease with many contradictions and 
challenges 85. Surgery alone is used to manage low-stage (stages I and II) 
neuroblastoma, but multiple-agent chemotherapy is the conventional therapy 
for patients in the more advanced stages of disease. Interestingly, infants 
with disseminated neuroblastoma have favourable outcomes with combined 
chemotherapy and surgery. In contrast, children older than 1 year with high-
stage neuroblastoma have very poor survival rates despite intensive 
multimodal therapy 85.  
1.5.1.1. Epidemiology of neuroblastoma  
 
Neuroblastoma is a malignancy of the cells of the neural crest. The neural 
crest forms in the third to fourth week of embryonal development and some 
of these cells differentiate and migrate to create the sympathetic nervous 
system. Tumours may arise anywhere along the sympathetic nervous 
system, but are found most frequently in the adrenal glands (approximately 
40% of tumours) or elsewhere in the abdomen, chest, or pelvis 86,87. 
Neuroblastoma is the most common tumour in children less than 1 year of 
age. It is the third most common childhood cancer, after leukaemia and brain 
tumours, and is the most common solid extracranial tumour in children. 
Neuroblastoma accounts for approximately 15 percent of all paediatric 
cancer fatalities 86. Many factors, such as age at diagnosis and stage of 
disease, in addition to the molecular, cellular and genetic features of the 
tumour, determine whether it will spontaneously regress or metastasize and 
become refractory to therapy 87. 
It has been suggested that the incidence of neuroblastoma has increased in 
recent years. It is of interest to determine whether this is in part the result of 
increased surveillance and screening or is rather due to increases or 
changes in potential risk factor distributions. Little is known about the causes 
of neuroblastoma, and currently no recommendations exist for disease 
prevention 86. 
32 
 
1.5.1.2. Current neuroblastoma therapy in the clinic 
 
Current trends in chemotherapy for the management of high-risk 
neuroblastoma include dose-intensive chemotherapy followed by resection of 
the primary tumour, myeloablative therapy using escalating 
chemotherapeutic combinations (possibly followed by autologous bone 
marrow infusion), and biological response modifiers that cause tumour 
differentiation and a reduction in tumour involvement of the bone marrow. 
The common chemotherapeutic agents include cisplatin, doxorubicin, 
cyclophosphamide and the epipodophyllotoxins (teniposide and etoposide). 
Radiotherapy is also used. Following treatment, patients receive ‘minimal 
residual disease therapy’, which currently consists of 13-cis-retinoic acid 
(which is thought to cause differentiation of neuroblastoma cells) and anti-
GD2 immunotherapy (Unituxin). Unituxin was recently approved by the FDA 
and EMA specifically for neuroblastoma (in combination with GM-CSF, 
Interleukin-2) and is a rare example of a cancer agent that was trialled in 
children first (i.e. before adults) 88-90. 
Despite achievements in neuroblastoma treatment field, there are still a lot of 
challenges. High-risk neuroblastoma continues to prove resistant to therapy: 
the overall survival in this disease while improved remains below 50 percent 
(Figure 1.12) 91,92. 
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Figure 1.12 The children's oncology group treatment trials in high risk Neuroblastoma 
91
. 
 
1.5.2. Glycobiology of neuroblastoma 
 
There is evidence that changes in glycolipids and protein glycosylation 
pathways are associated with neuroblastoma biological behaviour 32. Several 
tumour-associated carbohydrate antigens have been shown to be involved 
with tumour proliferation, invasion, angiogenesis, metastasis and immunity, 
such as the ganglioside GD2. This glycosphingolipid is highly expressed in 
neuroblastoma 93 and is the target for the aforementioned Unituxin, a 
monoclonal antibody. GD2 is a key example that supports targeting polySia 
in neuroblastoma. 
PolySia interferes with cellular adhesion, and correlates with neuroblastoma 
progression and poor prognosis, as well as the expression of ST8SiaII 32,94. 
High polySia-NCAM levels have been correlated with malignant potential and 
poor prognosis of neuroblastoma 32. 
PolySia has a direct impact on neuroblastoma tumour-cell growth. The 
presence of polySia-NCAM has been shown to increase proliferative cell 
activity in vitro 95. PolySia plays an important role as regulator of 
neuroblastoma cell migration. It was demonstrated that the migratory effect is 
NCAM-dependent, but independent of FGF receptor activity 57. Removal of 
polySia from the cell-surface led to reduced proliferation and metastasis 95. 
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1.6. Validation of polysialyltransferases as anti-cancer drug 
targets 
 
Several studies have been performed in order to validate polysialylation of 
NCAM or rather the enzymes responsible for this process as a potential 
target for cancer treatment. Those studies focused on determining the effect 
of inhibition of NCAM polysialylation on cancer growth, survival and 
metastasis. Studying the effect of inhibition of the NCAM polysialylation 
process was achieved using various techniques such as the use of 
endoneuroaminidase-NE (Endo-N), an enzyme which recognises and 
cleaves internal α-2,8-sialic acid bonds to digest polySia, siRNA knockdown 
of polysialyltransferase enzymes or by in vivo studies employing tumour cells 
with differential expression of polySia. These studies showed that removal of 
polySia from the cell surface led to the induction of NCAM signals, reduced 
proliferation, growth inhibition and increased cell-cell interaction of tumour 
cells 37,77,96. 
1.6.1. Endoneuroaminidase–NE treatment 
1.6.1.1. Effect of polySia removal on tumour cell growth and 
proliferation. 
 
Using Endo-N to specifically degrade polySia in vitro and to remove it from 
the cell surface, neuroblastoma (SH-SY5Y, Kelly, and LAN-5) and 
rhabdomyosarcoma (TE671) cells (all NCAM- and polySia-positive) showed 
a similar reduction in cell growth, while this was not observed using an 
NCAM- and polySia-negative neuroblastoma cell line (LS). Heat-inactivated 
Endo-NE, colominic acid or N-acetylneuraminic acid were used as control 
and led to no effect on cell growth. The reduction of tumour cell growth was 
confirmed by counting the cells in some of the experiments. The absence of 
apoptosis after Endo-NE treatment was confirmed by a cell-death ELISA, 
and the analysis of BrdU incorporation revealed that the Endo-NE-induced 
reduction of cell growth was associated with a significant decline in 
proliferation. Thus, the observed growth inhibition was due to reduced rates 
of proliferation 37. 
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1.6.1.2. Effect of polySia removal on NCAM-mediated cell-cell contact 
in tumour cells 
 
The cell surface distribution of polySia and NCAM was studied by 
Seidenfaden R., et al. using immunogold detection with energy-filtering 
transmission electron microscopy; polySia appears in clusters on SH-SY5Y 
cells and is predominantly localised at sites of tight cell-cell contacts. PolySia 
digestion by Endo-NE did not change NCAM-immunoreactivity at contact 
sites. However, a two day-incubation with Endo-NE led to an increase in 
NCAM-positive contact zones. It was found also that even if seeded as single 
cell suspension at low densities, the tumour cells used in this study never 
grew without any contacts between each other, which suggests that polySia 
expression correlates with decreased cancer cell-cell adhesion 37,97.  
1.6.2. SiRNA knockdown of NCAM and/or ST8SiaII/IV 
 
In agreement with the results obtained with Endo-NE treatment, siRNA 
knockdown of NCAM and/or ST8SiaII/IV, in a study performed by Schreiber 
et al., showed significant increase in the aggregation capacity of NCAM, 
polySia and ST8SiaII/IV positive pancreatic PANC-1 and AsPC-1 cells in the 
case of polysialyltransferase knockdown. Addition of a neutralizing E-
cadherin antibody to the siRNA-treated AsPC-1 cells completely abolished 
the increase in aggregation and thus confirmed that the improved 
aggregation was mediated by polySia-NCAM interaction with E-cadherin. 
The ability of PANC-1 cells to migrate was also examined after siRNA 
treatment. It was found that inhibition of ST8Sia-II/IV expression significantly 
reduced the enhanced cell migration 96. 
Instead of using SiRNA knockdown, ldlD-14 (Chinese hamster ovary) cells 
were utilised in a study by Feng Guan et al. The ldlD-14 cell line is a useful 
model for studying polySia role in NCAM function. The UDP-Gal 4-epimerase 
deficiency characteristic of ldlD-14 cells results in low internal pools of UDP-
Gal when cells are grown in the absence of Gal. Addition of Gal on N-glycan 
termini is the essential step for polySia synthesis on NCAM. In this situation, 
incomplete N-glycan on ldlD-14 cells lacked the factors of Gal for the 
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attachment of polySia. Using transfected ldlD/N140 cells, restoring normal 
cell phenotype was achieved by addition of Gal. Results showed that NCAM 
bearing polySia was associated with enhanced cell proliferation and 
migration, suggesting that polySia overexpression promotes metastasis 98.  
1.6.3. In vivo experiments (Correlation of polySia-NCAM expression 
with tumour metastatic potential) 
 
Several studies have been performed in order to examine the effect of 
NCAM polysialylation on tumour metastatic potential. It was found that 
tumours bearing polySia are highly metastatic and that polySia-NCAM 
expression correlates with metastatic occurrence. In a study by Daniel et al., 
a relationship between polySia expression and the metastatic process was 
established by manipulating polySia expression in a novel animal metastatic 
model in nude mice by using TE671 cells which strongly express polySia-
NCAM. Endo-N was verified to be non-toxic in vivo where no histological 
changes were observed after intra-peritoneal administration of 350 Endo-N 
units. It was found that lung and liver metastases as well as peritoneal 
carcinosis were formed after TE671 cells were injected intravenously, 
intramuscularly and intraperitoneously. Cleavage of polySia on NCAM by 
Endo-N treatment decreased the number of lung or liver metastases 78.  
In another study by Suzuki M. et al. polySia-expressing C6-ST8SiaIV/II 
glioma cells were inoculated into the caudate putamen of the mice brain. 
Significantly more tumour invasion was observed, in particular to the corpus 
callosum, as compared to mock-transfected cells. On the other hand, C6 
cells negative for polySia barely showed invasion to the corpus callosum 
under the same conditions 66. These results were further confirmed in most 
recent studies were polysialyltransferase deficient mice ST8siaII/IV-/- mice 
lacking polySia expression demonstrated decreased tumour growth and 
metastasis 38. These studies provide direct evidence that polySia contributes 
towards tumour metastatic potential. 
The polysialylation of NCAM was found to reduce the adhesiveness of 
tumour cells. In a study by Valentiner U. et al., lung metastases were 
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examined for both polySia-NCAM negative (Kelly and SK-N-SH) and positive 
(LAN-1 and LAN-5) tumours. It was found that neuroblastoma cells 
expressing polySia-NCAM disseminate as single cells in the parenchyma of 
the lung, whereas cells of tumours without or with weak polySia-NCAM 
expression leave the primary tumour and adhere as cell clusters to the 
vascular vessel but do not transmigrate or do so very slowly, respectively 77.  
These results, as a whole, indicate that, polysialylation of NCAM in different 
tumour types favours tumour metastasis and invasion and subsequently 
recurrence of the disease. Taken together, this validates the 
polysialyltransferase enzymes as anticancer drug targets. 
1.7. Polysialyltransferase inhibitors  
 
The significant effect of polySia on tumour prognosis and pathogenesis 
suggests a case for drugs that are designed to inhibit the polysialylation of 
NCAM. Moreover, the design of a selective inhibitor of ST8SiaII will help to 
elucidate the differences between the two enzymes, ST8SiaII and ST8SiaIV 
through the determination of the effect of selective inhibition of each enzyme 
on the chain length of the synthesised polySia chains and the percentage of 
the reduction of total polySia and consequently give an understanding on 
which enzyme is more important for polySia synthesis in tumour tissues. 
Although these two enzyme products are very similar in terms of substrate 
specificity, they show distinct mRNA expression patterns in tissue and 
developmental stage. Different studies showed that ST8SiaIV gene is 
constantly expressed in both normal and tumour tissues. In contrast, the 
ST8SiaII gene is not expressed in normal tissues, and its expression in 
tumour tissue is closely correlated with tumour progression. Crucially, in both 
cases gene expression in normal tissue does not correlate with polySia 
expression, since polySia expression is limited to the brain 99.  
It is thought that it is ST8SiaII enzyme which is most involved in tumour 
progression, and so the design of a selective inhibitor of ST8SiaII will help 
not only to inhibit NCAM polysialylation process but also to confirm and 
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explain which enzyme is more implicated in the tumour progress. Very few 
polysialyltransferase enzyme inhibitors are known. The only two groups of 
known polysialyltransferase enzyme inhibitors will be briefly discussed 100.    
1.7.1. N-acyl D-mannosamines 
 
Glycosylation requires several enzyme-catalysed steps to synthesise an 
activated form of a monosaccharide. For sialic acid synthesis, N-acetyl 
glucosamine is ﬁrst converted to N-acetyl mannosamine by N-acetyl 
glucosamine 2-epimerase. N-Acetyl mannosamine is then phosphorylated to 
N-acetyl mannosamine 6-phosphate by N-acetyl mannosamine kinase. The 
resulting N-acetylmannosamine 6-phosphate is conjugated to 
phosphoenolpyruvate by N-acetylneuraminic 9-phosphate synthase, through 
aldol condensation, forming N-acetylneuraminic 9-phosphate. The product in 
turn yields N-acetylneuraminic acid (NeuAc) by N-acetylneuraminic acid 9-
phosphatase. N-Acetylneuraminic acid is then activated by conjugation to 
CTP by N-acetylneuraminyl cytidyltransferase, forming cytidyl N-
acetylneuraminic acid 5-phosphate, cytidylmonophosphate (CMP)-NeuAc. 
This reaction occurs in the nucleus. In animal and plant cells, the transfer of 
sialic acid, as CMP-NeuAc, to acceptor carbohydrates takes place in the 
Golgi apparatus; thus, CMP-NeuAc needs to be transported to the lumen of 
the Golgi by the CMP-NeuAc transporter. Once there, CMP-NeuAc is 
transferred to acceptor glycans by various sialyltransferases (Figure1.13) 
101,102.     
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Figure 1.13 PolySia biosynthesis and activation pathways 
102,103 
 
The promiscuity of the polySia biosynthesis pathways has been exploited by 
several studies to remodel the cell surface landscape of tumours both in vitro 
and in vivo. Unnatural N-acyl D-mannosamines are an example of agents 
designed for the inhibition of NCAM polysialylation. These compounds were 
modified N-acetylmannosamines (ManAc) (Figure 1.14) (the physiological 
precursor of sialic acid) ultimately resulting in the introduction of unnatural 
sialosides into surface glycoconjugates 103, where the quaternary complex, 
transiently formed between the polysialyltransferases and NCAM in the Golgi 
apparatus, becomes destabilised by non-natural sialic acids, leading to a 
premature dissociation of NCAM and thus to a premature cessation of the 
polymer chain synthesis 104. In addition, these modifications serve to 
increase the immunogenicity of these antigens or, alternatively, to 
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metabolically label the tumour cells with non-natural sialic acids, followed by 
their specific targeting with therapeutic antibodies 103. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.14 Chemical structure of N-Acetyl mannosamine (A), general structure of N-acyl 
modified derivative (B) and chemical structure of cytidine monophosphate (C) 
105
. 
 
Different mannosamines have been studied for their ability to inhibit polySia 
biosynthesis. Flow cytometry and specific antibodies to different cell surface 
polySia have demonstrated that the unnatural sialic acid precursors ManProp 
and, significantly, ManBut are incorporated into growing polySia chains. 
ManBut was additionally found to inhibit the polySia biosynthesis process 106. 
A study performed by Horstkorte R. et al showed that using mutant Chinese 
hamster ovary (CHO) cells, which express polySia-free NCAM, stably 
transfected with ST8SiaII and IV, respectively and treating both cells with 
ManProp resulted in a reduction of polySia synthesis in cells expressing 
ST8SiaII but not ST8SiaVI which can be used to study the differences 
between ST8SiaIV and ST8SiaII activity.  
Small-molecule inhibitors such as N-butanoyl mannosamine (ManBut) and 
N-propanoyl mannosamine (ManProp) have the advantages of temporal 
control and reversibility. Transient disruption of polySia expression by N-
acylmannosamines might be used to study the roles of polySia in modulating 
(A) (B) 
(C) 
41 
 
cell adhesion and tumour metastasis. However, this evidence is the subject 
of debate since some studies argue against the ability of these unnatural 
sialic acid precursors to inhibit the NCAM polysialylation process, claiming 
that although N-acylmannosamine treatment results in lower expression of 
polySia, neither of the small molecule sialic acid precursors behave as 
metabolic inhibitors nor abrogated polySia expression 103,106. These 
contradictory reports in the literature are a focus of some of the work 
presented in this thesis: some of the experimental data generated in this 
thesis addresses these issues. 
1.7.2. Cytidine monophosphate (CMP) 
  
Several studies have shown that feeding cells N-acylmannosamines can 
inhibit polyST activity 106. In these studies, it was essential that all of the 
enzymes required for CMP-NeuAc synthesis noted above (Section 1.7.1.) 
tolerate the increase in size of the N-acyl group from an acetyl to a butyl 
group. In contrast, polysialyltransferases, in particular ST8SiaII (STX), utilise 
higher N-acylmannosamines (such as CMP-N-butylmannosamine) much less 
efficiently than CMP-N-acetylneuraminic acid. This inhibition leads to 
decreased synthesis of polySia by ST8SiaII. These observations suggest 
that glycosylation efficiency may decrease substantially when the structure of 
a precursor carbohydrate residue is modified 101. 
A variety of nucleotides and nucleosides have been evaluated for their effect 
on inhibition of polySia formation. Of the nucleotides studied, CMP was the 
most active, inhibiting sialoprotein assembly by 74.5% at a concentration of 1 
mM in an in vitro study as measured by Lary J. et al. Cytidine diphosphate 
and triphosphate were less effective, inhibiting by 51 and 37%, respectively, 
at a concentration of 2 mM. The monophosphate derivatives of adenosine, 
uridine, and guanosine inhibited this process by 42, 46, and 40%, 
respectively, but were less active than CMP. Similar results existed for the 
diphosphate nucleotides 107. Most of these studies were performed on cell 
lysates so direct enzyme inhibition by the nucleotides was not determined. 
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The cytidine compound has been more recently shown to inhibit 
polysialyltransferase in a competitive fashion 108,109. It appears that the 
nucleotide portion of the nucleotide-sugar binds directly to the active or 
regulatory site of the enzyme. Indeed, it is for this reason that analogues of 
CMP rather than of sialic acid have been tested for their inhibitory activity 
toward polysialyltransferase. However, it was found that CMP or its 
derivatives 2-O-methyl CMP and 5-O-methyl CMP, although being able to be 
transported to the Golgi apparatus and to compete with CMP-NeuAc, only 
decrease the expression of cell surface polySia by 30–40% 101. Since CMP 
may be converted and used for many natural synthetic reactions, the use of 
CMP may have unwanted side effects. Besides, CMP lacks drug-like 
properties since it is very polar and charged (Figure 1.14C). For these 
reasons CMP is likely to have limited therapeutic potential. However it can be 
used as a useful tool for studying polysialyltransferase enzyme activity. Until 
now, polySia could be efficiently modulated only by genetic manipulations or 
by enzymatic digestion 59,101,106.  
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1.8. Aims of the study 
 
The ultimate aim of the wider project for which the work presented in this 
thesis is a part, is to develop a potent polysialyltransferase inhibitor anti-
metastatic drug that helps improve the prognosis of neuroblastoma patients.  
The major aim of the work presented is this thesis was to design a 
quantitative, rapid and reliable cell-free assay to enable the analysis of 
potential polysialyltransferase inhibitors. A further aim was the development 
of quantitative cell-based methodology for analysis of tumour cell-surface 
polySia expression.  
Having successfully established both cell-free and cell-based assays, the 
goal was to evaluate potential polyST inhibitors, and to identify promising hits 
for more detailed study. Effects of polyST inhibition on a key facet of the 
metastatic process was explored, namely migration. Furthermore, effects of 
inhibition on key intracellular signalling pathways were explored, and the 
potential involvement of polySia on cellular behaviour under hypoxic 
conditions was investigated. 
These aims were achieved through the following objectives: 
 The development and optimisation of a cell-free chromatographic assay 
that can provide an accurate and robust quantitative analysis of polyST 
small molecule inhibitors.  
 The development of a cell-based chromatographic target assay in order to 
quantify the effect of the polyST inhibitors on polySia expression.  
 Evaluation of polyST inhibitors and selection of promising molecules for 
further investigations, using both cell-free and cell-based chromatographic 
assays. 
 Analysis of the ability of the promising inhibitors to inhibit neuroblastoma 
cell migration and to assess selectivity utilising isogenic cells. 
 Investigation of the possible additive anti-migratory effects of using these 
pathway inhibitors in combination with an ST8SiaII inhibitor. 
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 Evaluation of the potential role of polySia expression on cancer cell 
behaviour under hypoxic conditions. 
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Chapter 2. Development of cell-based and 
cell-free chromatographic assays for 
evaluation of polysialyltransferase 
(ST8SiaII) inhibitors 
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2.1. Introduction 
 
Despite their abundance and crucial rule, analysing glycosyltransferases is 
still challenging. The lack of efficient techniques for high throughput, 
sensitive and quantitative assessment of enzyme inhibition is one of the 
major factors that hinder the progress of drug discovery in the 
polysialyltransferase (polyST) area of glycoscience 110.  
Human sialyltransferases (STs) are a functional family of at least 18 different 
intracellular, Golgi membrane-bound glycosyltransferases 111. These 
enzymes have a slightly different enzymatic specificity when compared to 
each other 43. Studying polySTs presents particular challenges since they 
are less catalytically active than the majority of the ST family 112 and the 
catalytic mechanisms underpinning their function are still poorly understood. 
PolySTs could be considered as one of the few STs which are specific for a 
particular protein type, and in this case recognition seems to be dependent 
on the final folded form of the protein acceptor 45. All of these factors dictate 
a pressing need for a new strategy to assay polyST inhibition.  
The methods already described as ST assays in the literature can be broadly 
divided into four groups: radioactive assays, non-radioactive assays, 
phosphatase-coupled assays and chemical conjugation methods. These 
have been summarised in Table 2.5. The use of methods which involve 
chromatography for data analysis have been found to have many 
advantages over other techniques; they allow not only sensitive and 
quantitative analysis of glycosyltransferase activity, but can also reveal 
product profile characteristics for each enzyme. In this study we are 
interested in improving a chromatographic technique to make it utilisable for 
high throughput analysis of human polysialyltransferase activity and polyST 
inhibition. 
In order to develop an efficient method for polysialyltransferase analysis, the 
available techniques have been reviewed in order to understand the 
advantages and disadvantages of each technique to optimise an assay that 
evades the disadvantages and preserves the required qualities. 
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2.1.1. Radioactive assays 
 
Radioactive assays for analysis of polyST activity typically involve monitoring 
the transfer of radiolabelled sugars, most frequently radiolabelled CMP-[14C]-
NeuAc is used as a donor substrate 113, from the donors to acceptors where 
the detection of radioactive transfer requires the separation of products from 
substrates, which is typically achieved using methods such as filtration plate, 
column or thin-layer chromatography. Both identification and quantification of 
the reaction product are usually carried out using SDS-PAGE (sodium 
dodecyl sulphate polyacrylamide gel electrophoresis) and autoradiography 
114-116. 
The use of this assay for analysis of polySTs (ST8SiaII and ST8SiaIV) was 
described in different studies. For example, in a study carried out by Monika 
Marks et al., using a radioactive assay system, a clear difference in the 
ability of ST8SiaII and ST8SiaIV to polysialylate NCAM was demonstrated. In 
this study, Ig-purified recombinant zebrafish polySTs (ST8SiaIV and 
ST8SiaII) and NCAM proteins were incubated overnight in media containing 
the radioactive-labelled donor substrate CMP-[14C]Neu5Ac. The ability of 
both enzymes to polysialylate NCAM with the radioactive CMP-[14C]Neu5Ac 
was examined. The results were analysed using SDS-PAGE and 
autoradiography 116.   
The use of radioactive assays for analysis of polyST enzyme activity has 
been optimised in various studies. For example, in a study by Fukuda et al., 
an assay was optimised for the analysis of human ST8SiaIV. The enzyme 
activity was measured by incubating α-2,3-linked sialic acid in sodium 
cacodylate buffer and CMP-[14C]NeuNAc. To this substrate solution, the 
human ST8SiaIV enzyme solution was added. The product was directly 
subjected to SDS-PAGE and the incorporated radioactive sialic acids were 
visualised by fluorography 117. Another study involved the optimisation of 
different aspects of this assay; study by Liepkans et al., investigated the 
optimisation of the aforementioned assay conditions by using colorectal 
carcinoma cells (SW1116) membrane fractions instead of recombinant 
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enzyme as a source of ST8SiaIV 118. Optimising the assay through 
characterisation of the acceptor preference, by testing the ability of the 
ST8SiaIV enzyme to use different polysaccharides as acceptors was also 
performed 119. 
To sum up, radioactive analysis has been a useful approach for polyST 
analysis for over thirty years. The assay has been optimised in several 
studies, which has resulted in a highly sensitive and reliable method for 
polyST activity analysis. However, there are some major drawbacks to this 
technique. The technique does not show the characteristics of the reaction 
product in terms of polySia chain length (or molecular weight), which results 
in a failure to characterise any differences between the ST8SiaII and 
ST8SiaIV enzymes. Another disadvantage of the assay is that, to-date, the 
assay is not optimised for high throughput analysis, which is a significant 
requirement in the drug discovery field; the screening attrition rate in current 
drug discovery protocols suggests that one marketable drug emerges from 
approximately one million screened compounds. This leads to pressure to 
screen larger libraries in order to continue the pipeline 120,121. 
2.1.2. Non-radioactive assays 
 
Non-radioactive analysis of polySTs relies on reagents that can specifically 
bind to and thus detect substrates or products, such as fluorescent 
chemosensors, e.g. trisialyl lactoside (GT3), and enzyme-linked assays 122. 
The use of this technique has been described in a number of studies 
100,123,124. Most of the enzyme-linked assays depend on detection of polySia 
chains using anti-polySia antibodies (12E3, 12F8 or m735) such as enzyme-
linked immunosorbent assay (ELISA), which can efficiently detect both 
bacterial and human polySia 125.  
Unlike radioactive assays, optimisation for this technique for high throughput 
analysis has been achieved. In a study by Ching-ching Yu et al., a trisialyl 
lactoside (GT3) (Figure 2.15) serving as the acceptor substrate (in place of 
NCAM) was immobilised on a 384-well plate by click chemistry. Incubation 
with bacterial ST8SiaIV and CMP-sialic acid for 30 min resulted in 
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polysialylation. The immobilised polySia was then directly detected using a 
green fluorescent protein (GFP)-fused polySia-binding protein consisting of 
the catalytically inactive double mutant of an endosialidase (GFP-EndoNF 
DM) 126. This assay showed robust and reliable high throughput analysis of 
polySTs inhibitors. 
 
  
 
 
 
 
Figure 2.15 Chemical structure of trisialyl lactoside (GT3)(n=2) 
126
. 
Although high throughput analysis of polySTs inhibitors was achieved with 
this protocol, only bacterial polySTs enzymes were successfully analysed. 
Human PolySTs belong to CAZy family GT-29 while bacterial polySTs are 
grouped into their own CAZy family, GT-38 60. Mammalian and bacterial 
PolySTs share no significant sequence similarity. Although they both 
catalyse the same reaction, different cellular environments and different 
acceptor substrates are involved 126. Subsequently, high throughput analysis 
techniques specific for the human enzymes must be optimised. 
In summary, non-radioactive assays have yet to provide high throughput 
analysis of the human polySTs enzymes. They also have the disadvantage 
of the sensitivity of the results to the reaction conditions, such as non-specific 
antibody binding with enzyme-linked assays and background fluorescence 
associated with the use of GFP for the detection of enzyme inhibition 127,128. 
2.1.3. Phosphatase coupled assay 
 
The phosphatase coupled assay depends on the release of inorganic 
phosphate quantitatively from the leaving nucleoside phosphates (CMP-sialic 
acid) produced during polyST reactions. The released phosphate is then 
detected using malachite green phosphate detection reagent 122. 
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Phosphatase coupled assays have previously been used for the analysis of 
several enzymes, such as sulfotransferases. Sulfotransferases are a group 
of enzymes that transfer sulfate from the donor substrate 3’-
phosphoadenosine-5’-phosphosulfate (PAPS) to various acceptor 
substrates, generating 3’-phosphoadenosine-5’-phosphate (PAP) as a by-
product. Golgi-resident PAP-specific 3’-phosphatase is used to release the 
3’-phosphate from PAP, generating 5’-adenosine monophosphate (5’-AMP) 
129. The assay was also successfully applied to a number of different 
enzymes such as human glucokinase 111, and flaviviral RNA-dependent RNA 
polymerase (RdRp) enzymes 122. 
Using this assay allowed the analysis of a wide range of sialyltransferase 
enzymes. It was optimised for the analysis of human ST8SiaII enzyme, 
because the assay detects the leaving nucleotides common to most 
glycosyltransferases, the method may be universally applied to all enzymes 
of this nature (Figure 2.16) 122,130. 
 
 
 
 
 
 
Figure 2.16 Schematic representation of phosphatase-coupled glycosyltransferase assay. This 
strategy can be applied to any glycosyltransferase reaction where the leaving group contains a 
removable phosphate. Glycosyltransferase reaction with a monophosphonucleotide leaving 
group can be coupled to a 5′-nucleotidase. The inorganic phosphate released by the coupling 
phosphatase may be detected using various phosphate detection reagents 
131
.  
 
Key advantages of this approach are that it eliminates the need for both 
radioisotope labelling and substrate-product separation, and is high-
throughput compatible. This method can be used to obtain accurate kinetic 
parameters of the glycosyltransferase such as Michaelis–Menten kinetics 
(Km and Vmax values) and can be performed in multi-well plates and 
quantitated by a plate reader, thus making it amenable to high-throughput 
screening. 
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However, the assay shares a major drawback with the other aforementioned 
assays, which is the inability to provide sufficient resolution to characterise 
individual product lengths; i.e. it cannot be used to study the way the enzyme 
affects polySia chain length. Therefore this assay cannot provide detailed 
analysis of ST8SiaIV/ST8SiaII inhibition. Furthermore, the assay lacks 
sensitivity, with large concentrations of enzyme and substrate (NCAM) 
required. 
2.1.4. Chemical conjugation assay 
 
Relatively little is known about the precise molecular mechanisms underlying 
the polysialylation process. Such mechanistic investigations require sensitive 
and accurate methods that provide quantitative information and single 
product resolution.  
A range of fluorescently-labelled ganglioside analogues such as GT3–
FCHASE [6-(fluorescein-5-carboxamido) hexanoicacid N-
hydroxysuccimidylester], trisialyllactosyl–BODIPY (boron dipyromethene) 
and GD3–FCHASE have been used as a fluorescent acceptor molecule for 
the polysialylation reaction, combined with HPLC–FD. This technique has 
been used for bacterial polysialyltransferase characterisation and 
represented a major advance in this field, since it allowed HPLC-mass 
spectrometric analysis of the reaction product.  In this assay, the tri-sialylated 
oligosaccharide GT3-FCHASE is incubated with the polyST enzyme and the 
soluble product contained in the supernatant is analysed by HPLC. 
These acceptors have been shown to prime the polysialyltransferases 
from Escherichia coli K1, E. coli K92, Neisseria meningitidis serogroup B 
(NmB), and N. meningitidis serogroup C (NmC). Although these fluorescent 
acceptors provided mechanistic understanding into bacterial 
polysialyltransferase activity through providing molecular weight data of the 
product, the structures are fairly challenging owing to multistep chemo-
enzymatic syntheses. Most of the available fluorescent-tagged acceptor 
substrates require significant work to produce a milligram of pure compound. 
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Besides, these fluorescent acceptors have not been shown to prime 
mammalian polySTs 132.  
To sum up the findings obtained by reviewing the available methods for 
polySTs assessment, the ideal assay for ST8SiaII analysis should have the 
following features: ability to show the characteristics of the reaction 
product(s) in terms of polySia chain length (or molecular weight) in order to 
enable characterising the enzyme inhibition; allows for high throughput 
analysis of enzyme inhibitors and rapid analysis of results; the acceptor 
should ideally be a reagent that is readily available (or can be easily 
synthesised) and efficiently prime the human ST8SiaII enzyme and finally, 
the results should be reproducible and reliable. 
A study by Keys G. et al., used a new non-ganglioside fluorescent acceptor 
consisting of a trimer of α2,8-linked Sia (DP3) directly conjugated to a 1,2-
diamino-4,5-methylenedioxybenzene (DMB) label, which is synthesised in a 
single step from commercially accessible reagents (Figure 2.17) 132. This 
acceptor was found to offer a quantitative and high-resolution analysis of 
bacterial polySTs and was also shown to be useful for a mammalian (murine) 
enzyme. A comparative analysis carried out with a panel of six polySTs 
emphasised different mechanisms of chain elongation and subsequently 
dramatic differences in the length distribution of products. Altogether, the 
DMB–DP3 acceptor and HPLC–FD analysis provides a way to a complete 
mechanistic characterisation of the human polySTs 109. However the assay 
conditions were not optimised to be used for high throughput analysis.  
Here the use of DMB-DP3 as an acceptor for ST8SiaII was adapted in order 
to design a simple, reliable and high throughput assay. The principal of the 
developed assay is to optimize the conditions of the polysialylation reaction 
of DMB-DP3 with human ST8SiaII enzyme in order to yield a single product 
DMB-DP4 with one extra sialic acid added to the acceptor molecule. The 
product DMB-DP4 is the then quantified in the presence/absence of different 
ST8SiaII inhibitors and the percentage inhibition of product formation caused 
by each inhibitor is quantified (Figure 2.17).  
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Figure 2.17 Chemical reaction of DMB-DP3 synthesis 
133
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
54 
 
2.1.5. Aims and objectives 
 
In this chapter, optimisation of the conditions for a cell-free HPLC 
chromatography assay for use in simple, quantitative and high throughput 
analysis of small molecule polyST inhibitors is described. Furthermore, the 
development of a cell-based-HPLC technique for quantitative analysis of 
polySia expression is also reported. Cell-based assays can be distinguished 
from cell-free assays by the fact that cell-based assays offer the advantage 
of examining inhibitors within the full cellular context and functionality, in 
terms of the cell-signalling pathways, as it relates to the function of the 
ST8SiaII enzyme. 
A cell-based polyST inhibition assay that examines the recovery of polySia 
expression after biological removal (using the Endo-N enzyme), in the 
presence or absence of different polyST inhibitors has been previously 
reported 109. However, whilst this assay is effective, it has the disadvantage 
that it does not mimic the likely scenario in vivo, since in practice a polyST 
inhibitor will be administered to cells that already express polySia on the cell 
surface 109. 
In the cell-based assay described in this chapter, polySia chains from the 
cancer cell membrane were carefully cleaved using mild acidic hydrolysis or 
Endo-N enzyme after the incubation of the cell with different polyST 
inhibitors. The released polySia is then hydrolysed into sialic acid monomers, 
which are quantified with multiple reaction monitoring using ultra high-
pressure liquid chromatography (UPLC/MS/MS) and compared with the 
released sialic acid from untreated cells.  
Multiple Reaction Monitoring (MRM) is a type of highly selective (targeted) 
mass spectrometric analysis that allows fine-tuning of mass spectrometer to 
specifically detect molecular weights of interest. This approach allows for 
greater specificity, sensitivity, speed and quantitation of polyST inhibition 134. 
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The released sialic acid monomers were also examined using mass 
spectrometry in order to analyse any modification to the polySia structure 
caused by administration of N-acylmannosamine compounds. 
The results obtained from the cell-free assay were linked to the results 
obtained using SH-SY5Y neuroblastoma cells (which express ST8SiaII) in 
the developed cell-based assay. This enabled correlation of the results 
obtained from the cell-free assay to the effect of the inhibitor in the complex 
conditions of the cellular environment and also allowed for study of 
mechanistic aspects of different polyST inhibitors in vitro. 
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Table 2.5 Comparison of the commonly used methods for the assessment of sialyltransferase 
enzyme activity. 
    Method Principle Advantages Disadvantages 
Radioactive 
methods 
Monitoring the transfer 
of radiolabelled sugars 
from the donors to 
acceptors where the 
detection of radioactive 
transfer requires the 
separation of products 
from substrates, which 
is typically achieved 
using methods such as 
column or thin layer 
chromatography 
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Highly sensitive 
 
Reproducible 
 
Can be used for 
quantitative and 
qualitative analysis 
 
Amenable to high 
throughput analysis 
Time-consuming 
 
Special precautions are needed 
for the handling of radioactive 
materials 
Non-
radioactive 
methods 
Relies on reagents that 
can specifically bind to 
and thus detect 
substrates or products, 
such as fluorescent 
chemosensors that bind 
to nucleotide leaving 
groups and enzyme-
linked antibodies that 
bind to glycan products 
114,132
 
High specificity 
 
Safe to perform 
Time consuming 
 
The results are very sensitive to 
the reaction conditions 
Chemical 
conjugation 
methods 
Involves chemical 
conjugation on either 
donor or acceptor 
substrates, such as 
fluorescent-tagged 
acceptor substrates 
132
 
Quantitative 
 
High resolution analysis 
The use of HPLC needs special 
training 
 
Most of the available 
fluorescent-tagged acceptor 
substrates require significant 
work to produce a milligram of 
pure compounds 
 
To date, there is no such high 
resolution/high throughput 
assay system has been 
reported for the human 
polysialyltransferases analysis 
 
It is more difficult to attach 
labeled polySia than one 
labeled sialic acid monomer due 
to steric hindrance that is why it 
is more complicated to use this 
technique to assay 
polysialyltransferase than 
sialyltransferases. 
Phosphata-
se coupled 
assay 
Depends on the release 
of inorganic phosphate 
quantitatively from the 
leaving nucleoside 
phosphates produced 
during 
glycosyltransferase 
reactions 
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Can be used to obtain 
kinetic parameters of 
the glycosyltransferase 
 
High throughput 
screening 
 
Have been applied 
successfully to a wide 
range of 
glycosyltransferases 
including 
sialyltransferases 
Using this assay for testing 
glycosyltransferase enzymes 
couldn’t show a product profiles 
characteristic for each enzyme 
 
Insufficient resolution to 
characterise individual product 
lengths (can’t be used to study 
the way the enzyme is affecting 
the chain length) 
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2.2. Material and methods 
 
All general chemicals, media and media supplements were obtained from 
Sigma-Aldrich (Poole, UK) unless otherwise specified. Endo-N was obtained 
from Abcys (Paris, France). Human recombinant ST8SiaII was obtained from 
R&D Systems, United Kingdom. 
A) Cell-free chromatographic assay 
2.2.1. Gel electrophoresis and western blot analysis 
2.2.1.1.    Sample preparation 
 
Samples were prepared by incubating NCAM (2.5 ng/µL) with human 
ST8SiaII enzyme (12.5 ng/µl) suspended in manganese chloride (10 mM) 
and sodium cacodylate buffer (10 mM, pH 6.7) for five minutes at 37°C, the 
reaction then was started by adding CMP-N-acetylneuraminic acid (CMP-
Neu5Ac, 10 mM) and incubated at 37°C for 30 minutes. A negative control 
was prepared without the ST8SiaII enzyme to compare the results. Samples 
for analysis were incubated in one-quarter the final volume of loading buffer 
composed of Tris HCl (180 mM, pH 6.8), 40% glycerol, 4% SDS, 0.04% 
bromophenol blue and β-mercaptoethanol (200 mM). 
Samples were denatured by heating at 75°C for 10 minutes, cooled to room 
temperature and then loaded onto SDS-polyacrylamide gels consisting of 5% 
stacking gel and 6% resolving gel. The resolving gel was made up of tris 
base (0.37 M, pH 8.8), 6% acrylamide mix, 0.1% SDS, 0.1% ammonium 
persulfate and 0.08% TEMED, while the stacking gel was made of tris base 
(0.12 M, pH 6.8), 5% acrylamide mix, 0.1% SDS, 0.1% ammonium persulfate 
and 0.1% TEMED, both gels were prepared in distilled water. SDS-
polyacrylamide gels were stacked in an electrophoresis tank (BioRad, UK) 
filled with running buffer which consists of tris base (19 mM), glycine (192 
mM) and 0.2% SDS at pH 8.3. Besides the samples, one lane of the stacking 
gel was loaded with PageRuler plus pre-stained protein ladder (Fermantas, 
UK), electrophoresis was run at 20 mA for an hour and half. 
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2.2.1.2. Protein transfer from gels to PVDF membrane  
 
Blots were generated by transferring proteins from the gels to ethanol pre-
soaked polyvinylidene difluoride (PVDF) membranes using a transfer kit 
immersed in transfer buffer consisting of tris-base (19 mM), glycine (192 
mM), 0.04% SDS and 20% ethanol. The transfer was carried out at 40 mA 
for approximately 1.5 hours.  
2.2.1.3. Incubation of membranes with antibodies 
 
Blotted membranes were blocked by incubation with skimmed milk (0.05 
g/ml) prepared in 0.05% PBSB for an hour at room temperature. Membranes 
were then incubated in 1:3500 mouse anti-polySia-NCAM mAb overnight at 
4°C. Afterwards, membranes were washed three times with 0.05% PBSB 
each for 15 minutes and were incubated with 1:3500 HRP-labelled rabbit 
anti-mouse mAb for an hour at room temperature, then membranes were 
washed 3 times again with 0.05% PBSB buffer (each 15 minutes). 
2.2.1.4. Protein detection in membranes. 
 
Membranes were exposed to ECL chemiluminescent agent as described by 
the manufacturer, drained from excess agent and then exposed to X-ray film 
processor for 10 minutes. Films were then developed using Ilford film 
processor (Harman, Germany). 
2.2.1.5. ST8SiaII inhibition by CMP  
 
PolyST enzyme (ST8SiaII) and neural cell adhesion molecule (NCAM) were 
treated with various concentrations (0.1-10 mM) of cytidine monophosphate 
(CMP) and cytidine (5 mM), the reaction was initiated by the addition of the 
sugar-nucleotide donor, CMP-Neu-5Ac, and incubated for 30 minutes at 
37°C and then analysed on 6% SDS-polyacrylamide gel electrophoresis as 
described before. The reaction mixture of the samples is summarised and 
described below (Table 2.6) 
 
59 
 
Table 2.6 The reaction mixture for western blot analysis of the polysialylation of NCAM with 
ST8SiaII enzyme in the presence/absence of enzyme inhibitors at different concentrations (the 
concentrations in this table are the final concentrations of the reaction mixture).  
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2.2.2. High performance column chromatography analysis  
2.2.2.1. Analysis of sialic acid 
 
For labelling of sialic acid with the fluorescent dye 1,2-diamino-4,5-
methylenedioxybenzene (DMB), sialic acid (32.3 mg/ml) was dissolved in 
DMB (20 mM) with sodium hydrosulfite (40 mM) and β-mercaptoethanol (1 
M). The polySia solution was then mixed with an equal volume of ice-cold 
trifluoroacetic acid (40 mM, TFA). The reaction mixture was incubated for 24 
hours at 4°C. After the incubation was completed, the derivatisation reaction 
was stopped by the addition of one-fifth reaction volume of sodium hydroxide 
(200 µM). Aliquot of 1 µL of the reaction mixture was separated, diluted with 
99 µL of tris (100mM, pH 8.0)/ EDTA (5 mM) buffer and analysed by HPLC. 
2.2.2.2. Analysis of polySia chains 
2.2.2.2.1. Conditions of polySia labelling reaction 
For polySia labelling, the same conditions used for sialic acid labelling were 
used however, the concentration of polySia used was (10 mg/ml) instead of 
(32.3 mg/ml).  
2.2.2.2.2. HPLC analysis 
 
A Waters 2695 Alliance HPLC system operated by Masslynx software was 
connected with fluorescence (RF-10A) (Shimadzu, Japan) and photodiode 
array detectors (Waters 2996) (Waters, UK) and used to analyse samples. 
Separation was achieved using DNAPac© PA-100 analytical anion exchange 
column with diameters of 4 x 250 mm packed with 0.1 µM microbeads 
(Dionex, UK). DMB fluorescence (excitation 373 nm/emission 456 nm) was 
monitored with a fluorescence detector. The mobile phases used were: 
100% water (mobile phase A) and ammonium acetate buffer (5 M, pH 7.4, 
mobile phase B) with the following gradient (Table 2.7). The total run time 
was adjusted to 182.5 minutes followed by washing the column for up to 240 
minutes with 5.0 M ammonium acetate buffer. 
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Table 2.7 HPLC gradient for analysis of DMB-labelled polySia(Flow rate 1 ml/min)  
 
Time (minutes) % Mobile phase A % Mobile phase B 
0 100 0 
5 100 0 
15 92 8 
20 90 10 
35 87 13 
55 84 16 
145 75 25 
182.5 60 40 
190 0 100 
210 100 0 
240 100 0 
 
2.2.2.3. Optimisation of the DMB-labelling conditions 
 
In order to determine the optimum conditions for the polySia-DMB labelling 
reaction, different conditions of the reaction were explored, including different 
incubation times (30 minutes, 24, 48 hours), temperature (4, 50 °C) and 
different concentrations of the substrate. The efficiency of the assay was 
then determined by HPLC analysis. 
2.2.2.4. Analysis of polysialyltransferase (ST8SiaII) enzyme activity 
using DMB-DP3 
2.2.2.4.1. DMB-DP3 Labelling reaction and purification 
 
For the DMB labelling of DP3, the same conditions as polySia labelling were 
used. After the incubation was completed, the derivatisation reaction was 
stopped by the addition of sodium hydroxide (40 mM). The sample was 
diluted in distilled water (1:1) and then separation of the sample was 
accomplished by using two different systems: anion exchange 
chromatography or reversed phase chromatography. 
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DMB-DP3 purification by reversed phase chromatography  
Separation was achieved by reversed phase chromatography on a Hichrom 
RPB C18 column (25 cm x 4.6 mm, 250 A) (Hichrom, UK). Chromatography 
was performed at 1.2 ml/min with ammonium formate (5 mM, pH 6) (mobile 
phase A) and 55% methanol (mobile phase B). The elution of DMB-DP3 was 
performed with a linear isocratic method of 90 %: 10 %, mobile phase A: 
mobile phase B over 70 minutes. The separation was monitored by mass 
spectrometer (Waters ZMD) (Micromass, United Kingdom), photo diode 
array detector (373, 303 and 250 nm) and fluorescence detector (RF-10A), 
(excitation 373, emission 484 nm). A single fraction containing the DMB-DP3 
was collected (confirmed by detecting the molecular weight and comparing 
the retention time with standard DMB-DP3). Fractions from several runs 
were pooled and freeze dried. The dried material was weighed and dissolved 
in water to form 200 µM DMB-DP3 solution and stored at -20°C. 
DMB-DP3 purification by anion exchange chromatography  
A Waters 2695 Alliance HPLC system operated by Masslynx software was 
connected with fluorescence and photodiode array detectors and used to 
analyse samples. Separation was achieved using DNAPac PA-100 analytical 
anion exchange column (Dionex, UK) with diameters of 4 x 250 mm packed 
with 0.1 µM microbeads, DMB fluorescence (excitation 373 nm/emission 
456 nm) monitored with a fluorescence detector RF-10 AXL. The mobile 
phases used were: 100% water (mobile phase A) and ammonium acetate 
buffer (5 M, pH 7.4, mobile phase B) for 30 minutes and 1 ml/min flow rate, 
with the following gradient (Table 2.8). 
Table 2.8 HPLC gradient for DMB-DP3 purification using anion exchange chromatography (Flow 
rate 1 ml/min).  
Time (min) % Mobile phase A % Mobile phase B Flow rate (ml/min) 
0 100 0 1 
5 100 0 1 
25 98 2 1 
30 100 0 1 
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The peaks representing DMB-DP3 were collected from several purification 
runs at retention time between 9-11 minutes and freeze dried. The dried 
material was weighed and dissolved in water to form a 200 µM solution and 
stored at -20°C. 
2.2.2.4.2. General procedure for mass spectrometric analysis of DMB-
DP1, 3 and 4 
 
Liquid chromatography-mass spectrometry analysis was carried out using a 
Waters ZMD (Micromass, Manchester, United Kingdom) single quadrupole 
mass spectrometer connected in series to a Water Alliance 2695 system. 
The mass spectrometer was operated in negative ion electrospray mode. A 
solvent flow of 1.2 ml/min (split 1:10) with a nitrogen gas flow of 55.6 litres/h 
and a source temperature of 120°C was used to produce stable spray 
conditions. The cone voltage was set at 30 V, and this gave clear mass -
/spectra from these samples. The mass spectra were continuously scanned 
from m/z 100 to m/z 1500 throughout the entire high-performance liquid 
chromatography separation. Masslynx software was used to process the 
mass spectral data and produce both total ion chromatograms and single ion 
recording chromatograms for the key masses of interest. 
2.2.2.4.3 Measurement of polysialyltransferase (ST8SiaII) enzyme 
inhibition 
 
Human ST8SiaII enzyme analysis  
Recombinant human ST8SiaII enzyme (250 ng/µl) was incubated at 25°C 
overnight in solution of DMB-DP3 (10 to 100 µM), MgCl2 (5 mM), CMP-
Neu5Ac (0.5 mM) and sodium cacodylate buffer (0.1 M, pH 6.7). Aliquots 
were taken after different time points and the reaction was stopped using 10-
fold dilution of tris-HCl (100 mM, pH 8.0)/ EDTA (5 mM). The results were 
compared with a negative control (without the addition of the ST8SiaII 
enzyme). Samples were then analysed by either anion exchange or reversed 
phase HPLC. 
 
64 
 
Analysis of ST8SiaII enzyme inhibition using anion exchange HPLC 
system 
 
A Waters 2695 Alliance HPLC system operated by Masslynx software was 
connected with fluorescence and photodiode array detectors and used to 
analyse samples. Separation was achieved using DNAPac PA-100 analytical 
anion exchange column with diameters of 4 x 250 mm packed with 0.1 µm 
microbeads, DMB fluorescence (excitation 373 nm/emission 456 nm) 
monitored with a fluorescence detector RF-10 AXL. The mobile phases used 
were: distilled water (mobile phase A) and ammonium acetate (0.5 M, PH 
7.4, mobile phase B) with flow rate of 1.2 (ml/min) and the following gradient 
(Table 2.9): 
Table 2.9 HPLC gradient for Analysis of ST8SiaII enzyme activity using anion exchange HPLC 
system 
Time Flow rate (ml/min) % Mobile phase A % Mobile phase B 
0 1.2 100 0 
2 1.2 100 0 
9 1.2 63 37 
11 1.2 100 0 
12 1.2 100 0 
 
Analysis of ST8SiaII enzyme inhibition using a reversed phase HPLC 
system 
 
Reversed phase chromatography on a Hichrom RPB C18 column (25 x 4.6 
mm, 250 Å) (Hichrom, UK). Chromatography was performed at 1 ml/min with 
5 mM ammonium formate (pH 6, mobile phase A) and 100% methanol 
(mobile phase B). The elution of DMB-DP3 was performed with a linear 
isocratic method of 80 %: 20 %, mobile phase A: mobile phase B over 6 
minutes. The separation was monitored by photodiode array detector (373, 
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303 and 250 nm) and fluorescence detector (RF-10A), (excitation 373, 
emission 484 nm). 
Multiple reaction monitoring (MRM) Analysis 
 
DMB-DP3 and DMB-DP4 were subjected to analysis by electrospray UPLC-
MS using an Acquity UPLC Waters system and a Quattro Premier XE 
(Waters corporation, USA) mass spectrometer and an Acquity UPLC BEH 
C18 column (2.1 x 100 mm), the mobile phases used were: ammonium 
formate (5 mM, mobile phase A) and methanol (mobile phase B), with a flow 
rate of 0.3 ml/min and isocratic method of 80% mobile phase A: 20% mobile 
phase B. The peaks and masses were integrated using Masslynx software. 
The source temperature was set at 120 °C. MRM transitions acquired at unit 
resolution in both the Q1 and Q3 quadrupoles to maximise specificity. Cone 
voltage was adjusted to 25 V while collision energy was adjusted to 20 V for 
DMB-DP4 and 30 V for DMB-DP3 using positive ionisation mode. 
2.2.2.5. Analysis of the DMB-DP3 polysialylation reaction kinetics 
(Michaelis-Menten kinetics). 
 
To determine the kinetics of the DMB-DP3 polysialylation reaction by human 
ST8SiaII, activity was determined under the following conditions: ST8SiaII 
(250 ng/µl), MgCl2 (5 mM), CMP-Neu5Ac (0.5 mM) and sodium cacodylate 
buffer (pH 6.7, 0.1 M) and varying amounts of DMB-DP3, total volume was 
adjusted to 20 µl. The reaction mixture was incubated at 25° C for the 
indicated times. The reactions were terminated by adding Tris–HCl (100 mM, 
pH 8.0) / EDTA (5 mM). Samples were analysed using DNAPac PA-100 
analytical anion exchange column as mentioned before (Section 2.2.2.4.3). 
2.2.2.6. Analysis of the assay sensitivity and linearity 
 
In order to determine whether a direct relationship could be established 
between the concentration of the ST8SiaII inhibitor and DMB-DP3 
polysialylation product (DMB-DP4) peak area, known concentrations of CMP 
inhibitor were incubated with the reaction as described above (Section 
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2.2.2.4.3). The product DMB-DP4 peak area was recorded for each point 
and plotted against the corresponding CMP concentration. 
B) Cell-based chromatographic assay of polyST inhibition 
2.2.3. Cell Lines 
 
Human SH-SY5Y neuroblastoma cells, OSC-19 human oral squamous cell 
carcinoma, C6-STX glioma cells were obtained from the cell culture facility at 
the Institute of Cancer Therapeutics, University of Bradford. The 
methodology for the transfection of C6 cells with pcDNA3-STX plasmid 
inserted with cDNA encoded full length human STX, has been reported 
previously 66. This was carried out by collaborator (Dr. Minoru Fukuda) at the 
Sanford-Burnham Institute, La Jolla, CA., USA. 
SH-SY5Y cells were maintained in minimum essential medium (MEM) and 
nutrient mixture F-12 Ham (1:1), supplemented with 10% foetal bovine 
serum, 1% sodium pyruvate and 1% glutamine. OSC-19 cell lines were 
maintained in RPMI medium supplemented with 10% foetal bovine serum, 
1% sodium pyruvate and 1% glutamine while C6-STX glioma cells were 
maintained in MEM Alpha eagle with ultra-glutamine-I, deoxyribonucleoside 
and ribonucleosides supplemented with 10% foetal bovine serum. All cell 
lines were maintained in a humid atmosphere of 5% CO2 and 95% air at 37 
°C. 
2.2.3.1. Cell maintenance 
 
Cell lines were routinely maintained as monolayer cultures in T75 flasks, 
where the medium was changed every 4-5 days. As cells reached 60-85% 
confluency, they were washed with PBS and 5 ml of trypsin was added. Cells 
were then incubated for 5-10 minutes at 37ºC for detachment. After 
detachment, 5 ml of fresh medium was added and the cell suspension was 
centrifuged at 1000 g for 5 minutes. The supernatant was discarded and the 
cell pellet was re-suspended in fresh medium. Cells were stocked at early 
passages and discarded every 8 passages thereafter. 
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2.2.3.2. Cell counting 
 
As cells were detached and re-suspended in a fresh medium, 10 µl of the 
cell suspension was placed on a hematocytometer chamber, according to 
the procedure suggested by Sigma (Cook Book Sept 2010 Volume 12). Cells 
were counted under an inverted microscope at x20 magnification in ten areas 
of the chamber. Cell counts were expressed as (mean of 10 counts) x 104 
cells/ml.  
2.2.4. Growth curve of SH-SY5Y cells 
 
After cells were counted, the cell suspension was diluted in order to have an 
appropriate amount of medium and seeding density (1.5 x 105 cell/ flask). 
Five flasks of each cell line were seeded with the same density. The flasks 
were incubated in a humid atmosphere of 5% CO2 and 95% air at 37 °C. The 
duplicate plates were counted every 24 hours. The results were plotted on a 
log-linear scale. The population doubling time was determined by identifying 
a cell number along the exponential phase of the curve, tracing the curve 
until that number has doubled, and calculating the time between the two. 
2.2.5. Seeding of cell culture dishes 
 
Cells were seeded at the density of 2 x 105 cell/well in a six-well plate and 
incubated for 48 hours at 37°C in a 5% CO2 humidified atmosphere. 
2.2.6. Cell treatment 
 
After 48 hours incubation, different concentrations of ST8SiaII inhibitors (250, 
125 and 25 µM) were added in FBS-free medium (Endo-N protocol) or FBS-
containing medium (mild acidic hydrolysis protocol) and incubated for 24 
hours at 37° C in a 5% CO2 humidified atmosphere.  
2.2.7. Cleavage of polySia from the cell surface 
 
Two different protocols were used to remove polySia from the cell surface, 
namely using Endo-N and mild acidic hydrolysis: 
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2.2.7.1. Endo-N treatment 
 
SH-SY5Y, OSC-19 and C6-STX cells were treated with Endo-N (Abcys, 
France) (0.5, 1 and 3 µg/ml) for (24 hours), one well was used as negative 
control where no Endo-N was added. After 24 hours media were collected for 
analysis. 
 
2.2.7.2. Mild acidic hydrolysis 
 
SH-SY5Y, OSC-19 and C6-STX cells were collected by trypsinisation 
followed by centrifugation for 5 minutes at 1000 g. Cell pellets were treated 
with 100 μL of 0.5% Igepal CA-630 followed by incubation at 37 °C for 1 hour 
and vortexing for 5 minutes in order to solubilise polySia from the cell 
surface. The insoluble material was removed by centrifugation and the 
supernatant was used for analysis.  
2.2.8. Sialic acid labelling 
 
For determination of total Neu5Ac, samples were hydrolysed in TFA (0.1 M) 
for 2 h at 80 °C. TFA was removed under vacuum and the residue was 
incubated with the DMB reagent for 24 h at 4 °C as described previously 
(Section 2.2.2.1). 
2.2.9. HPLC analysis 
2.2.9.1. Mixed phase column-HPLC-fluorescence detector (FD) analysis 
of total sialic acids released from SH-SY5Y cell surface 
 
A Waters 2695 Alliance HPLC system operated by Masslynx software was 
connected with fluorescence (RF-10A) (Shimadzu, Japan) and photodiode 
array detectors (Waters 2996) (Waters, UK) and used to analyse samples. 
An Obelisc™ HPLC column (Sielc technologies, USA) column (with multiple 
separation mode; normal phase HPLC and ion exchange HPLC) was used 
for the separation of DMB labelled sialic acid separated from the cell surface 
and other DMB-labelled components of the cell. DMB fluorescence 
(excitation 373 nm/emission 456 nm) was monitored with a fluorescence 
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detector. The mobile phases used were: A (5 mM Ammonium formate) and B 
(100% acetonitrile) with the following gradient (Table 2.10).  
Table 2.10 Gradient used for the HPLC analysis of total sialic acids released from SH-SY5Y cell 
surface(Flow rate 0.8 ml/min). 
 
Time (minutes) % Mobile phase A % Mobile phase B 
0 0 100 
13 13 87 
14 0 100 
27 0 100 
 
2.2.9.2. Multiple reaction monitoring (MRM) analysis 
 
DMB-DP1 was subjected to analysis by electrospray UPLC-MS using 
Acquity UPLC Waters system and Quatro premier XE (Waters corporation, 
USA) mass spectrometer as described above. Cone voltage was adjusted to 
25 V while collision energy was adjusted to 20 V using positive ionisation 
mode. 
In the MRM assay, on the basis of the channels established in the present 
experiments, 5 μl of labelled samples (using the aforementioned conditions) 
proved to be sufficient for quantitative analysis of the inhibition of polySia 
synthesis caused by ST8SiaII inhibition. 
2.2.10. Immunofluorescence analysis of polySia-NCAM 
2.2.10.1. Coating of cell culture dishes and cell fixation 
 
SH-SY5Y, OSC-19 and C6-STX cells were seeded on cover slips onto six-
well plates (2 x 104 cell/well). Dishes were incubated for approximately 24 h 
at 37 °C, allowing cells to adhere and spread. For the detection of polySia 
inhibition with ICT-3128, cells were treated with different concentrations of 
inhibitor and incubated for 24 hours. Cells were washed twice with PBS and 
then fixed by incubating in 100% methanol (chilled at -20°C) at room 
temperature for 10 min. The cells then were allowed to air-dry for 10 
minutes at room temperature. Cells were rehydrated with PBS for 15 
minutes (three washes of 5 minutes each). 
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2.2.10.2. Blocking and incubation  
 
Cells were incubated with 1.5% normal mouse serum prepared in PBS 
(NRS-PBS) for 10 min to block unspecific binding of the antibodies. After 
removal of serum, cells were immunolabelled with mouse anti-polySia 
antibody (clone: mAb 735, 15 µg/ml) prepared in 1.5% NRS-PBS for 30 
minutes at room temperature for the detection of polySia expression. Cover 
slips were then washed three times in PBS for 5 minutes followed by 
incubation with TRITC-conjugated rabbit anti-mouse (dilution 1:50) 
secondary antibody prepared in PBS for 30 minutes in darkness.  A control 
sample was carried out by adding the secondary antibody only, to establish 
background fluorescence and non-specific staining of the primary antibody. 
2.2.10.3. Counter staining and mounting  
Cover slips were washed three times in PBS for 5 minutes and then 
mounted with Vectashield hardset fluorescent mounting medium containing 
DAPI. The resulting slides were stored at 4ºC until analysis. Samples were 
examined by fluorescence microscopy.  
2.2.11. Statistics 
 
All experiments were repeated three times independently unless otherwise 
specified. Statistical analyses were performed using Excel and GraphPad 
Prism software. Differences between two groups were evaluated with 
Student's t test (Two tailed) where the P value significance is: P value (P) 
>0.05 was deemed not significant, P < 0.05 * was statistically significant, P < 
0.01 ** and P < 0.001*** were statistically highly significant. 
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2.3. Results and discussion  
Section A) Cell-free chromatographic assay for analysis of 
ST8SiaII activity 
2.3.1. Synthesis of DMB-DP3 and validation of labelling protocol 
2.3.1.1. Gel electrophoresis and western blot analysis 
 
Western blot analysis is an established technique for the analysis of NCAM 
polysialylation that has been used in several previous studies 132,136. Western 
blot assay for polysialylation analysis utilises anti-polySia antibody (m735). 
NCAM is used as sialic acid acceptor and CMP-Sia is used as sialic acid 
donor. 
Here, western blot analysis has been used as a pilot experiment in order to 
determine the ability of recombinant human ST8SiaII enzyme to polysialylate 
NCAM in vitro and as a basis for comparison with the newly developed cell-
free HPLC assay (see section 2.3.9). 
NCAM polysialylation by human ST8SiaII 
 
Western blot analysis of NCAM polysialylation by human ST8SiaII illustrated 
the ability of the enzyme to add polySia to the NCAM molecule. PolySia-
expressing NCAM migrated as a large molecular mass band (above 250 
kDa, indicating a range of different polySia chain lengths). A second polySia-
NCAM band was also detected just below the original band, which could 
possibly be explained by the polysialylation of the ST8SiaII enzyme itself, 
since there is precedent in the literature for both ST8SiaIV and ST8SiaII 
enzymes themselves being modified by polySia chains, a process known as 
auto-polysialylation (Figure 2.18) 112,137.  
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Figure 2.18 Polysialylation of NCAM by human ST8SiaII enzyme.Lane 1 represents the negative 
control (without the ST8SiaII enzyme), lane 2 represents the polysialylation reaction. Blot is 
representative of three independent experiments. 
 
2.3.1.2. Validation of DMB labelling protocol using HPLC analysis  
 
The results obtained from western blot analysis confirmed that recombinant 
human ST8SiaII can polysialylate NCAM in vitro. However, this method 
cannot easily be used to screen large numbers of polyST inhibitor 
compounds since it is time consuming and non-quantitative. HPLC 
separation in conjugation with fluorescence detection (HPLC-FD) in contrast, 
potentially enables high throughput, sensitive and quantitative detection of 
polyST activity. As described earlier, DMB-DP3 is a potential acceptor in 
place of NCAM. HPLC was used for two purposes: first to purify labelled 
DMB-DP3 and provide pure material that is efficiently polysialylated by the 
human ST8SiaII enzyme, and secondly to detect polyST activity (and 
therefore polyST inhibitor activity) by determining the percentage of DMB-
DP3 converted to DMB-DP4.  
PolySia chains (in the form of commercially-available colominic acid) and 
sialic acid were first labelled and analysed in order to validate the labelling 
and HPLC analysis techniques. HPLC was then used to determine 
qualitatively and quantitatively the conversion of DMB-DP3 into DMB-DP4.  
2.3.1.2.1. Labelling and analysis of sialic acid  
 
Sialic acid was first labelled in a small scale and analysed by anion 
exchange–HPLC system in order to validate the labelling conditions and to 
choose the appropriate conditions for HPLC analysis before going any 
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further with the polySia and DP3 labelling and analysis. This would 
additionally minimise the cost of the study since sialic acid is much cheaper 
than polySia and DP3-Sia. 
It was found that the procedure used for sialic acid labelling, which was 
performed according to a previously published study 132, were appropriate 
and that the labelled DMB-sialic acid can be effectively detected and 
separated from the other impurities using a DNAPac PA100 anion exchange 
column in conjugation with fluorescence detector RF-10 AXL (excitation 
373 nm/emission 456 nm), as described in the materials and methods 
section, which provided a highly sensitive detection. It was found that the 
peaks could also be detected using photodiode array detector at 303, 250 
and 373 nm (Figure 2.19).  
 
Figure 2.19 Sialic acid labelling reaction detected by photodiode array detector at 303 nm (A), 
373 (B), 250 (C) and blank (D). 
2.3.1.2.2. Labelling and analysis of polySia chains 
2.3.1.2.2.1. Analysis of polySia chains 
  
In order to determine the separation efficiency of the anion exchange-HPLC 
system and the detectability of the DMB-polySia labelled chains by 
fluorescence, a polySia standard (colominic acid, partially hydrolysed and 
purified capsular polysaccharide from E. coli K1) was labelled with DMB at 
(A) 
(B) 
(C) 
(D) 
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4°C for 48 hours (Figure 2.20A). Separation of polySia according to the 
chains length was obtained using anion exchange column chromatography 
and fluorescence detection as described in the material and methods 
section. The separation of the polySia chains via this system depends on the 
difference in the charge: the DNAPac PA-100 analytical anion exchange 
column was used where the stationary phase is positively charged 
(microbead alkyl quaternary ammonium functionalised latex). The longer the 
polySia chain, with the higher negative charge, the higher the interaction with 
the stationary phase, and thus the later the elution from the column. It was 
found that by using a gradient of 5 M ammonium acetate as mobile phase, 
this analytical system was able to separate different chain lengths of polySia 
with excellent resolution (Figure 2.20B). However, it was not possible to 
obtain the mass associated with each peak, since the high ammonium 
acetate concentration of the mobile phase is incompatible with a mass 
spectrometer, a hurdle that has not been solved in any of the previously 
published studies. So far, detection of molecular weight has only been 
achieved by western blot or estimated by counting the number of peaks; the 
first eluted peak is DMB-DP1 then the second is DMB-DP2 and so on 
132,138,139. 
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Figure 2.20 Labelling reaction of polySia with DMB chemical reactions (A). PolySia (colominic 
acid) labelling with DMB as analysed by using HPLC-FD, DNAPac© PA-100 analytical anion 
exchange column (B).  
2.3.1.2.2.2. Optimisation of polySia derivatisation reaction conditions 
 
In order to determine the optimum conditions for the polySia-DMB labelling 
reaction, different temperatures and incubation times (Table 2.11) were 
explored. The efficiency of labelling was then determined after HPLC-FD 
analysis (the efficiency of labelling was determined by calculating the 
(A) 
(B) 
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percentage of the total peak area of each incubation condition compared to 
the total peak area produced by incubating the reaction for 30 minutes at 
50°C). It was found that incubating the reaction at 50°C for 30 minutes 
resulted in the highest total peak area when compared to incubation at 4°C, 
for either 24 or 48 hours. However, short polySia chains were found only 
when the incubation was performed at 4°C, as recorded by the absence of 
any peaks after short elution time (between 1.3 and 10.5 minutes) when the 
reaction was incubated at higher temperature (Figure 2.21A, B and C). This 
suggests that the optimum conditions for polySia derivatisation reaction that 
does not result in the breakdown of short chains, is by incubating at 4°C for 
48 hours. 
Table 2.11 Different conditions for the polySia derivatisation reaction. Relative peak areas 
normalised to the peak area obtained for the 30 min/50°C reaction conditions. These results 
represents mean of two duplicate independent repeats. 
  
Incubation conditions Relative peak area Absolute peak area 
30 minutes 50°C % 100  737537 
48 hours 4°C % 54.61 ± 7.2 402770 
24 hours 4°C % 13.7 ± 5.4 101058 
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Figure 2.21 HPLC chromatograms showing PolySia (colominic acid) labelling with DMB, 
analysed using anion exchange-HPLC after 30 minutes at 50°C (A) and 48 hour at 4°C (B). 
(A) 
(B) 
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Figure 2.21 C. PolySia (colominic acid) labelling with DMB using Anion exchange-HPLC 24 
hours at 4°C. . PolySia chains peaks start at 8.08 minute when the incubation is performed at 
24°C in (B-C) while at (A) smaller chain length are not detected.  
 
 
 
 
 
 
 
 
(C) 
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2.3.1.2.2.3. Optimisation of polySia HPLC analysis conditions 
 
An attempt to optimise the HPLC conditions (running time and gradient) for 
analysis of polySia chains was performed. A simpler gradient with a shorter 
running time (60 minutes instead of 240 minutes) was used and the limit of 
resolution of anion exchange-HPLC-FD method was examined; shortening 
the analysis time would be useful to analyse the effect of different inhibitors 
on the distribution of the chain length of polySia. Although studying this effect 
of polyST inhibitors was not the focus of this particular aspect of the study, it 
is useful to optimise the assay for different possible applications. 
Although the new method was able to separate short chains, it did not show 
the full separation achieved by using the previous longer gradient, which 
means that the short gradient would not be ideal for the analysis of the effect 
of polyST inhibitors on polySia chain length distribution (Figure 2.22). No 
further work was carried out on this optimisation since it was not expected 
that the DMB-DP3 would produce a wide range of different polySia acid 
chain lengths as suggested by previous study 109, which was approved 
during the analysis of the DMB-DP3 polysialylation product. 
 
Figure 2.22 Optimisation of polySia anion exchange-HPLC analysis conditions aiming to reduce 
the running time showing less efficient separation from the previously used longer gradient.  
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2.3.1.2.3. Labelling of DMB-DP3 
 
The same conditions used for polySia (colominic acid) chain labelling were 
successfully used for labelling DP3. However, for the labelled DMB-DP3 to 
be used for the analysis of different polysialyltransferase inhibitors, we had 
the additional requirement of high purity. Therefore the labelling step had to 
be followed with a highly efficient purification step.  
2.3.2. Purification of DMB-DP3 
2.3.2.1. Characterisation of impurities using mass spectrometry 
 
Two different HPLC separation methodologies were used to obtain highly 
pure DMB-DP3: RP-HPLC and anion exchange-HPLC. These systems were 
chosen for the purification of the compound after detailed analysis of the 
impurities to be removed was performed using RP-HPLC-MS. The mobile 
phases used were: mobile phase A (1% methanol, 0.01% formic acid (pH 
3.5) and mobile phase B (55% methanol, 0.01% formic acid, pH 5.8). It was 
found that the DMB-DP3 impurities were mainly: sialic acid monomer (DP1, 
molecular weight 309.2), DMB-DP1 (molecular weight 424.3) and [DMB-DP3 
- H2O] (molecular weight 988.3). [DMB-DP3 - H2O] is thought to be the 
lactonised form of DMB-DP3, which has been reported previously 140) (Figure 
2.23). These impurities have different charges and different polarity, caused 
by carboxylic acids in the different chemical structures, which allows both 
RP- and anion exchange-HPLC system to separate them effectively.  
 
 
 
 
 
  
  
Figure 2.23 Crude DMB-DP3 as detected by LC/MS at 373 nm.The numbers over the peaks 
represent the detected mass/charge (m/z) ratio.  
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2.3.2.2. Optimisation of DMB-DP3 purification conditions 
Reversed phase system 
 
Three systems were used in order to determine the optimum conditions for 
DMB-DP3 purification using RP-HPLC (Table 2.12). The purification of DMB-
DP3 dissolved in distilled water (1 µl DMB-DP3: 1000 µl water) was achieved 
first by RP-HPLC system where the mobile phases used were: 1% methanol, 
0.01% formic acid (pH 3.5) (mobile phase A) and 55% methanol, 0.01% 
formic acid (mobile phase B), the peaks were analysed by mass 
spectrometry. It was found that both lactonised and unlactonised forms of 
DMB-DP3 were detected (Figure 2.25A). 
Table 2.12 Conditions explored for DMB-DP3 purification by RP-HPLC. 
 
  
The formation of the lactonised form of DMB-DP3 during the purification 
process was previously reported in more than one study 132,140,141 and was 
attributed to the acidic conditions (Figure 2.24). In order to prevent the 
lactonisation of DMB-DP3 by reducing the mobile phase pH: Mobile phase A 
was changed from 1% methanol, 0.01% formic acid (pH 3.5) to ammonium 
formate buffer (pH 6). However, it was found that the lactonisation of DMB-
DP3 was not improved using this system (Figure 2.25B). 
System % Mobile phase A % Mobile phase B Method 
1 
1% methanol, 0.01% 
formic acid (pH 3.5) 
55% methanol, 0.01% 
formic acid 
(pH 5.8) 
Isocratic separation 
of 85% mobile 
phase A and 15% 
mobile phase B for 
50 minutes 
 
2 
5 mM Ammonium 
formate buffer  
(pH 6) 
55% methanol, 0.01% 
formic acid 
(pH 5.8) 
Isocratic separation 
of 85% mobile 
phase A and 15% 
mobile phase B for 
50 minutes 
3 
 
5 mM Ammonium 
formate buffer  
(pH 6) 
 
55% methanol 
(pH 7.2) 
Isocratic separation 
of 90% mobile 
phase A and 10% 
mobile phase B for 
50 minutes 
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Figure 2.24 DP3 lactonised forms. Structures of unlactonised alpha-2,8-linked sialic acid trimer 
(1), 1-monolactone trimer (2), 2-monolactone trimer (3), and dilactone trimer (4) 
142
 
 
A third attempt aimed at inhibiting the DMB-DP3 hydrolysis and lactonisation 
was performed by changing mobile phase B from 55% methanol, 0.01% 
formic acid (pH 5.8), to 55% methanol only (pH 7.2) and changing the 
gradient from 85% A, 15% B to 90% A, 10% B so better separation could be 
obtained. This system was found to successfully minimise the lactonisation 
of the DMB-DP3 (calculated by % peak area of lactonised form compared to 
the total peak area). Although, lactonisation was not completely abolished, it 
was found that changing the gradient also resulted in a more efficient 
separation (Figure 2.26). A single fraction containing the DMB-DP3 was 
collected between 11 and 15 minutes. Fractions from several runs were 
pooled and freeze dried. The dried DMB-DP3 was dissolved in water to form 
200 µM solution and stored at -20°C. 
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Figure 2.25 Different systems used for the purification of DMB-DP3. In the first system the used 
mobile phases were: 1% methanol, 0.01% formic acid (pH 3.5, mobile phase A) and 55% 
methanol, 0.01 formic acid (pH 5.8, mobile phase B) (A), in the second system the used mobile 
phases were: Ammonium formate buffer (pH 6, mobile phase A) and 55% methanol, 0.01 formic 
acid (pH 5.8, mobile phase B) (B).  
(A) 
(B) 
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Figure 2.26 Third RP-HPLC system used for the purification of DMB-DP3, the used mobile 
phases were: ammonium formate buffer (pH 6, mobile phase A) and 55%methanol (pH 7.2, 
mobile phase B) (C).  
 
 
 
 
 
 
 
 
 
 
 
(C) 
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Anion exchange HPLC system 
 
DMB-DP3 purification using anion exchange-HPLC was achieved using a 
DNAPac PA-100 analytical anion exchange column, 100% water (mobile 
phase A) and 5 M ammonium acetate buffer (pH 7.4, mobile phase B). Three 
peaks were detected using fluorescence detector. DMP-DP3 was determined 
to be the peak with the retention time of 9.42 min (Figure 2.27A), as 
confirmed by comparing its absorbance spectrum and retention time with 
DMB-DP3 standard (separated by RP-HPLC and its molecular weight 
confirmed using MS) since the mobile phase used in the anion exchange 
HPLC system is not compatible with the MS (5 M ammonium acetate) and 
therefore the DMB-DP3 peak cannot be detected directly by mass 
spectrometry. 
Although the peaks appeared well resolved when using fluorescence 
detection, when examined by the photodiode array detector at 303 nm and 
373 nm, it was found that there are in fact two peaks that are merged under 
the peak representing the DMB-DP3 (Figure 2.27A). In order to separate 
these peaks the gradient was changed (Table 2.13), which resulted in 
complete separation of the two peaks (Figure 2.27B, 2.27C). The peak 
representing DMB-DP3 was collected then from several runs and freeze 
dried, the solid was weighed and dissolved in distilled water to form a 200 
µM solution and stored at -20 °C (Figure 2.27D).  
Table 2.13 Mobile phases gradient and flow rate for DMB-DP3 purification using anion 
exchange–HPLC system. 
 
Time (min) % Mobile phase A % Mobile phase B HPLC Flow rate (ml/min) 
0 100 0 1 
5 100 0 1 
25 98 2 1 
30 100 0 1 
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Figure 2.27 DMB-DP3 purification by anion exchange-HPLC. The peak representing DMB-DP3 at 
9.42 minutes retention time using fluorescence detector was found to be two merged peaks 
when detected by photodiode array at 303nm (A). Changing the gradient that resulted in 
merged peaks (B) to the gradient described in table 2.13, enabled complete separation of the 
two merged peaks (C). (D) Purified DMB-DP3 by anion exchange-HPLC as observed by HPLC-
FD.  
 
 
 
(A) 
(B) 
(C) 
(D) 
87 
 
2.3.3. Evaluation of polysialyltransferase (ST8SiaII) enzyme 
activity 
 
After purification of DMB-DP3 was successfully achieved, the percentage of 
purity was determined. It was found that using the optimized methods the 
synthesised DMB-DP3 had a purity of ≥ 99%. The purity of the synthesised 
compound was calculated by dividing the peak area of the DMB-DP3 by the 
total peak area of all the detected peaks multiplied by 100. Both DMB-DP3 
purified by RP- and anion exchange HPLC was evaluated for their potential 
to act as acceptor for polysialylation reactions catalysed by human ST8SiaII. 
The incubation reaction was first performed according to the method used for 
the bacterial enzyme in a previously published paper 132.  
Human ST8SiaII incubation with the DMB-DP3 purified by RP-HPLC 
 
To determine the activity of human ST8SiaII, the recombinant enzyme was 
incubated at 25°C for 24 hours in 20 µl volume containing, Tris HCl (50 mM, 
pH 8), potassium chloride (25 mM), magnesium chloride (20 mM), 5% 
glycerol, DMB-DP3 (50 µM), sodium cacodylate (10 mM, pH 6.7), CMP-
Neu5Ac (1 mM) and manganese chloride (10 mM). The reaction was 
quenched using a 10-fold dilution of Tris-HCl (pH 8.0, 100 mM)/ EDTA (5 
mM). The results were compared with a negative control (without the addition 
of the ST8SiaII enzyme). It was found that using these conditions, which are 
the same conditions used with the bacterial enzyme in previously published 
paper 109, a very small yield of DMB-DP4 product was observed (Figure 
2.28A). As previously discussed in the introduction, although mammalian and 
bacterial PolySTs catalyse the same reaction, different cellular environments 
and different acceptor substrates are involved and this is likely to be the 
cause of the difference in the yield DMB-DP4. In an attempt to improve the 
efficiency of the reaction, the DMB-DP3 concentration was increased from 50 
µM to 100 µM and the reaction was again incubated at 25°C for 24 hours 
and then analysed by anion exchange HPLC.  
Although the DMB-DP4 yield was clearly improved (35% conversion) (Figure 
2.28B), the efficiency of the reaction was still sub-optimal. These conditions 
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utilise high concentrations of DMB-DP3 and involve a long incubation time. 
Ideally, a rapid screen is required, utilising minimal DMB-DP3 and other 
reagents (e.g. ST8SiaII) to keep costs to a minimum and to enable larger 
numbers of compounds to be screened as efficiently as possible. To sum up, 
these conditions were not ideal for high throughput analysis of ST8SiaII 
inhibitors. Therefore optimisation of the reaction buffers, DMB-DP3 
concentration and incubation time was performed in order to determine the 
most efficient conditions for the enzyme activity. 
 
 
 
Figure 2.28 Incubation reaction of RP-HPLC-purified DMB-DP3 with human ST8SiaII. (A) 
Incubation reaction of 50 µM RP-HPLC-purified DMB-DP3 with human ST8SiaII after 24 hours 
incubation (upper chromatogram), negative control of the reaction (lower chroatogram). (B) 
Incubation reaction of 100 µM RP-HPLC-purified DMB-DP3 with human ST8SiaII after 24 hours 
incubation (upper chromatogram), negative control of the reaction (lower chromatogram). 
 
2.3.3.1. Optimisation of the ST8SiaII incubation reaction buffers 
 
A second protocol of the incubation reaction was performed by using human 
ST8SiaII (250 ng/µl), DMB-DP3 (100 µM), MgCl2 (5 mM), CMP-Neu5Ac (0.5 
mM) and sodium cacodylate buffer (pH 6.7, 0.1 M) only, with the same 
incubation conditions previously described in protocol 1 (section 2.3.3). It 
was found that the reaction still proceeds after the removal of the remaining 
components (Tris HCl, KCl, MnCl2 and glycerol), which suggests they are not 
essential for enzyme activity in the absence of NCAM (Figure 2.29). 
(A) (B) 
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Comparing the results of both protocols using the same DMB-DP3 
concentration and the same incubation time revealed that there is no major 
difference in the peak area obtained (and thus product produced) between 
the two protocols.  
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Figure 2.29 Optimisation of the DMB-DP3/ST8SiaII incubation reaction buffers. The upper curve 
shows the peak area of DMB-DP4 produced using protocol 1; the lower curve shows the peak 
area of DMB-DP4 produced using protocol 2. These are duplicate results representative of two 
independent experiments.  
2.3.3.2. Determination of the optimum concentration of DMB-DP3  
 
Protocol 2 (with the optimum buffer composition) was repeated using a 
concentration range of DMB-DP3 from 10-100 µM and the same conditions 
as outlined previously, with incubation times of 2 and 24 hours. Both 20 µM 
and 100 µM DMB-DP3 concentrations showed no considerable difference in 
the DMB-DP4 product peak area after either 2 or 24 hours incubation (Figure 
2.30).  
Despite the optimisation of the RP-HPLC purified DMB-DP3 incubation 
reaction, still the efficiency was lower than the required; the product DMB-
DP4 at early incubation time (2 hours) was deemed insufficient to enable use 
for high throughput assessment of potential small molecule polyST inhibitors. 
The DMB-DP3 to DMB-DP4 conversion rate of less than 5% results in a very 
small peak area for DMB-DP4 and thus of limited utility in screening 
compounds. 
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Figure 2.30 Determination of the optimum concentration of DMB-DP3. The upper curve shows 
the peak area of DMB-DP4 after 24 hours incubation using 10, 20 and 100 µl of DMB-DP3, while 
the lower one shows the peak area of the product after 2 hours incubation. These are duplicate 
results representative of two independent experiments.  
2.3.3.3. Optimisation of the assay incubation temperature  
 
In order to optimise the incubation temperature of the assay, the ST8SiaII 
/DMB-DP3 reaction was repeated using different incubation temperatures; 
specifically, 15, 25, 37 and 50 ºC.  
It was found that incubating the reaction for 2 hours at 25ºC resulted in 
higher production of DMB-DP4 (Figure 2.31). This was surprising given that it 
was expected that incubation at 37ºC would result in the optimum production 
of DMB-DP4, since 37ºC is the normal body temperature. Nevertheless, 
significantly greater product formation was observed at 25ºC. This might be 
explained by the fact that the conditions and buffers used to perform the 
reaction in vitro are completely different from the conditions inside the body. 
The same observation was recorded by a previous study performed by Keys 
et al., where 25ºC was identified as the optimum temperature for both 
bacterial and murine polyST activity 132.  
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Figure 2.31 Different incubation temperature of DMB-DP3/ST8SiaII reaction.These are duplicate 
results representative of two independent experiments. 
 
2.3.3.4. Evaluation of the optimum purification strategy of DMB-DP3  
 
To determine whether the optimum purification strategy of DMB-DP3 is via 
anion exchange-HPLC or RP-HPLC, recombinant ST8SiaII (250 ng/µl) was 
incubated with anion exchange-purified DMB-DP3 (10-100 µM), MgCl2 (5 
mM), 0.5 mM CMP-Neu5Ac and sodium cacodylate buffer (pH 6.7, 0.1 M), 
with the same conditions as used previously. The results were compared 
with the DMB-DP3 purified using the RP-HPLC methodology. 
It was found that although the polysialylation efficiency was improved using 
the anion exchange-purified DMB-DP3, the % product peak area of DMB-
DP4 compared to the total peak area was still quite low at early incubation 
times (Figure 2.32).  
For the purification of DMB-DP3 using anion exchange column the mobile 
phases used were: 100% water (mobile phase A) and 5 M ammonium 
acetate buffer (pH 7.4, mobile phase B) while for the purification using RP-
HPLC system the mobile phases used were: ammonium formate buffer (pH 
6, mobile phase A) and 55% methanol (pH 7.2, mobile phase B). The final 
acidic pH of the mobile phases used with the RP-HPLC might have caused 
the reduction in the efficiency of labelling of the DMB-DP3 purified by this 
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method, due to the formation of lactonised form, compared to the DMB-DP3 
purified by the anion exchange system. 
 
Figure 2.32 Incubation of ST8SiaII with DMB-DP3 purified with RP-HPLC (lower curve) and 
anion exchange-HPLC (upper curve). These are duplicate results representative of two 
independent experiments.  
However, it was observed that both samples gave an equally high yield of 
the product DMB-DP4 after 24 hours of incubation with ST8SiaII. This could 
be explained by completion of the reversible lactonisation reaction of DMB-
DP3. In an attempt to decrease the lactonisation of DMB-DP3, solid material 
purified by anion exchange HPLC was dissolved in sodium cacodylate buffer 
(pH 8.2), incubated with human ST8SiaII enzyme and analysed by anion 
exchange-HPLC as described before. It was found that although the analysis 
of the DMB-DP3 dissolved in sodium cacodylate buffer (pH 8.2) showed only 
one peak on both RP- and anion exchange-HPLC with no sign of presence 
of the lactonised form, the high pH used was incompatible with the reaction 
(abolished enzyme activity). In order to improve the efficiency of the DMB-
DP3 polysialylation reaction by human ST8SiaII, the purification of DMB-DP3 
was re-visited after it was observed that anion exchange-purified DMB-DP3 
showed higher DMB-DP4 product than the RP-HPLC- purified DMB-DP3. 
2.3.3.5. Determination of the conditions required to minimise the 
lactonisation of DMB-DP3 
 
A combination of both RP-HPLC and anion exchange–HPLC was used with 
the optimised conditions for each technique as mentioned before, (the 
purified material with RP-HPLC was re-purified by anion exchange HPLC). It 
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was observed from the previous analysis that the polysialylation efficiency 
was improved when DMB-DP3 was purified by anion exchange HPLC, which 
could be explained by the difference of the pH of the mobile phase system 
used in each purification method. It was assumed that combining both anion 
exchange and reversed phase HPLC purification methodologies might 
enhance the efficiency of DMB-DP3 polysialylation to the target DMB-DP4. 
Peaks representing DMB-DP3 were pooled from several runs and freeze 
dried. The dried material was dissolved in cacodylate buffer (pH 6.7) and 
incubated at 37°C for 2 hours. 
An incubation of the sample at 37°C for 2 hours at pH 6.7 was performed, 
after the observation that both previously prepared samples gave a high yield 
of the product DMB-DP4 after 24 hours of incubation with ST8SiaII, in an 
attempt to allow the completion of the reversible lactonisation reaction of 
DMB-DP3. It was previously reported in different studies that the 
lactonisation reaction is reversible and controlled by pH of the medium. In 
accordance with that, incubating DMB-DP3 at 37°C for 2 hours at pH of 6.7 
may result to shift the reversible reaction towards the formation of the 
unlactonised form of the DMB-DP3, which is the form of the DMB-DP3 able 
to react with the enzyme (Table 2.14) 142.  
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Table 2.14 DP3 lactonisation reaction.Structures of a-2,8-linked sialic acid trimer (1), 1-
monolactone trimer (2), 2-monolactone trimer (3), and dilactone trimer (4) as well as the 
reaction pathway of lactonisation (bottom left) and hydrolysis (bottom right), table reproduced 
from 
142
  
 
Reactable form of DP3 with human ST8SIAII 
enzyme 
Unreactable form of DP3 with human ST8SIAII 
enzyme 
Unlctonised DP3 (the desired product) 
 
monolactone trimer 
 
 
 
monolactone trimer 
 
 
Dilactone trimer 
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The results showed that the efficiency of the polysialylation reaction was 
greatly improved using this protocol. It was found that compared to the 
product produced (product DMB-DP4 peak area/total peak area x100) with 
either RP-HPLC or anion exchange-HPLC without pre-incubation, this 
protocol showed considerably higher efficiency (Figure 2.33), which could be 
explained by either the combination of the purification techniques or the 
incubation of the sample for enough time to reverse the lactonisation 
process.  
  
Figure 2.33 Incubation reaction of ST8SiaII enzyme with DMB-DP3 purified with both RP-HPLC 
and anion exchange chromatography and equilibrated for 2 hours before incubation with the 
enzyme. These are duplicate results representative of two independent experiments.  
To determine whether the improvement in polysialylation efficiency was 
caused by the combination of the purification techniques or the pre-
incubation, the polysialylation of the DMB-DP3 prepared in this way was 
compared with DMB-DP3 previously prepared by either RP-HPLC or anion 
exchange HPLC but after incubation of both for 2 hours at 25°C (Figure 
2.35).  
It was found that the efficiency of DMB-DP3 polysialylation reaction was not 
extensively affected by the method of the purification, but that reversal of the 
lactonisation of the DMB-DP3 before the incubation with ST8SiaII is crucial. 
The equilibration of the DMB-DP3 allows any lactonised DMB-DP3 form to 
be converted to the unlactonised form, which increases the polysialylation 
efficiency. To further confirm this hypothesis, the polysialylation reaction of 
DMB-DP3 purified by RP-HPLC with and without equilibration was 
performed. The results clearly demonstrate that without equilibration the 
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reaction efficiency is very low especially at early time points compared to the 
equilibrated sample (Figure 2.34).  
 
Figure 2.34 Incubation of human ST8SiaII enzyme with DMB-DP3 purified by RP-HPLC, anion 
exchange HPLC or both techniques combined with/without incubation of the purified DMB-DP3 
for 2 hours at 37°C at pH 6.7. The results show that the efficiency of the polysialylation of DMB-
DP3 depends on the unlactonisation of DMB-DP3 before the reaction more than its method of 
purification. These are duplicate results representative of two independent experiments.         
The reduction in polysialylation reaction efficiency associated with the DMB-
DP3 lactonisation could be explained by the relative inhibition of the ST8SiaII 
enzyme ability to incorporate new sialic acid monomers within the lactonised 
structure and strongly suggests that the negatively carboxyl groups are key 
to activity. The human ST8SiaII enzyme catalyses the reaction of the 
incoming sialic acid and DMB-DP3 residue at the 2,8 positions. In the 
lactonised form of the DMB-DP3, the structure and charge of the molecule is 
different which could result in the molecule not being recognised by enzyme 
or doesn’t fit efficiently into active sites.   
To sum up, it was found that lactonisation of oligosialic acid (OSA) is 
catalysed by acid in aqueous solution and that lactonisation of OSA has an 
influence on its ability to interact with the human ST8SiaII enzyme, which 
might be explained by steric hindrance caused by the formation of the 
lactonised form. It was found also that, consistent with previous studies, 
lactonisation of DMB-DP3 is a reversible process. Conjugating RP-HPLC or 
anion exchange-HPLC purification of DMB-DP3 with its incubation at 37°C 
for 2 hours at pH 6.7 allows the reversal of the lactonisation process. 
Converting the lactonised forms to the unlactonised form consequently 
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allows for efficient interactions between DMB-DP3 and the human ST8SiaII 
enzyme, as demonstrated by the higher DMB-DP4 yield. 
2.3.4. Optimisation of the assay quantification technique 
 
In order to determine the mass of DMB-DP4 produced by the reaction of 
DMB-DP3 and ST8SiaII and to consequently quantify polyST inhibition with 
small molecule inhibitors, DMB-DP4 was synthesised and purified in the 
same way as described previously for DMB-DP3. Different concentrations 
and volumes of the standard DMB-DP4 were injected and a calibration graph 
for DMB-DP4 weight against peak area was plotted (Figure 2.35). The 
equation of the line produced from the calibration graph was then used for 
calculation of the mass of DMB-DP4 produced (in ng) in each analysis, which 
was then used to calculate the percent DMB-DP4 formation relative to 
control (no inhibitor was added).  
 
Figure 2.35 Calibration curve of the amount of nanograms of DMB-DP4 standard against peak 
area. These are duplicate results representative of two independent experiments.  
2.3.5. Optimisation of the assay running time 
 
In order to optimise the assay for a medium throughput screen, the gradient 
of the anion exchange-HPLC analysis used to detect the polysialylation of 
DMB-DP3 by ST8SiaII was modified from the original gradient (Table 2.13), 
which requires 30 minutes for analysis of each small molecule inhibitor, to 
the following gradient that requires only 11 minutes to analyse one inhibitor 
(Table 2.15). 
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Table 2.15 Optimised HPLC gradient for medium throughput analysis of polysialyltransferase 
inhibitors. Mobile phases used were distilled water (Mobile phase A) and 5M ammonium acetate 
(mobile phase B).  
 
Time Flow (ml/min) % Mobile phase A % Mobile phase B 
0 1.2 100 0 
2 1.2 100 0 
9 1.2 96.3 3.7 
11 1.2 100 0 
 
The reproducibility of the new gradient was tested by running different 
samples of DMB-DP3 polysialylated with human ST8SiaII and examining the 
retention time of both DMB-DP3 and the product DMB-DP4 for each sample. 
It was found that this gradient yielded reproducible results at which DMB-
DP3 elutes at 5.8 minutes while DMB-DP4 elutes at 7.5 minutes, confirmed 
by running standard DMB-DP3 and DMB-DP4 using the same gradient (the 
experiment was repeated three times) (Figure 2.36). 
 
 
 
 
 
 
Figure 2.36 Optimisation of the assay running time.A shorter gradient with a higher percentage 
of mobile phase B was used to decrease the time required for analysis of anti-polyST small 
molecule inhibitors from 30 minutes to 11 minutes.  
Although using this gradient resulted in a short running time and reproducible 
results, the solvent composition was further modified since the high molarity 
of mobile phase B (5M ammonium acetate) risked damaging the HPLC 
equipment (high concentration of ammonium acetate is corrosive to the 
HPLC material) 143. In the new gradient, the mobile phases used were: 0.5 M 
ammonium acetate (pH 7.4) (mobile phase B) and distilled water (mobile 
phase A) with the following gradient (Table 2.16): 
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Table 2.16 Optimised HPLC gradient for medium throughput analysis of polysialyltransferase 
inhibitors that utilise 0.5 M ammonium acetate instead of 5M ammonium acetate as mobile 
phase B. 
Time Flow (ml/min) %Mobile phase A % Mobile phase B 
0 1.2 100 0 
2 1.2 100 0 
9 1.2 63 37 
11 1.2 100 0 
12 1.2 100 0 
 
2.3.6. Analysis of the polyST assay reproducibility   
 
In order to assess the assay reproducibility and reliability, seven independent 
control samples using the same concentration of DMB-DP3, ST8SiaII 
enzyme and CMP-Sia were analysed. The percentage of the product DMB-
DP4 was calculated (relative to the total peak area) and the standard 
deviation and coefficient of variation were calculated.   
It was found that the results were reproducible with an average of 7.8               
% product and standard deviation of 0.58 and coefficient of variation of 0.07, 
meaning the results were reproducible (Figure 2.37). 
  
 
 
 
 
 
Figure 2.37 Analysis of the reproducibility of the results obtained by running seven 
independent control samples shows a standard deviation of 0.58 and coefficient of variation of 
0.07  
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2.3.7. Determination of the limit of detection of the product DMB-
DP4 
 
In order to determine the limit of detection of the product DMB-DP4 (smallest 
peak area that is distinguishable from baseline) produced in the DMB-DP3 
polysialylation reaction, different concentrations of standard DMB-DP4 were 
injected (1 – 50 nM). The peak area corresponding to each concentration 
was recorded and plotted against the DMB-DP4 concentration. It was found 
that using the previously mentioned optimised conditions of the assay 
chromatography, 1 nM (0.001 µM) concentration of DMB-DP4 could be 
detected (which is 1/10000 of the added concentration of DMB-DP3) (Figure 
2.38). 
 
 
 
 
 
 
 
Figure 2.38 Detectability of the product DMB-DP4 using anion exchange HPLC chromatography 
and fluorescence (RF-10A) (Shimadzu, Japan) detector (sensitivity set, 1 and gain set 3). These 
are duplicate results representative of two independent experiments.  
2.3.8. Analysis of the DMB-DP4 stability 
 
Since this assay is designed to be used for high throughput analysis, it is 
expected that a large number of ST8SiaII inhibitors would be analysed in the 
same day. These inhibitors would thus potentially remain in the HPLC 
machine overnight. If different time points and/or concentrations for a large 
number of inhibitors were assessed in the same 24 h period, the stability of 
the DMB-DP3 acceptor and DMB-DP4 product over this lengthy period are 
crucially important. So, in order to confirm the stability for the product DMB-
DP4 and DMB-DP3 present in each assay, a control assay (with no inhibitor) 
was tested for its content of DMB-DP3 and DMB-DP4 at different time points 
over 48 hours at room temperature. It was found that the DMB-DP3 and 
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DMB-DP4 content in the assay is stable over 48 hours at room temperature 
(Figure 2.39). 
 
Figure 2.39 Stability of DMB-DP3 and DMB-DP4 over 48 hours. The experiment is carried out by 
incubating DMB-DP3 and DMB-DP4 at room temperature for 48 hours, 10 µl of the sample at T0 
was analysed using HPLC then the same volume of the sample was analysed after a series of 
time points, peak area was detected and the percent of the peak area compared to T0 was 
calculated and blotted against the corresponding time point. The experiment was repeated 
three times and the standard deviation was calculated. 
2.3.9. Characterisation of Cytidine Monophosphate (CMP) as an 
ST8SiaII inhibitor 
Gel electrophoresis and western blot analysis 
 
CMP was used as a standard inhibitor to validate the developed cell-free 
HPLC high throughput assay. In order to have a reference from which to 
compare polyST inhibition achieved in the new assay, CMP was first 
analysed using western blot (a method employed in the lab previously). 
Using NCAM, in the presence of recombinant human ST8SiaII and CMP-
Neu5Ac (the substrate for polysialylation reactions), CMP was shown to 
abolish polysialylation consistent with previous studies 107,109. To identify the 
optimum concentration of CMP required for complete ST8SiaII enzyme 
inhibition, NCAM was used in the presence of recombinant human ST8SiaII 
and CMP-Neu5Ac (the substrate for polysialylation reaction) and different 
concentrations of CMP (0.1 - 10 mM). The results were compared with 
positive control (without CMP) and negative control (without ST8SiaII). It was 
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found that CMP significantly inhibited NCAM polysialylation at a 
concentration of 1 mM (no polySia was detected on western blot). The 
reaction was repeated using a narrower concentration range of CMP (0.1, 
0.25, 0.4, 0.8 and 1 mM) in order to determine the minimum concentration of 
CMP required for the inhibition of ST8SiaII enzyme, 0.4 mM CMP was found 
to completely inhibit the enzyme (Figure 2.40). The concentration-dependent 
inhibition of polysialylation of NCAM was indicated as a fainter bands rather 
than a change of the range of molecular weights. This suggests that CMP 
(and thus polyST inhibition) affects the number of polySia chains synthesised 
rather than modulating the length of individual chains. This is interesting and 
warrants further investigation. 
Previous studies by Yousef M. J. et al. showed that at 0.5 mM CMP 
produced no significant polyST inhibition when administered to cells, 
specifically the IMR-32 neuroblastoma cell line 109. This might be explained 
by the difference in the inhibition capacity of an inhibitor within cell-free and 
cell-based systems. This confirms that both cell-free and cell-based assays 
are required for a complete understanding of inhibitor activity. 
 
 
Figure 2.40 The effect of various concentrations of CMP on the polysialylation of NCAM. Lane 1 
represents the negative control (without the ST8SiaII enzyme), lane 2 represents the positive 
control (without CMP), lanes 3 - 7 represent reactions with 0.1, 0.25, 0.4, 0.8 and 1 mM CMP 
respectively. Blot is representative of three independent experiments.  
ST8SiaII inhibition by Cytidine  
 
Cytidine was evaluated as a possible negative control. This would also 
determine the significance of the phosphate group as present in CMP, for 
inhibition of ST8SiaII. Cytidine did not significantly inhibit the polysialylation 
process (Figure 2.41), even at high concentrations (5 mM), which is 
consistent with previous studies 101 and confirms that the phosphate group is 
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necessary for ST8SiaII inhibition. Cytidine thus served as a useful negative 
control to aid validation of the assay. 
To sum up, the results obtained by western blot validated the developed cell-
free HPLC high throughput assay and confirmed the concentration required 
for complete inhibition of polySia synthesis. CMP and cytidine were 
consequently utilised as tool compounds for validation of a cell-free 
chromatographic assay.  
 
Figure 2.41 The effect of cytidine on the polysialylation of NCAM by ST8SiaII enzyme. Lane 1 
represents the negative control (without the ST8SiaII enzyme), lane 2 represents the positive 
control (without cytidine) and lane 3 represents the reaction with 5 mM Cytidine. Blot is 
representative of three independent experiments.  
2.3.10. Analysis of polysialylation reaction kinetics, assay 
sensitivity  
 
The study of enzyme kinetics is important as it helps explain how enzymes 
function. Michaelis–Menten kinetics is one of the best-known models of 
enzyme kinetics that describes two values, Km and Vmax. Vmax (maximum 
velocity) represents the maximum reaction rate achieved by the system, at 
maximum (saturating) substrate concentrations. The Michaelis constant Km is 
the substrate concentration at which the reaction rate is half of Vmax. Km thus 
provides a measure of affinity of the substrate for the enzyme 144. 
ST8SiaII activity was determined by incubating the enzyme with CMP-
Neu5Ac and varying amounts of DMB-DP3 acceptor. The assay kinetic 
parameters (Km, Vmax) were then calculated (Figure 2.42A, B). The Km value 
of the DMB-DP3 was calculated using a Lineweaver-Burk plot (Figure 
2.42B). The experiment was repeated and the average Km value was 
calculated (Km = 29.5 µM, consistent with previous study 
109). The Vmax value 
of the reaction was also calculated using the same plot (Vmax= 14.8 
µmol/min/mg).  
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The Vmax value of polyST/ CMP-Neu5Ac reaction was previously reported in 
different studies (Vmax= 58.8 ± 2.1). However, these studies reported the 
reaction using the bacterial ST8SiaII rather than the human enzyme, which 
suggests that the human enzyme does not convert as much substrate to 
product per unit of time, when the enzyme is saturated with substrate 
compared with the bacterial enzyme. 
In order to determine the assay sensitivity towards a small concentration of 
inhibitor and the ability to establish a direct relationship between the 
concentration of the ST8SiaII inhibitor (CMP) and DMB-DP3 polysialylation 
product (DMB-DP4) peak area, the activity of ST8SiaII, as measured by 
DMB-DP4 product formation, was assessed in the presence of varying 
concentrations of CMP. The concentration of DMB-DP3 acceptor was 
maintained at a constant level. It was found that a direct relationship between 
CMP inhibitor concentration and the degree of DMB-DP3 polysialylation 
could be established and that even small changes in the concentration of the 
inhibitor could be observed in the product formation (Figure 2.42C). In order 
to determine the inhibition constant (Ki) value of CMP, the concentration 
required to produce half maximum inhibition of polyST activity, which was 
used as standard inhibitor for the assay, three concentrations of CMP were 
used (20, 50 and 150 µM). Each concentration was assessed in the 
presence of different concentrations (250, 425 and 500 µM) of CMP-Sia 
(sialic acid donor). The Ki value, the concentration of inhibitor which is 
required to decrease the maximal rate of the reaction to half of the 
uninhibited value, was determined using Dixon plot. The experiment was 
repeated and the average Ki value was found to be 12 µM (Figure 2.42C) 
which is consistent with previously published studies 109. 
Here we have determined the Ki value of the inhibitor rather than an IC50 
value since Ki value is an intrinsic quantity that is independent of the 
substrate (ligand) but depends on the enzyme (target) and inhibitor. In 
contrast the IC50 value depends on the concentrations of the enzyme (or 
target molecule), the inhibitor, and the substrate (or ligand) along with other 
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experimental conditions 145. In short, an IC50 can vary between experiments, 
whereas the Ki is an absolute value. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.42 Michaelis-Menten data (A), Lineweaver-Burk plot (B) and Dixon plot (C). Km of DMB-
DP3 for ST8SiaII (derived from x axis intercept, Lineweaver-Burk plot) was calculated as 29.5 
µM and Vmax value (calculated from y axis intercept) was calculated as 14.8 µmol/min/mg. The Ki 
value of CMP was calculated from the Dixon plot. Graph lines converge above the x axis; where 
they intersect is -Ki. Data points are from a single determination representative of two 
independent experiments. 
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2.3.11. Optimisation of chromatography to allow high throughput 
analysis of polyST inhibition 
2.3.11.1. Reversed phase-HPLC 
 
Previously we have optimised the assay chromatography for medium 
throughput analysis of polyST inhibition using anion exchange-HPLC 
(Section 2.3.5). In order to optimise the HPLC assay for high throughput 
analysis of small molecule ST8SiaII inhibitors, further optimisation was 
carried out by analysing the assay using RP-HPLC instead of anion 
exchange-HPLC.  
RP-HPLC allows for rapid, sensitive and reproducible analysis due to the fact 
that the column needs no time for re-equilibration between analyses since 
the method is isocratic rather than the gradient elution used with anion 
exchange chromatography. Another advantage of using RP-HPLC is the 
ability to conjugate it with mass spectrometry, which allows for very specific 
product characterisation and provides molecular weight information. 
The mobile phases used were: ammonium formate (5 mM, mobile phase A) 
and methanol (mobile phase B), with a flow rate of 1 ml/min and an isocratic 
gradient of 80% mobile phase A: 20% mobile phase B. Using this method, 
DMB-DP4 eluted at 3.9 minutes while DMB-DP3 eluted at 4.9 minutes 
(Figure 2.43A). Six samples were run using this method to assess the 
reproducibility of the analysis (Figure 2.43B). It was found that the retention 
time of both DMB-DP3 and DMB-DP4 were reproducible throughout the six 
repeats, which confirmed the reliability of the developed chromatography. 
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Figure 2.43 Optimisation of the chromatography to allow high throughput-HPLC analysis. Using 
isocratic method reduced the run time and allowed direct re-injection of new samples without 
the need to re-equilibrate the column between analyses. A) The first peak at 3.9 minutes 
represents DMB-DP4 while the second peak at 5.9 minutes represents DMB-DP3, B) the 
reproducibility of the results when running 6 samples of standard DMB-DP3 and DMB-DP4 
consecutively. The last chromatogram shows DMB-DP3 only.  
2.3.11.2. MRM analysis 
 
In order to set an MRM channel for specific DMB-DP3 and DMB-DP4 
detection, the mobile phases used were: ammonium formate (5 mM, mobile 
phase A) and  methanol (mobile phase B), with a flow rate of 0.3 ml/min and 
isocratic method of 80% mobile phase A: 20% mobile phase B. The mass 
spectra were continuously scanned from m/z 300 to m/z 1200 for DMB-DP3 
and m/z 1500 for DMB-DP4 throughout the entire HPLC separation and the 
mass spectrometer was operated in positive ion electrospray mode. The 
optimal cone voltage and collision energy associated with each transition 
were established, the run time was optimised to 6 minutes where the DMB-
DP3 and DMB-DP4 eluted at 2.5 and 1.8 minutes respectively (Figure 2.44). 
 
 
 
(A) 
(B) 
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Figure 2.44 MRM analysis of DMB-DMB3/4. Example of mass spectrum used for MRM channel 
setting of DMB-DP3/4 showing parent ion selection for DMB-DP3 analysis (A) and daughter ion 
selction (B). (C) Detection of DMB-DP3 (C) and DMB-DP4 using the optimised MRM technique, 
with either photodiode array detector (upper chromatogram) or mass spectrometry (lower 
chromatogram). (D) Table showing MRM transitions, cone voltage (CV) and collision energy 
(CE) determined for DMB-DP3 and DMB-DP4. 
 In the MRM assay, on the basis of the channels established in the present 
experiments, 5 μl of labelled samples (10 mM DMB-DP3, 250 ng ST8SiaII) 
proved to be sufficient for quantitative analysis of the inhibition of polySia 
synthesis caused by ST8SiaII inhibition. 
Transitions 
Molecular 
weight 
(mwt) 
Z 
Parent 
ion 
(m/z) 
Daughter 
ion 
(m/z) 
CV 
(V) 
CE 
(eV) 
Dwell time (s) 
DMB-DP3 1007.9 +1 1009 407.9 25 20 0.2 
DMB-DP4 1299.15 +2 651.25 408 25 30 0.2 
(C) (D) 
(E) 
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2.3.12. Evaluation of novel small molecule potential ST8SiaII 
inhibitors 
 
Using the developed high throughput cell-free chromatographic assay, a 
panel of small molecule ST8SiaII inhibitors that were designed at the Institute 
of Cancer Therapeutics (University of Bradford) were evaluated. These 
compounds are listed in Table 2.17. 
The compounds synthesised were designed as polyST inhibitors based on 
the results of molecular modelling studies carried out at the ICT. The 
compound structures are variations to ICT-3125. Small changes to functional 
groups were made in order to find out the effects on biological activity. CMP 
was included as a known, previously studied inhibitor. 
The average product (DMB-DP4) formation relative to control sample was 
calculated in order to identify the most promising compounds, and to 
determine hits to be further analysed in more complex assays (Table 2.17, 
Figure 2.45). Each experiment was repeated three times and the standard 
deviation and standard error mean was calculated. 
According to the results obtained from this assay, it was found that the most 
active polyST inhibitors were ICT-3234 (78.6 ± 2.8% inhibition at 5 µM), ICT-
3233 (61.6 ± 2.6% inhibition at 12.5 µM), ICT-3276 (78.7 ± 7.22% inhibition 
at 25 µM), and ICT-3143 (37.5 ± 9.1% inhibition at 12.5 µM). The polyST 
inhibition, as measured by reduction of polySia expression was found to be 
concentration-dependent (Figure 2.46). 
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Figure 2.45 Representative examples of the chromatograms produced using the developed 
HPLC technique (RP) for the analysis of the inhibition of ST8SiaII enzyme using different 
inhibitors.The lower line represents the control reaction (no inhibitor), with the production of 
DMB-DP4 (left peak in each chromatogram), while the upper line represents the DMB-DP4 
production after incubation of ST8SiaII with polyST inhibitors (DMB-DP4 production is reduced 
or inhibited completely).  
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Table 2.17 Evaluation of a series of novel small molecule polyST inhibitors using the cell-free 
HPLC assay developed in this study. Each experiment was repeated three times and the 
standard deviation and standard error mean was calculated.  
Inhibitor % Average DMB-
DP4 formation 
Standard deviation Standard error mean 
ICT-3276, 250 µM 8.1 2.1 1.2 
ICT-3276, 125 µM 14.8 1.3 0.7 
ICT-3276, 25 µM 21.3 7.2 4.1 
CMP, 250 µM 30.6 1.0 0.6 
CMP, 125 µM 38.3 3.2 1.8 
CMP, 25 µM 86.7 2.3 1.3 
ICT-3233, 50 µM  19.7 2.7 1.5 
ICT-3233, 25 µM 37.6 2.8 1.6 
ICT-3233, 12.5 µM 38.4 2.6 1.5 
ICT-3125,250 µM 8.8 1.9 1.1 
ICT-3125,125 µM 11.3 1.0 0.5 
ICT-3125,12.5 µM 87.0 10.0 5.8 
ICT-3274, 25 µM 3.5 0.6 0.3 
ICT-3274, 5 µM 69.8 18.0 10.4 
ICT-3143, 50 µM 35.6 3.4 1.9 
ICT-3143, 25 µM 51.5 7.9 4.5 
ICT-3143, 12.5 µM 62.4 9.1 5.3 
ICT-3234, 12.5 µM 20.7 2.2 1.2 
ICT-3234, 5 µM 21.1 2.8 1.6 
ICT-3126, 250 µM 88.9 7.7 4.4 
ICT-3130, 250 µM 77.8 9.0 5.2 
ICT-3142, 250 µM 36.6 2.9 1.6 
Cytidine, 250 µM 84.7 15.3 8.8 
L-fucose, 250 µM 88.9 5.4 3.1 
ICT-3242, 250 µM 57.4 10.2 5.8 
ICT-3245, 250 µM 92.5 22.4 12.9 
ICT-3246, 250 µM 114.9 9.9 5.7 
ICT-3247, 250 µM 65.7 9.0 5.2 
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Figure 2.46 Evaluation of the inhibition of polySia synthesis by a series of novel small molecule 
ST8SiaII inhibitors using the cell-free HPLC assay developed in this study.Each experiment was 
repeated three times. * P< 0.05, ** P<0.01 and *** P < 0.001. 
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Section B) Cell-based chromatographic assay for analysis of 
ST8SiaII activity 
 
Following successful demonstration of polyST inhibition and identification of 
promising compounds, the next step was to evaluate these compounds in 
cells. The second major part of this study was therefore the development of a 
cell-based chromatographic assay for the analysis of polyST inhibition, as 
represented by reduction of cell-surface polySia expression. Although cell-
free assays play a very important role in the early stages of the drug 
discovery process, cell-based assays are the next logical step since they 
have additional complexity and functionality, for example in terms of 
intracellular cell signalling pathways. They additionally allow assessment of 
the ability of individual compounds to penetrate cell membranes. 
2.3.13. SH-SY5Y cell growth curve 
 
In order to develop a cell-based chromatographic assay, the doubling time of 
the cell line to be used had to be calculated in order to determine the suitable 
seeding density of the six-well plates used in this assay. A growth curve of 
SH-SY5Y cells was plotted as described in the materials and methods 
section. Plotting the number of cells/ml of the duplicate flasks for five 
consecutive days showed that SH-SY5Y cells have a doubling time of 48 
hours (Figure 2.47). According to these results, 2 x 105 cell/ml was seeded in 
a 6 well plate (2 ml/well) and the cells were incubated for 48 hours to double 
and form 70-80% confluent wells before treatment with ST8SiaII inhibitors.  
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Figure 2.47 Growth curve of SH-SY5Y cells showing that the cell line requires 48 hours for 
duplication.These results represents mean of three independent experiments.  
2.3.14. Use of Endo-N for the removal of polySia from the cell 
surface 
2.3.14.1. Optimisation of Endo-N concentration 
 
Endoneuraminidase-N (Endo-N) is an endosialidase which degrades rapidly 
and specifically linear polymers of polySia with a minimum length of 7-9 
residues146. Cells were treated with Endo-N (0.5, 1 and 3 µg/ml) for 24 hours, 
while one well was used as negative control where no Endo-N was added. 
After 24 hours, media was collected for analysis using mixed phase column - 
HPLC-FD as described in the material and methods section (Section 
2.2.9.1).  
 
 
 
 
 
 
 
 
Figure 2.48 Optimisation of the concentration of Endo-N required for the removal of polySia 
from SH-SY5Y cell surface suggests a linear relationship between the concentration of Endo-N 
and the released polySia up to the concentration of 3 µg/ml. These are duplicate results 
representative of two independent experiments.  
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A linear relationship between the concentration of Endo-N and the released 
polySia up to the concentration of 3 µg/ml was detected (Figure 2.48). Two 
drawbacks were recorded with this technique, however: the presence of 
sialic acid in the control sample where no Endo-N was added, which might 
be due to the presence of sialic acid in fetal bovine serum (FBS) added to 
the medium, and the need to use high concentration of expensive Endo-N in 
order to remove polySia from the cell surface. 
2.3.14.2. Optimisation of incubation media to eliminate sialic acid in 
control sample 
 
In order to overcome the issue of the presence of sialic acid in the control 
samples, media was removed from the cells, after cells were attached to the 
six-well plate, and the cells were washed twice with PBS before adding 
Endo-N in FBS-free medium. It was found that using this technique resulted 
in the disappearance of sialic acid from the control samples. In order to 
further confirm that FBS was the source of the sialic acid in the control, FBS-
containing medium was analysed by HPLC. It was found that the amount of 
sialic acid in the control sample was equivalent to the amount of sialic acid 
when injecting the same volume of media only. 
The incubation of cells with Endo-N in FBS-free medium was not a perfect 
solution, however, since FBS contains growth factors required for the cell to 
survive, grow and divide. Maintenance of the cells for 24 hours in FBS-free 
medium might affect the cells, causing them to rupture and release the sialic 
acid present within and therefore give unreliable results. Therefore, a control 
sample where no Endo-N was added has to be examined with every analysis 
to confirm that no such rupture and release of sialic acid occurred as a result 
of the use of FBS-free medium. 
2.3.14.3. Optimisation of SH-SY5Y cell number 
 
In order to minimise the quantity of Endo-N used in the experiment and 
consequently reduce the associated costs, a 24-well plate was used instead 
of using 6 well plate, thereby reducing the amount of media required to cover 
the cells from 2 ml to 0.5 ml. However, this approach proved unsuccessful 
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since the amount of sialic acid produced from the associated lower number 
of cells (105 total cell number was used instead of 4 x 105 used previously in 
the 6 well plate) produced an undetectable amount of sialic acid. 
2.3.15. Use of mild acidic hydrolysis for the removal of polySia 
from the cell surface 
 
Instead of using Endo-N to remove polySia from the cell surface, 
solubilisation of cell-bound polySia was achieved by using a mild non-ionic 
non-denaturing detergent; IGEPAL CA-630, according to previously 
published methodology 147. Cells were collected by trypsinisation followed by 
centrifugation for 5 minutes at 1000 g. Cell pellets were treated with IGEPAL 
followed by incubation at 37 °C for 1 h and vortex mixing for 5 minutes in 
order to solubilise polySia from the cell surface. After removal of the 
insoluble material by centrifugation, the supernatant was then incubated with 
triflouroacetic acid (TFA) for 2 hours at 80°C in order to hydrolyse polySia 
into sialic acid monomers which were then derivatised with DMB (as 
described previously). 
Although using this approach did not result in complete removal of polySia 
from the cell surface, the amount of detected sialic acid was equivalent to 
that detected using 1 µg/ml of Endo-N. This approach solved the problem of 
having free sialic acid in the control sample since the medium was discarded 
and only the cells were used (Figure 2.49). It significantly reduced the cost of 
the assay. In order to confirm that using acidic hydrolysis resulted in the 
removal of the same amount of polySia from the cell surface and 
consequently give reproducible results, three independent experiments with 
the same cell seeding number and incubation time were analysed, it was 
found that the standard deviation didn’t exceed ±10%.  
To sum up, using mild acidic hydrolysis for the removal of polySia from the 
cell surface instead of using Endo-N allowed for a reliable, cost-effective 
assay and eliminated the need to use FBS-free medium which was 
problematic as previously discussed. 
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Figure 2.49 Comparison between the amounts of sialic acid present in control samples using 
Endo-N or mild acidic hydrolysis for the removal of polySia from SH-SY5Y cell surfaces. These 
are duplicate results representative of two independent experiments.  
In order to confirm that using mild acidic hydrolysis to remove polySia from 
SH-SY5Y cell surface results in the removal of polySia chains and not the 
sialic acid monomers also normally present on the cell surface 148, a control 
sample was performed in which cells were treated in the same way as 
described before but without adding TFA for 2 hours at 80°C. In this case 
polySia is not hydrolysed to sialic acid monomers and therefore any detected 
DMB-DP1 will be the result of the solubilisation of sialic acid monomers from 
the cell surface by IGEPAL CA-630 (Figure 2.50). No sialic acid was 
detected in this control sample, which confirmed the release of only polySia 
from the cell surface using this mild acid hydrolysis protocol which is 
consistent with previously published studies 147.  
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Figure 2.50 Schematic representation of the design of the control for polySia removal using 
mild acidic hydrolysis 
2.3.15.1. Optimisation of polySia solubilisation technique  
 
In order to improve the efficiency of solubilisation of polySia from cell surface 
using IGEPAL, two different techniques were used. The first involved 
incubation of the cell pellet with 100 µl of 0.5% IGEPAL at 37 °C for 1 h and 
vortex mixing for 5 minutes while the second involved vortex mixing the cell 
pellet with IGEPAL for the entire 1 h. Neither of these two techniques was 
found to increase the efficiency of polySia solubilisation: there was no 
difference in the efficiency using any of the techniques and they all resulted 
in solubilisation of polySia equal to 1 µg/ml of Endo-N.  
2.3.16. Labelling and detection of standard DMB-DP1  
 
A DMB-DP1 standard was prepared using the same technique previously 
described for DMB-DP3 and DMB-DP4. Standard DMB-DP1 was analysed 
using an Obelisc™ mixed-phase HPLC column, 5 mM ammonium formate 
(mobile phase A), Acetonitrile (mobile phase B) and 0.8 ml/min flow rate as 
described in the methods and materials section.  
The Oblesic column is a mixed phase column that operates with multiple 
separation modes (normal phase, ion exchange and hydrophilic interaction 
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chromatography). This column has the advantage of efficient separation of 
polar and charged analytes, which makes it a good choice for separation of 
DMB-DP1 from the other components within the cell. The total run time was 
adjusted to 13 minutes, since DMB-DP1 was eluted at 10.87 minutes (Figure 
2.51), followed by washing the column for up to 27 minutes with 100% 
acetonitrile to allow re-equilibration of the column after the end of the 
gradient.                
The same method was used for the analysis of sialic acid released from cells 
with/without adding ST8SiaII inhibitors. The DMB-DP1 standard was re-
injected with each analysis to ensure the reproducibility of the results (the 
same elution time was observed as previously recorded). 
 
 
 
 
 
 
 
 
 
Figure 2.51 Analysis of standard DMB-DP1 using the Oblesic mixed phase column. 
 
2.3.17. Cell-based analysis of ST8SiaII inhibitors 
2.3.17.1. Mixed phase-HPLC analysis 
 
Analysis of inhibition of polySia expression using CMP in a cell-based assay 
has previously been reported 109. In the in-house study by Al-Saraireh et al., 
5 mM CMP was found to cause approximately 40% inhibition in polySia 
synthesis as examined using flow cytometry and IMR-32 cells (NCAM +; 
ST8SiaII +; polySia +). 
CMP was therefore used to validate the developed assay. CMP (5 mM) was 
added to the cells for 24 hours, and the polySia released from the cell 
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surface was analysed using HPLC. It was found that 5 mM CMP resulted in 
32.1 ± 0.6 % inhibition of polySia expression, which is consistent with the 
results reported previously 109.  
After validation of the assay, selected promising compounds identified from 
the cell-free HPLC assay for polyST inhibition were then evaluated. 
However, it was found that using the previously described HPLC 
methodology was not ideal for this particular assay. Two peaks were found to 
overlap at the same retention time of DMB-DP1. When the molecular weight 
of these peaks was analysed by MS it was found that they represent 
compounds with molecular weights of 424.2 and 383.1 (Figure 2.52). These 
suggest the presence of DMB-labelled sialic acid and N-deacetylsialic acid 
respectively. 
The formation of de-acetylated sialic acid has been previously reported in a 
number of studies. Study by Chikako M. et al., reported the modification of 
sialic acid in several cultured lymphocytic leukemia cell lines, through first 
de-N-acetylation of sialic acid moiety through ubiquitous de-N-acetylationyre-
N-acetylation cycle, followed by the dehydrative cyclisation of de-N-acetyl 
sialic acid to form ‘‘cyclic sialic acid’’. This study suggested a possible 
physiological significance of this reaction to be a rapid inactivation of selectin 
binding activity at the cell surface 149. 
The presence of the second peak representing de-acetylated sialic acid 
reduced the quantification efficiency of the technique since it resulted in 
broadening of the peak and overlapping with adjacent peaks. A second 
drawback of the technique was that DMB doesn’t only label sialic acid; it was 
found that DMB also labelled other components of the cell extract, which 
resulted in multiple unidentified peaks, also reducing the efficacy of the 
detection of the sialic acid peak through overlapping with it (Figure 2.53). In 
order to overcome these problems, an MRM technique using UPLC/MS/MS 
was developed for the detection of DMB-DP1. 
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Figure 2.52 Analysis of released sialic acid using mild acidic hydrolysis and mixed phase-HPLC 
technique showing two peaks of labelled sialic and de-acetylsialic acid at the same retention 
time. Labelling of other components of the cells with DMB which are adjacent to the DMB-sialic 
acid peak is also shown.  
 
2.3.17.2. MRM analysis of DMB-DP1 
 
In order to set an MRM channel for specific DMB-DP1 detection, the mobile 
phases used were: ammonium formate (5 mM, mobile phase A) and 
methanol (mobile phase B), with isocratic method of 80% mobile phase A: 
20% mobile phase B. The optimal cone voltage and collision energy 
associated with each transition were established and the run time was 
optimised to 6 minutes where the DMB-DP1 eluted at 4.9 minutes (Figure 
2.53A). 
 
Transitions 
Molecular 
weight 
(mwt) 
Z 
Parent 
ion 
(m/z) 
Daughter 
ion 
(m/z) 
CV 
(V) 
CE 
(eV) 
Dwell time 
(sec) 
1 425.4 +1 426 229.23 25 20 0.2 
2 425.4 +1 426 313.02 25 20 0.2 
Standard DMB-labelled sialic acid 
Overlapping peaks of DMB-labelled sialic acid and de-acetylated sialic acid 
DMB-labelled components of the cell 
(A) 
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Figure 2.53 MRM transitions, cone voltage (CV) and collision energy (CE) determined for DMB-
DP1 (A). Experimental conditions: Waters mass spectrometer; 5 mM ammonium formate used 
as mobile phase A, methanol was used as mobile phase B, flow rate was set to be 0.3 ml/min 
with isocratic method of 80% mobile phase A: 20% mobile phase B. B, C) Detection of ST8SiaII 
inhibition with 5 mM CMP using the optimised technique shows specific detection of one peak 
representing DMB-DP1 at 4.9 minutes. (D) Chemical structure of the parent ion of DMB-DP1. 
Results represents mean of three independent experiments. Example of mass spectrum used 
for MRM channel setting of DMB-DP1 showing parent ion selection for DMB-DP1 analysis (E) 
and daughter ion selection (F). 
5 mM CMP was analysed using the optimised TFA protocol along with the 
MRM analysis; it was found that using this technique enabled highly efficient 
quantitative detection with no overlapping peaks of de-acetylated DMB-sialic 
acid (Figure 2.53B, C). 
2.3.18. Applications of the developed cell-based HPLC assay 
2.3.18.1. Application of the cell-based HPLC assay to understand the 
mechanism of action of N-acylmannosamine compounds 
 
The effect of N-acylmannosamine derivatives treatment on polySia 
expression in NCAM- and ST8SiaII -expressing cell lines has been a matter 
of debate; some studies suggest that treatment of polySia-expressing cells 
with N-acylmannosamine compounds significantly reduces their cell surface 
polysialylation through competitive inhibition of ST8SiaII 150. On the other 
hand, other studies have shown that N-propanoylsialic acid (SiaProp), 
generated from N-propanoylmannosamine (ManNProp), is readily accepted 
(F) 
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by polySTs and permits the extension of modified polySia (in the form of 
polySiaProp) on NCAM. It is suggested that, despite being immunologically 
distinct, the subtle structural differences in polySia resulting from the 
incorporation of SiaProp residues do not alter the anti-adhesive properties of 
polysialylated NCAM 151. 
In this experiment, SH-SY5Y cells were treated with ManNProp (ICT-3128, 
250 µM) for 24 hours and the ability of ManNProp to either incorporate into 
the polySia chains (giving modified polySia) or to block the polySia synthesis 
by competitive inhibition of ST8SiaII enzyme was examined. 
 
 
 
 
 
Figure 2.54 Analysis of the effect of ManNProp treatment on SH-SY5Y polySia synthesis 
showing the incorporation of the compound in the polySia chains giving modified prop-Sia (A), 
immunofluorescence staining of manNProp treated cells and control untreated cells with m735 
mAb (specific for polySia) and 13D9 mAb (specific for modified Prop-Sia) shows that treatment 
of SH-SY5Y cells with ManNProp results in the formation of modified Prop-Sia chains (B). Scale 
bar represents 250 µm. 
The results were analysed using mixed-phase HPLC technique to determine 
the synthesis of the modified prop-Sia chains and/or polySia chains. A 
second peak was detected at an elution time of 9.8 minutes (Figure 2.54A). 
The molecular weight was found to be equal to the molecular weight of DMB-
N-propanoylsialic acid (439.2) when analysed with mass spectrometry. This 
suggests that ManNProp was ultimately incorporated in the polySia chain 
resulting in the formation of modified polySia chains but did not inhibit 
polySia formation. These results were confirmed by staining SH-SY5Y cells 
that had been treated with ManNProp with M735 mAb (specific for polySia) 
 M735 13D9 
Control 
  
ICT-3128 
(0.25 mM) 
  
(A) (B) 
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and 13D9 mAb (specific for modified Prop-Sia) 152 and comparing them to 
control untreated cells (Figure 2.54B). It was found that control cells stained 
negative for Prop-Sia and positive for polySia while ManNProp-treated cells 
stained positive for both.  
 
To sum up, this work confirmed that administration of ManNProp to SH-
SY5Y cells resulted in modified polySia chains (Prop-Sia) and did not 
significantly cause competitive inhibition of ST8SiaII. This is the first 
conclusive evidence to resolve the conflicting reports in the literature.  
Confirmation of the incorporation of ManNProp into polySia on cancer cell 
membrane starts a new discussion about the potential significance of polySia 
chain modification on cancer cell migration, invasion and recognition by the 
body’s natural immunity. Sialylated oligosaccharides on the cell surface of 
bacteria are thought to provide a protective barrier to evade detection and 
attack by the host’s immune system 153. Therefore, changes in polySia 
structures on cancer cell surface might render them recognisable to immune 
cells, which requires further investigation. 
The results obtained in this study have been confirmed with mass 
spectrometry giving the molecular weight of the released monomers from the 
sialic acid chains unlike earlier studies, which utilised HPLC-FD or western 
blot. This will allow the study of not only the inhibitory effects but also the 
mechanism of action of different polySTs inhibitors in the complex functional 
system of the cell. 
2.3.18.2. Application of cell-based HPLC assay for quantitative 
detection of polySia expression in different cancers  
 
To-date, ELISA and western blot have been the main techniques used for 
the quantification of polySia expression in different cancers154-156. Although 
they both provide a robust, specific and clear qualitative measurement of 
polySia expression, the quantification associated with these assays is always 
problematic. Besides that, the antibodies required for these assays are highly 
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costly and need specific measurements to be target specific. Here we have 
used the developed cell-based HPLC assay to measure polySia expression 
in different cell lines. PolySia was harvested from the cell surface of SH-
SY5Y, C6-STX and OSC-19 cell lines (106 cells/cell line) as described 
previously and quantified using MRM technique.  
The results were presented as a percentage of polySia expression relative to 
that observed with C6-STX cells. It was found that SH-SY5Y expressed 
91.6%, while OSC-19 expressed 98.9% of that measured with C6-STX cells. 
This technique can also be amended to express the results as nanograms of 
polySia per given number of cells by using a calibration curve of standard 
DMB-DP1 with known concentrations (the same technique used for the 
quantification of DMB-DP4 in the aforementioned cell-free HPLC assay). The 
results were confirmed using immunofluorescence which showed similar 
expression of polySia in the three cell lines (Figure 2.55).  
The results obtained from this assay regarding SH-SY5Y and C6-STX cell 
lines were consistent with previously published data109,157. However, this was 
the first report of analysis of the expression of polySia in a head and neck 
cancer cell line (i.e. OSC-19). Sialic acid has previously been reported as a 
tumour marker in head and neck cancer 158, but here it was proved for the 
first time that polySia is also over-expressed in head and neck cancer. This 
may have a significant effect on the prognosis of the disease. Further studies 
with different head and neck cancer cell lines are required, but this is an 
exciting initial finding. 
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Figure 2.55 Analysis of polySia expression in SH-SY5Y, C6-STX and OSC-19 cell lines using the 
developed cell-based chromatographic assay, showing that SH-SY5Y express 91.6% while 
OSC-19 express 98.9% relative to C6-STX cells (A). The results were confirmed using 
immunofluorescence staining with m735 mAb specific for polySia, where it was found that the 
three cell lines showed similar expression of polySia (B). Results represents mean of three 
independent experiments. Scale bar represents 250 µm. 
2.3.18.3. Application of cell-based HPLC assay for quantitative analysis 
of polySia synthesis inhibition by selected polyST inhibitors  
 
Using the developed high throughput cell-based chromatographic assay, a 
panel of small molecule polyST inhibitors was evaluated. This panel included 
two sets of compounds; hit compounds identified from the cell-free 
chromatographic assay, namely: ICT-3143, ICT-3233, ICT-3234, ICT-3276 
and other compounds including CMP-sialic acid precursors (N-
acylmannosamines) including ICT-3176, ICT-3128 and ICT-3141. The 
difference in the mechanism of action of both will be discussed in detail in the 
next chapter. Average polySia expression relative to control was calculated 
following compound administration in each case (Table 2.18, Figure 2.56).  
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Table 2.18 Analysis of a panel of polyST inhibitors using the new cell-based HPLC assay. Each 
experiment was repeated three times and the standard deviation and standard error mean was 
calculated.  
Inhibitor % Average polySia synthesis relative to 
control 
Standard deviation Standard error 
mean 
ICT-3176, 250 µM 49.4 9.5 6.7 
ICT-3176, 500 µM 22.0 5.7 4.0 
ICT-3125, 250 µM 109.3 2.2 1.5 
ICT-3141, 250 µM 70.4 6.2 4.4 
CMP, 5 mM 73.4 7.8 5.5 
ICT-3234, 250 µM 28.5 4.8 3.4 
ICT-3233, 250 µM 27.8 4.2 2.9 
ICT-3234,125 µM 71.6 7.1 5.0 
ICT-3233, 125 µM 73.8 1.6 1.1 
ICT-3234, 25 µM 68.8 1.6 1.1 
ICT-3233, 25 µM 79.5 12.0 8.5 
ICT-3143, 25 µM 83.7 4.6 3.3 
ICT-3276, 12.5 µM 83.0 5.2 3.7 
ICT-3276, 15 µM 70.5 3.1 2.2 
ICT-3276, 20 µM 63.5 4.6 3.3 
ICT-3128, 250 µM 100.1 2.5 1.8 
ICT-3128, 500 µM 74.1 5.4 3.8 
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Figure 2.56 The reduction of polySia expression following administration of polyST inhibitors 
(A). (B) and (C) represent examples of chromatograms produced using the new cell-based 
assay for analysis of ST8SiaII inhibitors such as ICT-3234 and 3176 respectively, D) represents 
the analysis of different controls of the assay first control (upper) represents sialic acid 
released from polySia chains in untreated cells, control two (lower) represents analysis of 
sample at which all the chemicals and media were added but without adding cells in order to 
analyse the presence of any sialic acid monomers in the media.  * P< 0.05, ** P<0.01 and *** P < 
0.001. 
According to the results obtained from this assay, it was found that the most 
active polyST inhibitors were ICT-3276 (36.4 ± 4.6% inhibition at 20 µM), 
ICT-3234 (71.4 ± 4.8% inhibition at 250 µM), ICT-3233 (72.1 ± 4.2% 
inhibition at 250 µM) and ICT-3176 (78 ± 5.7% inhibition at 500 µM). The 
polyST inhibition, as measured by reduction of polySia expression was found 
to be concentration-dependent. 
The results showed that the rationally-designed polyST inhibitors generally 
exhibited higher potency than N-acylmannosamine compounds. This could 
be explained by the fact that some N-acylmannosamine compounds such as 
ManNProp have the ability to be incorporated in the polySia chains, giving 
modified polySia instead of terminating polySia chain elongation, as has 
been discussed earlier in this chapter and supported by previous studies 
(Section 2.3.18.1) 106,148.  
Comparing the results of the cell-based and cell-free chromatographic 
assays shows correlation between the results from the two assays; 
compounds that showed the highest inhibition of recombinant ST8SiaII in the 
cell-free assay also showed the highest polyST inhibition in the cell-based 
(D) 
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setting. This further validates the novel cell-free chromatographic assay for 
high throughput analysis of small molecule polyST inhibitors. 
However, in cell-free assay it was found that ICT-3234 and ICT-3233 exhibit 
higher inhibitory effect than compound ICT-3276 while in cell-based assay 
compound ICT-3276 showed higher inhibitory effect than both ICT-3234 and 
ICT-3233, this could be explained by the possible difference in the uptake of 
the inhibitors in the cell-based setting that may be caused by difference in 
the polarity of the compounds. 
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2.4. Conclusion 
 
PolySia over-expression is characteristic for several malignant tumours and 
is highly correlated with tumour growth and metastasis. The role of polySia in 
cancer progression highlights the need for selective polyST inhibitors (or 
inhibitors of polySia biosynthesis). The aim of the work discussed in this 
chapter was to develop reliable, sensitive and high throughput techniques for 
quantitative analysis of polyST inhibition in cell-free and cell-based protocols.   
To obtain a highly pure and easy-to-handle fluorescent acceptor for fast and 
reliable testing of recombinant human polyST enzyme inhibition in the cell-
free assay, a DMB-labelled oligosialic acid acceptor (DMB-DP3) was 
synthesised. Methods of labelling and purification were optimised to give 
high yields of a ≥99% pure compound.  
In order to optimise the assay to be used for high throughput analysis of 
polyST inhibitors, a MRM method for the analysis of the assay product was 
developed using UPLC/MS/MS. This technique allowed the analysis of one 
inhibitor analytical sample in just six minutes. Besides, use of RP-UPLC 
allowed for rapid, sensitive and reproducible analysis, with the ability for the 
method to be conjugated with mass spectrometry to allow very specific 
product characterisation and generation of molecular weight information. 
The second major part of the study involved the development of a cell-based 
chromatographic assay for the analysis of cell-surface polySia expression. In 
this assay, Endo-N and mild acidic hydrolysis techniques for harvesting 
polySia from the cell surface were used and optimised. The advantages and 
disadvantages of each technique were investigated in order to establish a 
reproducible, efficient and reliable technique. MRM analysis of the released 
sialic acid was also achieved, which allowed a very sensitive quantitative 
analysis of the effect of different polyST inhibitors on polySia biosynthesis 
and expression.  
This new technique has been applied to study different aspects of polyST 
activity. The analysis of monomers released from polySia chains on the cell 
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surface and their identification with mass spectrometry allowed the 
investigation of potential modifications in the structure of these polySia 
chains caused by different inhibitors.  
Another application of the developed cell-based assay was to give a 
quantitative and/or semi-quantitative measurement of polySia expression on 
the cell surface of different cancer cells. This technique can replace the 
multi-step, costly and less specific ELISA and western blot-based methods, 
which are the major techniques to have been used to date for the 
measurement of cellular polySia expression. We were able to demonstrate 
and quantify the expression of polySia in OSC-19 human head and neck 
cancer cells for the first time, and to compare levels with that observed in 
neuroblastoma cell line.  
Two panels of polyST inhibitors were examined using these assays. The first 
set of compounds included rationally-designed polyST inhibitors synthesised 
at the Institute of Cancer Therapeutics. Investigation of these compounds 
contributed to understanding structure-activity relationships, which enables 
the determination of the chemical groups responsible for the interaction with 
ST8SiaII enzyme. This data will allow modifications to the structure of the 
compounds to be made in future, to optimise the potency of the inhibitors.  
The second panel of compounds included CMP-sialic acid precursors (N-
acylmannosamines). The effect of these compounds on the synthesis of 
polySia has always been a matter of debate. Some studies demonstrate that 
all artificial sialic acid precursors including ManProp, ManNBut and 
ManNPent strongly inhibit polySia biosynthesis 106,151,159. Other studies 
suggest the capacity of human cell lines to incorporate unnatural sialic acids 
into modified polySia chains 104,150.  
We have proved that treating tumour cells with ManNProp results in 
incorporation of modified sialic acid into the polySia chains. This was 
confirmed using LC/MS analysis, for the first time, to confirm the molecular 
weight of the monomers. The modified polySia chains were identified. 
Findings were further confirmed by immunofluorescence staining of the 
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treated cells with 13D9 (anti-propSia) and m735 (anti-polySia) monoclonal 
antibodies.  
In conclusion, the developed techniques provide a quantitative and highly 
sensitive assay format for testing of polyST activity in both cell-free and cell-
based settings. Both qualitative and quantitative information gained from 
these assays will continue to give new mechanistic insights into this 
important class of enzyme. 
Analysis of different polyST inhibitors enabled the assessment of their 
potency and the identification of the most active compounds for further 
investigation. In order to determine the effect of polyST inhibition on cancer 
cell function, study in more complex assays is required. This will be explored 
in the next chapter. 
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Chapter 3. Evaluation of selected novel 
polysialyltransferase inhibitors in cell-based 
functional assays 
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3.1. Introduction 
 
In the previous chapter, the development and optimisation of cell-based and 
cell-free high throughput chromatographic assays that allow for quantitative 
and sensitive analysis of polySia inhibition was described. Consequent to the 
development and validations of the assays, a series of rationally designed 
polyST inhibitors has been evaluated in order to determine the most 
promising compounds. In the work described in this chapter, selected small 
molecule inhibitors were analysed using MTT, migration and 
immunofluorescence assays in order to examine the effect of polyST 
inhibition on the migration of neuroblastoma SH-SY5Y cells and investigate 
their selectivity. 
Current drug discovery strategies include target-based screening, phenotypic 
(functional) screening, modification of natural substances and biologic-based 
approaches; such as identifying monoclonal antibodies 160. The focus of 
target-based screening is a gene product, known as a target. Molecular and 
chemical knowledge is used to investigate specific molecular hypotheses. On 
the other hand, the focus of phenotypic (functional) screening is to measure 
a clinically meaningful phenotype in a physiologically relevant system such 
as an animal or cell; the assays do not require prior understanding of the 
molecular mechanism of action 161. 
There has been an increasing interest in the use of phenotypic screens in 
drug discovery as an alternative to target-focused approaches 162. A frequent 
question is whether target-based approaches or phenotypic approaches 
provide better starting points for drug discovery. 
A study by Swinney and Anthony found that among the 183 small-molecule 
drugs across all therapeutic areas approved between 1999 and 2008, 58 
(32%) were discovered using phenotype-based approaches. Importantly, 28 
(56%) of the 50 small-molecule first-in-class new molecular entities identified 
in their study resulted from phenotypic screening approaches, whereas 17 
(34%) resulted from target-based approaches160,162.  
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Focusing on target-based drug discovery in the absence of validated 
molecular mechanisms of action (MMOAs) was suggested to be a major 
technical factor contributing to the high attrition rates of small-molecule first-
in-class medicines observed in the clinic 162. 
A key conclusion of that paper, repeated in more recent reviews, was that 
phenotypic assays have the advantage of identifying drug leads and clinical 
candidates that are more likely to possess therapeutically relevant MMOAs. 
From this conclusion, one can infer that target-based drug discovery is not 
an inferior approach but that it is more likely to fail if target modulation is 
prioritized at the expense of understanding the most desirable MMOAs. 
These mechanisms can best be demonstrated by functional and phenotypic 
assays 162,163. 
Here we have expanded our understanding of the molecular mechanism of 
action of the hit polyST inhibitors, determined previously by the 
chromatographic assays, using a 2D scratch migration assay and 
immunofluorescence assay, having confirmed non-cytotoxic compound 
concentrations using an MTT viability assay. 
3.1.1. MTT viability assay 
 
MTT (3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) is a 
colorimetric assay that measures specific aspects of cellular metabolism. 
The mechanism underpinning the assay relies on the up-take of MTT 
tetrazolium salt (colourless) and its reduction by mitochondrial reductases by 
actively growing cells, which transform it into a coloured formazan product 
that can be quantified by measuring absorbance using a spectrophotometer 
(Figure 3.57) 164,165.  
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Figure 3.57 Scheme of reduction of MTT to formazan 
166
. 
 
The MTT assay is thus a very useful tool to obtain information about cell 
viability in a high throughput manner 165. Measurement of cell viability and 
proliferation forms the basis for numerous in vitro assays of a cell 
population’s response to external factors. The MTT cell viability assay 
measures the cell proliferation rate and conversely, when metabolic events 
lead to apoptosis or necrosis, the reduction in cell viability 167. Here MTT 
viability assays have been employed to select non-toxic concentrations of 
compounds to be evaluated in the 2D migration and immunofluorescence 
assays. 
3.1.2. Scratch 2D migration assay 
 
The in vitro scratch assay is an easy, low-cost and well-developed method to 
measure cell migration in vitro. The basic steps involve creating a scratch in 
a cell monolayer. Upon creation of a new artificial gap in a confluent cell 
monolayer, the cells on the edge of the newly created gap will move toward 
the opening to close the scratch until new cell–cell contacts are re-
established. Capturing images at the beginning and at regular intervals 
during cell migration to close the scratch and comparing the images allows 
the quantification of the migration rate of the cells (Figure 3.58, 168).  
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Figure 3.58 Schematic representation of the principal of 2D scratch migration assay 
169
. 
 
One of the major advantages of this technique is that it mimics to some 
extent migration of cells in vivo. For example, removal of part of the 
endothelium in the blood vessels will induce migration of endothelial cells 
into the denuded area to close the wound. Furthermore, the patterns of 
migration as sheets of cells also mimic the behaviour of these cells during 
migration in vivo. Another advantage of the in vitro scratch assay is its 
particular suitability to study the regulation of cell migration by cell-matrix and 
cell–cell interactions. In other popular methods such as Boyden chamber 
assays, preparation of cells in suspension before the assays disrupts cell–
cell interactions169,170. 
Here we have used the assay to evaluate the effect of polyST inhibition on 
the migration of different cell lines. The results contribute to our 
understanding of the structural requirements for a good inhibitor, by 
assessing selectivity by comparing effects on the migration of cell lines that 
express polySia and NCAM, NCAM only or are polySia and NCAM negative. 
CFA0 CFA1 
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3.1.3. Assessed polysialyltransferase inhibitors 
 
Two panels of polysialyltransferase inhibitors (polyST) were assessed using 
the aforementioned assays; polyST competitive inhibitors (hit compounds as 
determined by the chromatographic assays) and N-acylmannosamine 
compounds. 
3.1.3.1. Rationally-designed competitive polysialyltransferase inhibitors 
 
ICT-3233, 3234, 3143, 3276, 3268 and 3271 are polyST competitive 
inhibitors that have been derivatized from the parent compound ICT-3125 
and designed using computer assisted drug design. ICT-3125 was originally 
identified from virtual screening of commercially available libraries, using a 
homology model structure of the ST8SiaII enzyme. In competitive inhibition, 
a molecule similar to the substrate competes for occupation of the active site, 
but blocks activity of the enzyme (Figure 3.59) 171.  
 
 
 
 
 
 
 
 
 
 
Figure 3.59 Schematic representation of the mechanism of action of competitive inhibition. 
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3.1.3.2. N-acylmannosamine compounds 
 
Different N-acylmannosamines have been studied for their ability to inhibit 
polySia biosynthesis. As mentioned earlier (Chapter 1, Section 1.7.1), small-
molecule inhibitors such as ManBut and ManProp have the advantages of 
temporal control and reversibility. In the previous chapter it was shown that, 
using cell-based chromatographic assay, treating cells with these inhibitors 
resulted in either modification of polySia structures (ICT-3128) or significant 
inhibition of polySia expression (ICT-3141). 
Here, we have assessed the in vitro cytotoxicity of ManPent (ICT-3141), 
ManProp (ICT-3128) and ICT-3176 and compared this with the cytotoxicity of 
the rationally designed inhibitors.  
Table 3.19 Summary of the compounds to be studied in this chapter. 
 
 Inhibitor molecules 
Hit rational-designed ST8SiaII 
inhibitors 
(Selected through both cell-
based/cell-free chromatographic 
assays) 
ICT-3276 
ICT-3234 
ICT-3233 
ICT-3143 
ICT-3125 
N-acyl mannosamine inhibitors 
ICT-3128 
ICT-3141 
ICT-3176 
ICT-3149 
 
To sum up, the work presented in this chapter has three main aims. The first 
aim was the analysis of the in vitro cytotoxicity of the rationally designed 
inhibitors and compare them with the N-acylmannosamine compounds 
(Table 3.19), and to use these results to select suitable non-toxic 
concentrations to be further used for the migration assay. The second aim 
was the analysis of the effect of polyST inhibitors, selected via both cell-free 
and cell-based chromatographic assays, on the migration of polySia-NCAM 
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expressing neuroblastoma SH-SY5Y cells. Additionally, the selectivity of 
these inhibitors was analysed using the C6 glioma isogenic system and 
polySia negative colorectal carcinoma cell line (DLD-1) as negative control. 
Finally, the third aim was to characterise cell-surface polySia expression 
after polyST inhibition with hit inhibitors using immunofluorescence. 
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3.2. Material and methods 
 
All the materials are purchased from Sigma Aldrich, UK unless otherwise 
specified. 
3.2.1. Cell lines used in this study 
 
Cell lines were maintained as described previously in chapter 2. DLD-1 
colorectal adenocarcinoma cells and C6-WT glioma cells were obtained 
from the cell culture facility at the Institute of Cancer Therapeutics, 
University of Bradford. The methodology for the transfection of C6 cells with 
pcDNA3-STX plasmid inserted with cDNA encoded full length human STX, 
has been reported previously 66. This was carried out by collaborators (Dr. 
Minoru Fukuda) at the Sanford-Burnham Institute, La Jolla, CA., USA. 
DLD-1 cell line were maintained in RPMI medium supplemented with 10% 
foetal bovine serum, 1% sodium pyruvate and 1% glutamine while C6 wild 
type glioma cells was maintained in MEM Alpha eagle with ultra-glutamine-
I, deoxyribonucleoside and ribonucleosides supplemented with 10% foetal 
bovine serum. All cell lines were maintained in a humid atmosphere of 5% 
CO2 and 95% air at 37 °C. 
3.2.2. Growth curves of cell lines 
 
Cells were maintained and counted as described earlier (Chapter 2). After 
cells were counted, the cell suspension was diluted in order to have an 
appropriate amount of medium and that cells achieve a proper seeding 
density (1.5 x 105 for SH-SY5Y cell line, 2.5 x 104 for C6 cell line and 5 x 
105 for DLD-1 cell line). Five flasks of each cell line were seeded with the 
same cell density. The plates were incubated in a humid atmosphere of 5% 
CO2 and 95% air at 37 °C. The duplicate plates were counted every 24 
hours. The results were plotted on a log-linear scale. The population 
doubling time was determined by identifying a cell number along the 
exponential phase of the curve, tracing the curve until that number has 
doubled, and calculating the time between the two. 
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3.2.3. Migration assay 
3.2.3.1. Coating of cell culture dishes 
 
Cells were seeded onto six-well plates to create a confluent monolayer (1 x 
106 for SH-SY5Y cell line, 5 x 105 for C6 cell lines and 8 x 105 for DLD-1 cell 
lines). Dishes were incubated for approximately 24 h at 37 °C, allowing 
cells to adhere and spread completely.  
3.2.3.2. Scratch assay 
 
Cell monolayers were scraped in a straight line to create a "scratch" with a 
p200 pipette tip. The debris were removed and the scratch edge was 
smoothened by washing the cells once with the growth medium (1 ml) and 
then replace it with polyST inhibitor-containing medium (2 ml) or fresh 
medium (containing DMSO in concentration equivalent to the concentration 
of polyST inhibitor) for the control. 
To obtain the same field during the image acquisition, markings were 
created to be used as reference points close to the scratch. The reference 
points were made by an ultrafine tip marker on the outer bottom of the dish. 
After the reference points were made, the dish was placed under a phase-
contrast microscope, and the reference marks were left outside the capture 
image field but within the eye-piece field of view. The first image of the 
scratch was then acquired using a Lumascope 500 microscope.   
Plates were placed in a tissue culture incubator at 37 °C for 16, 24 and 41 h 
for C6, SH-SY5Y and DLD-1 cell lines respectively. The time-frame for 
incubation for each cell line was determined according to the results 
obtained from growth curves. The dishes were taken out of the incubator to 
be examined periodically and then returned to resume incubation. After the 
incubation, plates were placed under the Lumascope microscope, 
reference points were matched, the photographed region acquired at the 
first image was aligned and a second image was acquired 168. 
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3.2.3.3. Data analysis 
 
The images acquired for each sample were analysed quantitatively by 
using ImageJ software. For each image, distances between one side of 
scratch and the other were measured at certain intervals (µm). By 
comparing the images from time 0 to the last time point the percentage of 
wound closure of each compound was measured = (CFA0-CFA1) / CFA0) x 
100 and then compared to the control to obtain the % of migration = (wound 
closure % with compound / wound closure % of control) x 100, where CFA0 
is wound size or cell-free area at T0 and CFA1 is wound size or cell-free 
area at T (16/24 or 41) (Figure 3.59). 
3.2.4. MTT assay 
 
3.2.4.1. Reagent Preparation 
 
MTT stock solution (12 mM) was prepared by adding sterile water (20 ml) to 
MTT (100 mg) and vortex mixing until dissolved. Occasionally there was 
some particulate material that did not dissolve; this was removed by filtration 
or centrifugation. Once prepared, the MTT solution was stored up to four 
weeks at 4°C, protected from light. 
3.2.4.2. Coating of cell culture dishes 
 
Cells were seeded onto 96-well plates to create a confluent monolayer (1 x 
104 cells for the SH-SY5Y cell line, 5 x 103 for the C6 cell line and 8 x 103 
for DLD-1 cells). Dishes were incubated for approximately 24 h at 37 °C, 
allowing cells to adhere and spread completely. For each plate, three wells 
were coated with fresh medium, these wells were used later to measure the 
background absorbance.  
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3.2.4.3. Cell treatment with potential polyST inhibitors 
 
After 24 hours incubation, media in the 96 well plates was aspirated, and 
cells were washed once with the growth medium (200 µl). This was then 
replaced with polyST inhibitor-containing medium (200 µl) at different 
concentrations (500, 250, 125, 12.5 and 1.25 µM), or fresh medium 
(containing the same concentration of DMSO as in the polyST inhibitor 
containing medium. DMSO was limited to a concentration of 0.1%, which 
was proven to have no effect on cells viability) as a control. 
3.2.4.4. MTT treatment 
 
Cell line cultures were removed from the incubator into a laminar flow hood. 
Re-constituted MTT was added in an amount equal to 10% of the culture 
medium volume. Cultures were then re-incubated for 4 hours at 37 ºC. After 
the incubation period, cultures were removed from incubator and the 
resulting formazan crystals were dissolved by adding an amount of MTT 
solubilisation solution (DMSO) equal to the original culture medium volume. 
Solutions were pipetted up and down to completely dissolve the MTT 
formazan crystals. 
3.2.4.5. Data analysis 
Absorbance of the samples was measured spectrophotometrically at a 
wavelength of 540 nm. The background absorbance of multi-well plates 
was also measured and subtracted from the absorbance observed with the 
test samples. 
The absorbance reading acquired for each sample was analysed 
quantitatively. For each reading, the absorbance of the multi-well plates 
was subtracted and the % viability of each compound concentration was 
calculated (= absorbance with the polyST inhibitor / absorbance of control x 
100). The experiments were repeated three times (three independent 
experiments) and for each experiment 4 technical repeats were carried out.  
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3.2.5. Immunofluorescence analysis of polySia-NCAM 
 
Immunofluorescence assay was performed as previously described in 
chapter 2 (Section 2.2.10). For the detection of polyST inhibition, cells were 
treated with different concentrations of inhibitor and incubated for 16 hours. 
Cells were immunolabeled with mouse anti-polySia antibody (clone: mAb 
735, 15 µg/ml) for the detection of polySia, or mouse anti-NCAM antibody 
(RNL-1, 10 µg/ml) (abcam, UK) for the detection of NCAM expression or Ki-
67 antibody for the detection of cell proliferation (ab15580,1 µg/ml) (abcam, 
UK). 
3.2.6. Inhibitors stock preparation 
 
All inhibitors stock solutions were prepared in DMSO and diluted in fresh 
medium before use to form a final DMSO concentration ≤ 0.1%.  
3.2.7. Statistics  
 
All experiments were repeated three times independently unless otherwise 
specified. Statistical analyses were performed using Excel software. 
Differences between two groups were evaluated with Student's t test (Two 
tailed) where the P value significance is: P value (P) >0.05 was deemed not 
significant, P < 0.05 * was statistically significant, P < 0.01 ** and P < 
0.001*** were statistically highly significant. 
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3.3. Results and discussion 
 
3.3.1. Confirmation of polySia-NCAM expression in the cell lines 
used in the study 
 
Four different cell lines were used in order to further investigate the activity of 
hit polyST inhibitors previously determined by the chromatographic assays; 
SH-SY5Y, C6-STX, C6-WT and DLD-1. Although the expression of polySia 
and NCAM of these cell lines were previously investigated and reported in 
the literature 109, here we carried out two experiments to further confirm 
these findings; immunofluorescence and western blotting. 
3.3.1.1. Immunofluorescence detection of polySia-NCAM in different cell 
lines 
 
In order to investigate the expression of polySia and NCAM in different cell 
lines, cells were seeded on a cover slip onto six well plates (2 x 104 cell/well) 
and immunolabeled with anti polySia antibody (mAb 735) or anti NCAM 
antibody (RNL-1). The cells were then mounted with Vectashield hardset 
fluorescent mounting medium containing DAPI for the detection of DNA 
content and nuclei. Samples were examined by fluorescence microscopy. 
The results obtained were consistent with the literature: SH-SY5Y and C6-
STX were found to be polySia and NCAM positive, C6-WT was polySia 
negative and NCAM positive and finally, DLD-1 was both polySia and NCAM 
negative (Table 3.20). 
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Table 3.20 Expression of polySia and NCAM in SH-SY5Y, DLD-1, C6-STX and C6-WT cell lines. 
Scale bar represents 250 µm. Results represents three independent experiments.  
 
Cell line PolySia Expression NCAM expression 
SH-SY5Y 
  
DLD-1 
  
C6-STX 
  
C6-WT 
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3.3.1.2. Western blot detection of polySia in different cell lines 
 
For further confirmation western blot analysis was performed, as described in 
chapter 2. The blot was probed with either mAb 735 for the detection of 
polySia (1:3000) or B-actin antibody (1:5000, sigma). Antibody reactivity was 
detected by using anti-mouse fluorescent secondary antibody (1:500) 
(WesternDot 625, life technologies) and infrared digital imaging.  
 
 
 
 
 
 
 
 
Figure 3.60 Western blot analysis of polySia expression in C6-STX, C6-WT, SH-SY5Y and DLD-1 
cell lines using fluorescence detection. Blot represents three independent experiments.  
The results obtained by western blot analysis confirmed the expression of 
polySia in SH-SY5Y and C6-STX cell lines, while no expression was 
detected with either C6-WT or DLD-1 cell lines (Figure 3.60). The polySia 
band appeared as continuous smear between 250 and 100 KDa, indicating 
the expression of different polymer chain lengths (degrees of polymerisation, 
DP). This method was used only as a confirmative qualitative assay since 
the previously developed cell-based HPLC assay, described earlier in 
chapter 2, allowed more accurate method for quantitative detection of 
polySia expression. 
 
 
                                            (KDa ) 250 – 
                            
  
                                                       130 – 
                            
                                                    
                                                       100 – 
            
  
  
  
  
                                         (B-actin)  50 – 
                      C6-STX C6-WT  SH-SY5Y  DLD-1 
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3.3.2. MTT assay: establishment of non-toxic concentrations of 
polyST inhibitors 
 
The MTT assay (as described above) was used to assess the in vitro 
cytotoxicity of the hit polySTs inhibitors used in this study. Absorbance 
values were blanked against DMSO and the absorbance of cells exposed to 
medium only (no polyST inhibitor) were taken as 100 % cell viability (control). 
The percent cytotoxicity of the treated cells was calculated using the formula: 
% cytotoxicity = (% cytotoxicity of control/ % cytotoxicity of treated cells) x 
100%.  
The IC50 and IC20 values for the STX inhibitors for each cell line was also 
calculated from the following equation:  
IC50 = [(50-A)/ (B-A)] x (D-C) + C 
IC20 = [(80-A)/ (B-A)] x (D-C) + C 
Where: 
A = the first point on the curve, expressed as percent inhibition, that is less 
than 50% (80% for IC20) 
B = the first point on the curve, expressed as percent inhibition, that is 
greater than or equal to 50% (80% for IC20). 
C = the concentration of inhibitor that gives A% inhibition 
D = the concentration of inhibitor that gives B% inhibition.  
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Figure 3.61 Analysis of viability of SH-SY5Y, C6-STX/WT and DLD-1 cell lines after treatment 
with different polyST inhibitors after 24, 16 and 41 hours respectively. Results represent three 
independent experiments.  
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Figure 3.62 Results of MTT assay of different polyST inhibitors on different cell lines. 
Concentrations of agent that caused loss of viability in more than 20% of the cell population 
compared to control were considered to be toxic. Each experiment was repeated three times 
and the standard deviation was calculated.  
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According to the results obtained from the MTT assay (Figure 3.61, 3.62), 
the range of concentrations of each inhibitor used to perform migration 
assays was determined. The concentrations that caused less than 20% 
reduction in the viability of the cells compared to the control (IC20) were 
chosen as non-toxic concentrations (Table 3.21). 
Table 3.21 IC50 and IC20 values of different polyST inhibitors as determined by MTT assay on 
different cell lines. The results represent mean values of three independent experiments.  
 
Cell line C6-STX C6-WT SH-SY5Y DLD-1 
Viability 
IC50 
(µM) 
IC20 
(µM) 
IC50 
(µM) 
IC20 
(µM) 
IC50 
(µM) 
IC20 
(µM) 
IC50 
(µM) 
IC20 
(µM) 
ICT-3233 359±7 256±12 372±10 277±4 338±3 192±13 312±4 164±21 
ICT-3234 332±10 190±9 335±4 207±18 183±6 67±8 171 ± 4 74±11 
ICT-3143 346±8 223±7 371±10 274±19 350±18 85±14 326 ± 6 80 ± 7 
ICT-3176 > 500 377±5 > 500 > 500 367±10 238±9 243 ± 21 116±24 
ICT-3128 > 500 494±13 > 500 384±15 > 500 > 500 > 500 399±4 
ICT-3125 > 500 > 500 > 500 > 500 > 500 > 500 > 500 > 500 
ICT-3149 > 500 > 500 > 500 > 500 > 500 > 500 > 500 438±3 
ICT-3141 > 500 > 500 > 500 > 500 > 500 380±15 > 500 > 500 
ICT-3271 > 500 401±4 > 500 > 500 > 500 > 500 - - 
ICT-3276 263±7 44±6 235±3 60±2 407±5 85±3 - - 
ICT-3268 > 500 290±6 > 500 290±4 > 500 411±4 - - 
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3.3.3. Migration assay 
3.3.3.1. Optimisation of incubation time 
 
In order to determine the optimum incubation time required for the migration 
assay, two factors were considered; the time required for closure of at least 
80% of the induced scratch in the cell line monolayer, and time required for 
cell proliferation i.e. the incubation time had to be less than the cell doubling 
time to ensure that the measured effect is due to migration only and not 
proliferation.  
Doubling time for C6-WT, C6-STX, DLD-1 and SH-SY5Y cell lines was 
determined by constructing a growth curve, and using the exponential phase 
of the curve. It was found that 24 and 48 hours were the doubling times for 
C6-WT/C6-STX and DLD-1/SH-SY5Y cells respectively, using full growth 
medium. Two time points, below 24 hours, where thus used to determine the 
suitable incubation time required to induce 80% closure of the scratch in C6-
WT/STX cell lines; 13 and 16 hours and 24, 41 hours, below 48 hours, for 
DLD-1/SH-SY5Y cell lines. 
It was found that 16, 24 and 41 hours are the most suitable incubation times 
for performing of scratch assay on C6-STX/C6-WT, SH-SY5Y and DLD-1 cell 
lines respectively (Table 3.22). 
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Table 3.22 Optimisation of incubation times for migration assay using C6-WT, C6-STX, DLD-1 
and SH-SY5Y cell lines. The optimum incubation time was defined as the time required for 70-
85% closure of the initial scratch. 16, 41 and 24 hours were used as the optimum incubation 
time for C6-WT/STX, DLD-1 and SH-SY5Y cell lines respectively. Results represents three 
independent experiments.  
 
3.3.3.2. Detection of cell proliferation using immunofluorescence 
assay 
 
The Ki-67 protein is a cellular marker for proliferation 172; an antibody for Ki-
67 was used as an indication of proliferation of the C6-STX and C6-WT cells 
at the edge of the scratch after 16 hours incubation. The assay was used 
with C6-STX and C6-WT cell lines specifically because the incubation time 
 
T = 0 h T = 13 h T = 16 h 
C6-WT 
   
C6-STX 
   
DLD-1 
T = 0 h T = 24 h T = 41 h 
   
SH-SY5Y 
T = 0 h T = 16 h T = 24 h 
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(16 hours) and the doubling time (24 hours) for these cell lines were close to 
each other. 
It was confirmed by this assay that after 16 hours incubation of C6-WT and 
C6-STX cell lines no evidence of proliferation was detected at the edge of 
the scratch, as evidence by a lack of immunostaining (Table 3.23). 
Table 3.23 Immunofluorescence staining of C6-WT and C6-STX cell lines with Ki-67 proliferation 
marker suggesting an absence of proliferation at the edge of the scratch in the migration assay 
after 16 hour incubation. Scale bar represents 250 µm. Results represents three independent 
experiments.  
 
Ki-67 
immunofluor
-escence 
staining 
T0 T16 
C6-STX 
  
C6-WT 
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3.3.3.3. Results of scratch assay using different polySia inhibitors on 
different cell lines 
 
Following the determination of the hit compounds that caused significant 
inhibition of ST8SiaII using the high throughput HPLC analysis, the impact of 
ST8SiaII inhibition on tumour cell migration was investigated using the 
scratch assay. 
ICT-3234, ICT-3233, ICT-3143, ICT-3268, ICT-3271 and ICT-3276 were 
investigated for anti-migratory effects on the four cell lines using different 
concentrations. ICT-3125, the parent molecule from which the other 
compounds were derivatised, was additionally included as a baseline control 
(Table 3.24 A-F). Its anti-migratory effects were also investigated in order to 
study the outcome of structural changes made to other molecules in the 
series on polyST inhibitory activity.   
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Table 3.24A Evaluation of the effects of ICT-3234 on the migration of C6-STX, C6-WT, SH-SY5Y and DLD-1 
cells. The compound was evaluated at the concentrations shown. Images in the next four tables are 
representative of the scratch induced in the cell line monolayer at T0 and T16/24 or 41 after treatment with 
the inhibitor. NP = not performed since the concentration was determined as toxic by MTT assay. Results 
represent three independent experiments.  
 
C6-STX Control 250 µM 125 µM 25 µM 
Initial scratch 
    
16 hours 
incubation 
    
C6-WT Control 250 µM 125 µM 25 µM 
Initial scratch 
    
16 hours 
incubation 
    
SH-SY5Y Control 250 µM 125 µM 25 µM 
Initial scratch 
 
NP 
 
 
24 hours 
incubation 
 
NP 
 
 
DLD-1 Control 250 µM 125 µM 25 µM 
Initial scratch 
 
NP NP 
 
41 hours 
incubation 
 
NP NP 
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Table 3.24B Migration assay of ICT-3143 using different cell lines and different concentrations. 
 
 
C6-STX Control 250 µM 125 µM 25 µM 
Initial 
scratch 
 
NP 
  
16 hours 
incubation 
 
NP 
 
 
C6-WT Control 250 µM 125 µM 25 µM 
Initial 
scratch 
    
16 hours 
incubation 
    
SH-SY5Y Control 250 µM 125 µM 25 µM 
Initial 
scratch 
 
NP NP 
 
24 hours 
incubation 
 
NP NP 
 
DLD-1 Control 250 µM 125 µM 25 µM 
Initial 
scratch 
 
NP NP 
 
41 hours 
incubation 
 
NP NP 
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Table 3.24C Migration assay of ICT-3233 using different cell line and different compound concentrations. 
 
 
C6-STX Control 250 µM 125 µM 25 µM 
Initial scratch 
    
16 hours 
incubation 
    
C6-WT Control 250 µM 125 µM 25 µM 
Initial scratch 
    
16 hours 
incubation 
    
SH-SY5Y Control 250 µM 125 µM 25 µM 
Initial scratch 
 
NP 
  
24 hours 
incubation 
 
NP 
  
DLD-1 Control 250 µM 125 µM 25 µM 
Initial scratch 
 
NP 
  
41 hours 
incubation 
 
NP 
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Table 3.24D Migration assay of ICT-3125 and CMP using different cell line and different compound 
concentrations 
 
 
C6-STX Control 5 mM Control 250 µM 
Initial 
scratch 
    
16 hours 
incubation 
    
C6-WT Control 5 mM Control 250 µM 
Initial 
scratch 
   
 
16 hours 
incubation 
    
SH-SY5Y Control 5 mM Control 250 µM 
Initial 
scratch 
    
24 hours 
incubation 
    
DLD-1 Control 5 mM Control 250 µM 
Initial 
scratch 
  
 
 
41 hours 
incubation 
 
   
CMP ICT-3125 
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Table 3.24E Migration assay of ICT-3268 and 3271 using different cell lines 
 
 
C6-STX Control 250 µM 125 µM 25 µM 
Initial 
scratch 
ICT-3268 
    
16 hours 
incubation 
    
C6-WT Control 250 µM 125 µM 25 µM 
Initial 
scratch 
    
16 hours 
incubation 
 
   
C6-STX Control 250 µM 125 µM 25 µM 
Initial 
scratch 
ICT-3271 
  
  
16 hours 
incubation 
    
C6-WT Control 250 µM 125 µM 25 µM 
Initial 
scratch 
    
16 hours 
incubation 
 
   
167 
 
Table 3.24F Migration assay of ICT-3276 using different cell lines and different concentrations 
 
 
 
 
 
 
 
 
 
 
 
 
C6-STX Control 12.5 µM 15 µM 20 µM 
Initial 
scratch 
    
16 hours 
incubation 
    
C6-WT Control 12.5 µM 15 µM 20 µM 
Initial 
scratch 
    
16 hours 
incubation 
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Figure 3.63 Effect of selected polyST inhibitors on the migration of C6-STX, C6-WT, SH-SY5Y and C6-WT 
cells. The results were observed after 41, 24 and 16 hours for DLD-1, SH-SY5Y and C6-STX/WT cells 
respectively. The missing concentrations represent the toxic concentrations as determined by MTT assay. 
The results represent the mean of three independent experiments.  
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ICT-3234, ICT-3233, ICT-3143 and ICT-3276 were found to exert a significant anti-
migratory effect on C6-STX cell line at a concentration of 250 µM; for ICT-3143 
(50.73 % inhibition), ICT-3233 (37.1% inhibition) and ICT-3234 (68.1% inhibition), 
and 15 µM for ICT-3276 (36.81 % inhibition). Besides, ICT-3234 (125 µM) showed 
also a significant inhibitory effect on SH-SY5Y cell line (66.04% inhibition). 
However, only ICT-3276 (15 µM), ICT-3233 (250 µM) and ICT-3234 (125 µM) 
showed a significant inhibition of the migration of C6-STX cell line without 
simultaneously showing any activity on C6-WT cells, which indicated that the 
compounds at these concentrations were both active and selective (Figure 3.63, 
Table 3.25). Both ICT-3268 and ICT-3271 were found to be not completely soluble 
in media. It was noticed that the both inhibitors re-precipitate after solubilisation in 
media.  
Table 3.25 Percentage of migration of C6-STX and C6-WT cells after treatment with different polyST 
inhibitors compared to untreated control cells and P significance of different polyST inhibitors effect on the 
migration of C6-STX and C6-WT cell lines at different concentrations. * P< 0.05, ** P<0.01 and *** P < 0.001. 
Results represent the mean of three independent experiments.  
 
Although ICT-3276 showed promising results with 56 ± 7.4 % inhibition of C6-STX 
migration and exerted no effect on the migration of C6-WT cells when administered 
at a 20 µM concentration, it was noticed that during the incubation of the cells, the 
C6-STX C6-WT 
Inhibitor % migration P value Significance 
% 
migration 
P value Significance 
CMP, 5 mM 69 0.019 * 93 0.067 Not 
ICT-3233, 25 µM 96 0.595 Not 87 0.109 Not 
ICT-3233, 125 µM 84 0.141 Not 94 0.702 Not 
ICT-3233, 250 µM 54 0.021 * 74 0.260 Not 
ICT-3234, 25 µM 83 0.245 Not 91 0.551 Not 
ICT-3234,125 µM 69 0.012 * 89 0.528 Not 
ICT-3276, 12.5 µM 103 0.567 Not 129 0.074 Not 
ICT-3276, 15 µM 68 0.020 * 125 0.066 Not 
ICT-3276, 20 µM 44 0.001 *** 114 0.183 Not 
ICT-3125, 250 µM 101 0.936 Not 96 0.493 Not 
ICT-3143, 25 µM 111 0.399 Not 99 0.965 Not 
ICT-3143, 125 µM 82 0.042 * 80 0.024 * 
ICT-3143, 250 µM 49 0.024 * 59 0.023 * 
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morphology of cells changed. Despite this, it was confirmed using the MTT assay 
that the compound had no effect on cell viability at this concentration (Table 3.21). 
To further confirm that the compound did not have a toxic effect on the cells, C6-
STX cells were incubated for 16 and 48 hours with 20 µM of ICT-3276 after which 
the media with the inhibitor was removed and fresh media was added to examine 
the recovery of the cells. After 16 hours the morphology of the cells treated with the 
compound had changed slightly (confirming that observed in the migration assay) 
and after 48 hour of incubation most of the cells changed from the normal nerve-like 
shape to a circular shape. This effect was reversed after the removal of the 
compound and addition of fresh media for 24 hours (Figure 3.64). It was thus 
concluded that the measured effect in the migration assay was not associated with 
cytotoxicty. These findings are interesting and warrant further investigation. 
ICT-3276 was found to be the most potent and selective compound of all the 
rational-designed inhibitors tested so far, thus close attention must be paid for the 
aforementioned effect. The change in cell morphology was observed in the C6-STX 
cells but not C6-WT cells, which suggests that this change may be due to a polySia-
associated activity. The next steps would be to assess the effect of the same 
concentration of agent on both SH-SY5Y and DLD-1 cell lines to examine whether it 
is exclusive to polySia expressing cells. Examining the cell cycle phase of the C6-
STX cells after treatment with the compound and comparing the result with 
untreated cells using flow cytometry and propidium iodide would also give valuable 
information about whether the compound is causing change in cell cycle phases. 
 
 
 
 
 
 
 
 
Figure 3.64 Effect of incubation of C6-STX cells with ICT-3276 (20 µM) over 16 and 48 hours and the 
recovery of the cells after removal of the compound and addition of fresh media for another 24 hours. 
Control cells are shown in the first panel showing no change in cell morphology over 72 hours while the 
              T0                                            T16                                                 T48                                  Recovery (T72) 
                                                                                                                                                                                  (Fresh media) 
Control 
ICT-3276  
 (20 µM) 
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addition of ICT-3276 on the lower panel showed changes in morphology, which was reversed by removal of 
the compound and addition of fresh media. Results represent three independent experiments.  
 
3.3.4. Determination of inhibition of ST8SiaII by measurement of 
polySia expression using immunofluorescence 
 
Hit compounds which have shown the most potent and selective anti-
migratory effect towards cells that express polySia over the control cell lines 
were chosen for further analysis using immunofluorescence. Examination of 
polySia chains with immunofluorescence allowed the confirmation of the 
results obtained earlier. 
In this assay ICT-3234, ICT-3276 and ICT-3176 were incubated with C6-STX 
cells for 16 hours. DAPI (4′,6-diamidino-2-phenylindole); a nuclear and 
chromosome counterstain, which emits blue fluorescence upon binding to AT 
regions of DNA, was used to label cell nuclei. PolySia expression was 
detected in the presence/absence of different concentrations of the inhibitors. 
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Table 3.26A Expression of polySia after treatment of C6-STX cells with different concentrations 
of ICT-3234, 3276 and 3176 for 16 hours, detected using mAb 735 polysia antibody. Scale bars 
represents 250 µm. Results represents three independent experiments.  
 
 
 
 DAPI mAb 735 Overlay 
Positive 
control 
   
Negative 
control 
   
ICT-3234, 
250µM 
   
ICT-3234, 
125µM 
   
ICT-3234, 
25µM 
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Table 3.26B Expression of polySia after treatment of C6-STX cells with different concentrations 
of ICT-3276  
 DAPI mAb 735 Overlay 
Positive 
control 
   
ICT-3276, 
50µM 
   
ICT-3276, 
20µM 
   
ICT-3276, 
15µM 
   
ICT-3276, 
12.5µM 
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Table 3.26C Expression of polySia after treatment of C6-STX cells with different concentrations 
of ICT-3176 
 
 
 
 
 DAPI mAb 735 Overlay 
Positive 
control 
   
Negative 
control 
   
ICT-3176, 
500µM 
   
ICT-3176, 
250µM 
   
ICT-3176, 
25µM 
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Immunofluorescence confirmed the effects of ICT-3234 and ICT-3276 as 
inhibitors of polySia synthesis in a concentration-dependent manner, 
consistent with results obtained from cell-free and cell-based HPLC-
chromatographic assays and migration assay. ICT-3176 was also examined 
by immunofluorescence. It was found that it also leads to a concentration-
dependant inhibition of polySia synthesis. However, the inhibitory effect was 
found to be less than the observed for ICT-3234, which is also consistent 
with the results obtained by the cell-based chromatographic assay (Figure 
3.26A-C).  
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3.4.  Conclusion 
 
In this chapter a number of phenotypic functional assays were exploited in 
order to investigate the molecular mechanisms of action of selected polyST 
inhibitors. In order to measure the effect of these inhibitors on the migration 
of cancer cells, polySia-NCAM expression of the four selected cell lines 
(namely SH-SY5Y, C6-STX, C6-WT and DLD-1) was first confirmed using 
immunofluorescence and western blotting. Next, the incubation time required 
for each cell line to induce 80% wound closure was determined.  
Cell migration in the presence of inhibitor was then evaluated in order to 
provide information to investigate the effect of changes in the chemical 
structures of rationally designed inhibitors on their selectivity. ICT-3276, 3234 
and 3233 were found to be the most active compounds with selective activity 
towards cell lines that express polySia, with inhibition of the cell migration 
capacity of 59.06 ± 5.8%, 37.1 ± 9.46% and 30.3 ± 6% for ICT-3276 (20 µM), 
ICT-3233 (250 µM) and ICT-3234 (125 µM) respectively on C6-STX cells. 
This is alongside an absence of inhibition on control cell lines. This effect 
was not caused by reduction of cell viability as confirmed by MTT assy.  
To sum up, hit molecules selected using the previously described cell-free 
and cell-based chromatographic assays were further evaluated using 
phenotypic functional assays. A significant correlation between the potency 
of the compounds recorded by the chromatographic assay and their potency 
as migration inhibitors was established. This provides further evidence for 
the role of the compounds as polyST inhibitors.  
For the first time, data demonstrating rationally designed polyST inhibitors 
that exhibit selective and significant inhibitory effect (on migration and 
polySia expression) on polySia expressing cell lines has been presented. 
ICT-3276 is the first reported rationally designed polyST inhibitor that shows 
a significant inhibition in the migration of polySia expressing cells with no 
significant effect on non-expressing cells at a concentration of 15 µM. The 
information generated from these assays will contribute to generation of a 
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structure activity relationship (SAR) for STX inhibitors, which will aid the 
subsequent design of new inhibitors in the future. 
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Chapter 4. Initial investigation of the potential role of 
polySia during cancer metastasis under hypoxic and 
normoxic conditions 
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4.1. Introduction 
 
As we have explored in earlier chapters, the expression of polySia on NCAM 
plays a key role in cell migration. Full understanding of its role in NCAM-
dependent or NCAM-independent modulation of cell motility and cell–matrix 
adhesion is yet to be established 57. Polysialylation of NCAM does not 
contribute only to specific NCAM-NCAM interactions, but also regulates 
overall NCAM interactions with other molecules. In this latter mode, the 
molecule can have both a positive and a negative effect on a wide variety of 
contact-dependent cellular events 173,174.  
Besides increasing inter-membrane repulsion due to the increased negative 
charge, polySia chains also modulate the NCAM-NCAM interactions, as well 
as NCAM interactions with other molecules that promote tumour metastasis. 
Additionally, it was observed that polySia also affects other cell interactions 
that do not appear to depend directly on NCAM’s intrinsic binding function 
173. A study by Ichiro Fujimoto et al., has shown that regulation by polySia 
occurs with adhesion receptors as diverse as an Ig-CAM, a cadherin such as 
L1, C-cadherin and an integrin such as αvβ1 integrin, and does not require 
NCAM functional domains other than those minimally required for 
polysialylation. This study suggested that the inhibitory effects of polySia-
NCAM on cell adhesion are independent of the nature of the adhesion 
system and of any intrinsic binding or signalling properties of the NCAM 
polypeptide itself 175. However, full understanding of the mechanism by which 
polySia promotes cancer metastasis is still to be defined. 
 
In this chapter, two areas in which polySia exerts its effects have been 
explored: (1) the possible additive anti-migratory effects of using certain 
intracellular signalling pathway inhibitors in combination with a polyST 
inhibitor, and (2) the effect of polySia expression on cancer cell behaviour 
under hypoxic conditions. In the next few pages, the background to each of 
these areas will be considered. 
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4.1.1. Understanding the interaction of polySia with different 
cancer signalling pathways 
 
NCAM was initially identified as a cell adhesion molecule exhibiting 
homophilic and heterophilic binding properties. However it was shown later 
to exert trans binding interactions with molecules of different classes, such 
as different members of the Ig-CAM superfamily including integrins, 
cadherins, growth factor receptors and components of the extracellular 
matrix and possibly others 36. In accordance with the protein's complexity, it 
has been involved in several cellular functions, mainly during neural 
development and plasticity and also in oncogenesis 30. 
To date, a number of heterophilic ligands of NCAM have been reported, such 
as: glial cell line-derived neurotrophic factor (GDNF), fibroblast growth factor 
receptor 1 (FGFR 1), and GDNF family receptor α, the L1 cell adhesion 
molecule, TAG-1/axonin-1, neurocan, phosphacan, agrin, various types of 
collagen, heparin, heparan/chondroitin sulfates, cellular prion protein, the 
glucocorticoid receptor, receptor tyrosine kinase B, platelet-derived growth 
factor (PDGF), brain-derived neurotrophic factor (BDNF), rabies virus, ATP, 
spectrin, focal adhesion kinase, and various cytoskeletal components 35,176. 
The interaction of NCAM with different heterophilic ligands is controlled by its 
polysialylation state 35. When NCAM is polysialylated to a very low degree or 
not polysialylated a two-dimensional zipper formation predominates, and 
consequently there is no room between the NCAM molecules for interactions 
with other molecules due to the tight packing. On the other hand, trans 
homophilic interactions between polysialylated NCAM molecules results in 
the formation of one-dimensional zippers, leading to the formation of thread-
like clusters of NCAM molecules and allowing association between NCAM 
and other molecules 35. 
In order to examine the potential additive anti-migratory effects of using a 
polyST inhibitor in combination with certain signalling pathway inhibitors 
which were previously reported to be modulated with polySia expression, 
neuroblastoma cells were incubated with non-toxic concentration of a polyST 
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inhibitor in the presence/absence of the selected pathways inhibitors. The 
difference in cell migration between the control cells (treated with polyST 
inhibitor only) and the cells treated with both polyST and signalling pathway 
inhibitors was recorded to examine the potential additive anti-migratory 
effect. 
Specifically, crizotinib, PF-573228, axitinib, GNF-5837 and SU-5402 were 
used to study the role of c-MET/ALK, FAK, VEGFR, TRK and FGFR 
respectively on polySia-mediated tumour cell migration (Table 4.27). These 
pathways have been chosen to be studied since they have been previously 
reported to be associated with polySia. In the next few paragraphs, the link 
between the polysialylation status of NCAM and the activity of the 
aforementioned signalling pathways will be discussed.  
Table 4.27 Mechanism of action of the signalling pathway inhibitors used in this chapter. 
 
Inhibitor Target signalling pathway Reference 
SU-5402 FGFR 
177,178
 
Crizotinib c-Met/ALK 
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PF-573228 FAK 
180
  
Axitinib VEGFR 
181
 
GNF-5837 TRK 
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4.1.1.1. Hepatocyte growth factor receptor (c-MET)  
 
c-MET is a receptor tyrosine kinase that, after binding with its ligand, 
hepatocyte growth factor, activates a wide range of different cellular 
signalling pathways, including those involved in cancer cell proliferation, 
migration and invasion 183. Expression of c-MET and its ligand has been 
observed in tumour biopsies of most solid tumours and c-MET signalling has 
been documented in a wide range of human malignancies. Studies suggest 
that c-MET-positive status indicates poor prognosis 184,185. 
Tyrosine phosphorylation has been previously implicated in the regulation of 
cadherin function: receptor tyrosine kinases such as epidermal growth factor 
receptor (EGFR), hepatocyte growth factor receptor (c-MET) and fibroblast 
growth-factor receptor (FGFR), phosphorylate E-cadherin, β-catenin, γ-
catenin p120-catenin and neuronal (N)-cadherin, resulting in the disassembly 
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of the cell adhesion complex and disruption of cadherin-mediated cell–cell 
adhesion 28,96.  
Polysialylation of NCAM was also reported previously to represses cadherin-
mediated cell-cell adhesion. C-Met activity was found to be regulated by 
modification of its terminal sialic acid structure 186. These findings raise the 
question about a possible role for polySia on c-MET activity. 
4.1.1.2. Anaplastic lymphoma kinase (ALK) 
 
Anaplastic lymphoma kinase (ALK), a transmembrane receptor tyrosine 
kinase (RTK), originally identified in the nucleophosmin (NPM)–ALK chimera 
of anaplastic large cell lymphoma, has emerged as a novel tumourigenic 
player in several human cancers. ALK receptor expression, originally 
documented in a variety of cancer lines, has been documented in many 
neuronal tumours such as glioblastoma, and mesenchymal neoplasms 
including melanoma and rhabdomyosarcoma. In this context, ALK over-
expression or gain of function mutations have been demonstrated to be 
tumourigenic 187. 
ALK has additionally been identified as a neuroblastoma predisposing gene, 
and activating mutations have also been identified in a subset of sporadic 
neuroblastoma tumours. ALK protein expression is significantly up regulated 
in some metastatic neuroblastoma cases, and overexpression of either 
mutated or wild type ALK, is a poor prognosis indicator for those patients. 
Inhibition of ALK activity in neuroblastoma cell lines has already been studied 
and targeted by using specific small molecules. ALK has 16 highly conserved 
putative sites of N-linked glycosylation in the extracellular domain. It was 
demonstrated that inhibition of N-linked glycosylation impairs ALK 
phosphorylation and disrupts downstream pro-survival signalling, as well as 
cell viability, in neuroblastoma cell lines harbouring mutated or amplified 
ALK. This suggests that inhibition of this post-translational modification could 
be a promising therapeutic approach 32.   
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4.1.1.3. Focal adhesion kinase (FAK) 
 
Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that 
increasingly has been implicated in cancer progression 180. FAK has been 
identified as a key mediator of signalling by integrins, a major family of cell 
surface receptors for extracellular matrix, as well as other receptors in both 
normal and cancer cells 188. Activated (phosphorylated) FAK forms a binary 
complex with Src family kinases, which can phosphorylate other substrates 
and trigger multiple intracellular signalling pathways to regulate various 
cellular functions. 
Previous studies have shown that polySia removal with Endo-N results in a 
significant increase in the number of peripheral focal adhesions per cell, 
characterized as FAK 57. It was found that homophilic interactions between 
non-polySia-NCAM accelerate FAK phosphorylation 44,189. Here we studied 
the possible role of FAK activity on polySia-mediated cell migration. 
4.1.1.4. Vascular endothelial growth factor (VEGF) 
 
VEGF is a potent angiogenic factor which is up-regulated in many tumours 
and its contribution to tumour angiogenesis is well defined 190. Anti-VEGF 
strategies to treat cancers were designed to target the pro-angiogenic 
function of VEGF and thereby inhibit neovascularisation. Two of the most 
well-known drugs that have been successful at slowing the progression of 
disease stimulated by VEGF are monoclonal antibodies bevacizumab and 
ranibizumab 191. However, anti-VEGF therapies may have a dual effect since 
evidence is accumulating to support the existence of both paracrine and 
autocrine VEGF loops within tumours 192. It has been suggested that direct 
stimulation of tumour cells by VEGF may protect the cells from apoptosis and 
increase their resistance to conventional chemotherapy and radiotherapy 193.  
Previous studies have suggested that VEGF has an essential role in guiding 
directed migration and consequently, it has an important role in cancer 
invasion and metastasis 194. A glycosylation-dependent pathway that 
compensates for the absence of cognate ligand and preserves angiogenesis 
in response to VEGF blockade has been identified 195. In-house experiments 
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showed that treatment with polyST inhibitor down-regulated VEGFR3 
phosphorylation (data not shown). Here we investigate the effect of 
combining polyST and VEGF inhibition on the migration of cancer cells. 
4.1.1.5. Tropomyosin receptor kinase (TRK) 
 
Trk receptors are a family of tyrosine kinases that regulates synaptic strength 
and plasticity in the mammalian nervous system 196. Tropomyosin-related 
kinase B (Trk-B), which serves as a receptor for brain-derived neurotrophic 
factor (BDNF) and for neurotrophic factor 4 (NT4), has been found to be a 
potentially important mediator of the invasive properties of neuroblastoma 197 
and head and neck cancers and a mediator of the epithelial-mesenchymal 
transition (EMT) 198. 
BDNF dimer binds directly to polySia to form a large complex with a 
molecular weight greater than 2000 kDa under physiological conditions. 
BDNF, after making a complex with polySia, can bind to the BDNF receptors, 
TrkB and p75NTR. The complex formation of BDNF with polySia was found 
to up-regulate growth and survival of neuroblastoma cells. AZD6918, a novel 
potent and selective inhibitor of the Trk tyrosine kinases was found to 
increase the sensitivity of neuroblastoma to etoposide 199. These findings 
suggest that polySia functions as a reservoir of BDNF and other neurotrophic 
factors and may serve to regulate their local concentrations on the cell 
surface 200. 
4.1.1.6. Fibroblast growth factor receptor (FGFR) 
 
Abnormalities in FGF and the FGFR pathway have been associated with 
progression of a wide spectrum of malignancies including myeloma, breast, 
endometrial, genitourinary, neuroblastoma and gastric cancers 201,202. Initial 
efforts in targeting FGFRs with small-molecule tyrosine kinase inhibitors 
(TKIs) have been tempered by challenges in the drug development process, 
which illustrates the complexities of developing drugs that target uncommon 
genomic alterations in tumours, as well as poor tolerability mainly related to 
non-specificity and off-target effects. Multiple pharmaceutical companies are 
at different stages of pursuing FGFR blockade, mostly using small-molecule 
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TKIs, but other approaches using monoclonal anti-FGFR antibodies and FGF 
trapping molecules are also being investigated. Recently, selective potent 
FGFR TKIs (eg, JNJ-42756493, BGJ398, AZD4547, LY287445, and 
TAS120) are being investigated with high in vitro kinase activity and 
specificity against FGFR1, FGFR2, and FGFR3 (enzymatic concentration 
that causes 50% inhibition [IC50], < 10 nM) in the hope of having a more 
tolerable safety profile by reducing off-target effects 203. 
FGFR is one of the most studied heterophilic partners of NCAM. Binding of 
FGFR to NCAM has attracted the attention of many researchers due to its 
functional implications. The FGFR family consists of four members of 
tyrosine kinase receptors that are typically activated upon binding of cognate 
growth factors, the FGFs, which results in the recruitment and activation of 
specific effectors that, in turn, trigger a set of signalling pathways 204,205. 
These signalling pathways are implicated in the regulation of key cell 
behaviour, such as proliferation, differentiation, migration, and survival, and 
are fundamental to embryonic development, regulation of angiogenesis, and 
wound healing in adults. Dysregulation of the FGF/FGFR signalling pathway 
has been associated with many developmental disorders and with cancer 
where it has been recognized that FGFRs are overexpressed in many cancer 
cell types 205. 
Although the FGFR/NCAM interaction was originally reported in neurons 
where it was implicated in neurite outgrowth, recent studies showed 
evidence of physical interaction between the two proteins on non-neural cell 
types 206. The ability of polysialylated NCAM to bind to and activate FGFR, 
results in the induction of a migratory and invasive phenotype to cancer cells 
through the induction of certain pathways involved in cell migration such as 
signalling pathways, mediated by PKCβII, AKT family members and SRC 
family members 206. Importantly, polySia-NCAM stimulated FGFR undergoes 
dimerisation to the cell surface resulting in sustained signalling 36.  
In some cancer cells, an interaction between NCAM and FGFR1 appears to 
stabilise receptors on the cell surface and may thereby potentiate signalling 
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by endogenous FGFs 207. In other cancer cells an interaction between NCAM 
and the FGFR4 appears to orchestrate the formation of a higher order-
signalling complex that can signal independently of the conventional ligands 
30,207. Likewise, in neurons CAMs appear to be able to act as surrogate 
ligands for the FGFR and signal via the receptors independently of FGFs 
30. Two molecular switches are thought to regulate the NCAM-FGFR 
interaction: adenosine triphosphate (ATP) and polySia.  
In one study, it was found that removal of polySia results in growth inhibition 
in neuroblastoma cell lines, a process that is mediated by NCAM-FGFR 
interactions 37. Additionally, polySia promotes NCAM-mediated cell migration 
in an FGFR-dependent manner 189. This means that modulating FGFR-
NCAM binding by inhibiting NCAM polysialylation is a potential mechanism 
for preventing the dissemination of metastatic tumour cells. 
To sum up, several studies have suggested a possible role for polySia in the 
activity of c-MET/ALK, FAK, VEGFR, TRK and FGFR signalling pathways 
which opens a debate about whether inhibition of these pathways would 
result in an additional anti-metastatic activity when used in combination with 
polyST inhibitors, which is the main focus of the first section of this chapter. 
In the next few pages the background for the second section of this chapter, 
which involves initial experiments focused on exploring the effect of polySia 
expression on cancer cell behaviour under hypoxic conditions, will be 
discussed. 
4.1.2. Exploring the effect of polySia expression on cancer cell 
behaviour under hypoxic conditions 
 
The tumour microenvironment is intimately connected with the evolution of 
cancer. In particular, hypoxia, a condition of low oxygen tension occurring in 
poorly vascularised areas, has a profound effect on tumour cell growth, 
metastasis, susceptibility to apoptosis, and resistance to radio- and 
chemotherapy 208. As a tumour grows, blood supply to the cancer cells often 
becomes inadequate due to dysfunctional and leaky tumour vasculature, 
leading to poor or irregular oxygen delivery and tumour hypoxia (Figure 
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4.65). Normal cells would eventually die under extreme hypoxic conditions, 
however, cancer cells have genetic alterations that enable them to adapt and 
thrive in the hypoxic tumour microenvironment. In this way the cancer cells 
are able to “hijack” the adaptive mechanisms used to cope with hypoxia by 
activating a number of pathways that favour their survival 209,210. 
In solid tumours, oxygen delivery to the respiring neoplastic and stromal cells 
is frequently reduced or even abolished by a number of factors: deteriorating 
diffusion geometry since oxygen is only able to diffuse 100–180 µm from the 
end of the nearest capillary to cells before it is completely metabolised 211, 
severe structural abnormalities of tumour microvessels and disturbed 
microcirculation 212, in addition to anaemia and the formation of 
methaemoglobin or carboxyhaemoglobin which reduce the blood's capacity 
to transport O2. As a result, areas with very low (down to zero) oxygen partial 
pressures exist in solid tumours, occurring either acutely or chronically. 
These micro-regions of very low or zero O2 partial pressures are 
heterogeneously distributed within the tumour mass and may be located 
adjacent to regions with normal O2 partial pressures. In contrast to normal 
tissue, neoplastic tissue can no longer fulfil physiologic functions 213. 
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Figure 4.65 The vascular network of normal tissue versus tumour tissue. Normal vasculature 
(a) is hierarchically organised, with vessels that are sufficiently close to ensure adequate 
nutrient and oxygen supply to all cells. Tumour blood vessels (b) are chaotic, dilated, tortuous 
and are often far apart and have sluggish blood flow. As a consequence, areas of hypoxia and 
necrosis often develop distant from blood vessels 
210
.  
The tumour microenvironment affects behaviour and prognosis of the 
malignant tumour. Tumour hypoxia has been associated with poor prognosis, 
enhanced loco-regional spread and metastatic potential 214.  In reality there 
have been many difficulties to overcome. Established hurdles, such as the 
difficulties associated with modulating protein-protein interactions, mean that 
many pharmaceutical companies are reluctant to invest in what is seen to be 
a high-risk area 209. However, validating a target that can block the 
metastasis of both hypoxic and normoxic tumour cells would be an attractive 
proposition. 
Tumour cells in hypoxic regions have a number of hallmarks that make them 
very difficult to treat. Typically, hypoxic cancer cells are characterised by 
elevated interstitial pressure 215,216, low extracellular pH, glucose deprivation, 
high lactate levels, decreased partial oxygen pressure (pO2 <10 mmHg), 
accumulation of macrophages 217-219 and recruitment of the stromal cell 
components of the tumour microenvironment. Furthermore, hypoxic cells 
include the so-called ‘cancer stem cells’ that are believed to be the engines 
driving continuous production of cancer cells 220,221. They are also highly 
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invasive and can metastasise away from the primary location to other sites 
222 (Figure 4.66).  
Figure 4.66 Hallmarks of hypoxic cancer. 
The response to hypoxia is associated with changes in gene expression 223. 
Hypoxia activates, among others, hypoxia-inducible transcription factors 
(HIF-1α and HIF-2α), which trans-activate the hypoxia-responsive element 
(HRE) present in the promoter of many genes encoding angiogenic, 
metabolic and metastatic factors and contributes to the acquisition of the 
tumour aggressive phenotype 224,225. 
Hypoxia has a negative effect on cancer patient’s prognosis, it has been 
considered as a stressor which selects cells with increased resistance to 
apoptosis and thus indirectly contributes to treatment resistance. Two 
different factors have been considered to explain the negative effect of 
hypoxia on the cancer patient’s prognosis. The first factor involves the direct 
interference of hypoxia with anticancer therapy. The efficacy of ionising 
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radiation, and also a number of cytotoxic drugs and cytokines, depends 
directly on adequate oxygen levels. The second factor involves the effects of 
hypoxia on the biology of tumour and stromal cells since hypoxia is related to 
malignant progression, increased invasion, angiogenesis and an increased 
risk of metastasis formation 214 
Recent studies suggest that both hypoxia and the extracellular matrix (ECM) 
significantly contribute to cancer metastasis. Throughout tumour progression, 
changes in the composition and content of the ECM changes both its 
biophysical and biological properties and these significantly affect tumour 
and stromal cell properties such as proliferation and motility. Recent studies 
have shown a direct link between hypoxia and the composition of the ECM, 
which was formerly thought of as independent contributors to metastatic 
spread.  This suggest a new model in which multiple micro environmental 
signals might unite to synergistically regulate metastatic outcome 222. 
Here we have studied the effect of polySia expression, a main regulator of 
cancer cell-cell adhesion and a pro-migratory molecule on the behaviour of 
cancer cells under hypoxic conditions. 
Hypoxia promotes cancer cell invasion and metastasis through inducing EMT 
226. A study by Justin V. et al., has shown that the exposure of non-
mesenchymal SNB75 and U87 cells to hypoxia induced a strong change in 
cell morphology that was accompanied by enhanced invasive capacity and 
the acquisition of mesenchymal marker expression. It was identified that a 
HIF1α signalling axis promotes hypoxia induced mesenchymal shift and 
invasion in glioblastoma cells 227. 
There is a positive correlation between HIF-1α and the N-cadherin 
expression profile 226. Besides, involvement of HIF in the induction of 
carbohydrate determinants, such as sialyl Lewis x and sialyl Lewis, was 
evident in study performed by Tetsufumi Koike et al 228. This suggests that 
there might be a cross talk between polySia and HIF that results in 
modulation of cell behaviour under hypoxic conditions. 
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On the other hand, as mentioned earlier, polySia is suggested to be a 
modulator of the activity of a number of cancer cell signalling pathways such 
as c-MET/ALK, FAK, VEGFR, TRK and FGFR. It was found that some of 
these signalling pathways are also modulated by cancer cell 
hypoxic/normoxic status such as FGFR and c-MET. In a study by C. Blick, it 
was found that hypoxia, in part via suppression of miR-100, induces FGFR3 
expression in bladder cancer, both of which have an important role in 
maintaining cell viability under conditions of stress 229. Another study has 
shown that in several cancer cell types, hypoxia activates the c-MET 
promoter, which contains hypoxia inducible factor-1 (HIF-1) binding sites, 
which can enhance the stimulating effect of SF/HGF on tumour cell migration 
230.  
This gives strong rationale for studies aimed at the exploring the possible 
role of polySia on cancer cell behaviour under hypoxic conditions, with the 
potential to provide a biochemical basis for the development of therapeutic 
strategies that can specifically block both cancer metastasis and survival 
within the heterogeneous hypoxic/normoxic characters of tumours. 
To sum up, the aim of this chapter is to carry out initial investigations of the 
possible additional anti-metastatic effects of using certain signalling pathway 
inhibitors in combination with a polyST inhibitor. Additionally, pilot studies are 
performed in order to investigate the possible role of polySia on the 
behaviour of cancer cells under hypoxic conditions.  
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4.2. Materials and methods 
 
All the materials are purchased from Sigma Aldrich, UK unless otherwise 
specified. 
4.2.1. Cell lines 
 
Cell lines were maintained as previously described in chapter 3. For studies 
carried out under hypoxic conditions, all the media used were incubated for 
at least 48 hours under hypoxic conditions (0.1% Oxygen) before being 
added to the cells.  
4.2.2. 3-[4,5- Dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium 
bromide (MTT) assay 
 
The MTT assay was performed as previously described in chapter 3. 
4.2.3. Migration assay 
 
The migration assay was performed as previously described in chapter 3 
(Section 3.2.3). Different cell lines were seeded in six well plates in the same 
density described previously, and cultured for 24 h. For studying the possible 
additive anti-migratory effect of combining polyST inhibitors with different 
SPIs: SU-5402, crizotinib, PF-573228, axitinib and GNF-5837 were added at 
concentrations of 10, 2, 3, 2.5 and 2 µM respectively. Each inhibitor was 
added to two wells, to one of them ICT-3176 (250 µM) was also added. In 
one well ICT-3176 (250 µM) only was added to be used as a control and to 
another well fresh media (containing DMSO in concentration equivalent to 
the concentration of the added inhibitors in the other wells) was used as 
negative control, to compare the migration of the cells in the presence and 
absence of the inhibitors. After 24 hours, images were taken. 
For studying the effect of polySia expression on the migration of cancer cells 
under hypoxic conditions, migration assay was performed under normoxic 
versus hypoxic conditions (0.1% Oxygen) and images were taken after 16, 
24 or 41 hours depending on the cell line, as described in chapter 3. 
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4.2.4. Growth curve 
 
C6-STX and C6-WT cells were maintained and counted as mentioned earlier 
(Section 3.2.2). After cells were counted, cell suspensions were diluted in 
order to have an appropriate amount of the medium and to achieve a proper 
cell seeding density (2.5 x 104). Ten flasks of each cell line were seeded with 
the same density. Five plates of each cell line were incubated in a humid 
atmosphere of 5% CO2 and 95% air at 37 °C while the other five flasks were 
maintained in a hypoxic chamber (Whitley-H35-hypoxystation) in a humid 
atmosphere of 5% CO2, 0.1% O2 and 95% nitrogen gas at 37°C. The 
duplicate plates were counted every 24 hours. The results were plotted on a 
log-linear scale.  
4.2.5. Adhesion assay 
 
4.2.5.1. Cell lines preparation  
 
C6-STX and C6-WT cell lines were seeded in a concentration of 2 x 105 in 
two flasks (T75) per each cell line. One flask of each cell line was incubated 
in a humid atmosphere of 5% CO2 and 95% air at 37 °C while the other flask 
was maintained in the hypoxic chamber in a humid atmosphere of 5% CO2, 
0.1% O2 and 95% nitrogen gas at 37°C, all the media and buffers used with 
the hypoxic flask were kept in hypoxic conditions at least 48 hours before the 
experiment.  
4.2.5.2. Pre-coating of multi-well plates 
 
Matrigel™ matrix (VWR, USA) was diluted from stock solution to form a final 
concentration of 40 µg/ml using ice cold PBS (pH 7.4). Matrigel solution (200 
µl) was added to the required number of wells in 24-well plates, which were 
incubated at 37 °C. After two hours, excess Matrigel was removed by 
inverting the multiwell plate over a plastic reservoir and tapping gently. The 
wells were then washed twice with cold PBS.  
Blocking solution (500 µl) consisting of DMEM media with 10% FBS was 
added to each well to block non-specific binding. The plates were then 
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incubated at 37 °C. After 30 minutes the wells were washed once with cold 
PBS and fresh culture medium was added (200 µl) and the plates were 
incubated at 37 °C. 
4.2.5.3. Cell counting and seeding  
 
Hypoxic and normoxic C6 cell lines were trypsinised and counted. 2 x 104 
cells in 100 µl medium were added to the pre-coated 24-well plate. For each 
condition of each cell line, 3 wells were seeded for each technical repeat. 
Culture medium (300 µl) was added to one well to be used as a blank to 
calculate the background staining. The plates were incubated at 37 °C for 30 
minutes. For the hypoxic conditions all the steps were carried out in a 
hypoxic chamber. 
4.2.5.4. Cell fixation and quantification 
 
After incubation of the cells in the Matrigel-coated plates for 30 minutes, non-
adherent cells were removed by inverting the plates on a plastic reservoir. 
Wells were washed two times with ice-cold PBS (300 µl) containing CaCl2 (1 
mM) and MgCl2 (1 mM). Cells were fixed by adding ice-cold 100% methanol 
(300 µl). After 10 minutes, wells were washed with PBS three times and 
0.5% crystal violet solution (100 µl), prepared in 20% ethanol, was added. 
Plates were placed on a shaker and incubated with crystal violet for 10 
minutes at room temperature.  
Excess crystal violet was removed by immersing the plates in large beakers 
filled with distilled water, three immersions of one minute each. Crystal violet 
was then recovered by adding 100% methanol (200 µl) to each well. The 
plates were placed on the shaker for 15 minutes at room temperature. 100 µl 
of the extracted crystal violet was transferred to 96 well-plate.  
4.2.5.5. Data analysis 
 
Absorbance of the samples was measured spectrophotometrically at a 
wavelength of 540 nm. The background absorbance of multi-well plates was 
also measured and subtracted from the 540 nm measurements. 
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The absorbance reading acquired for each sample were analysed 
quantitatively. For each reading, the absorbance of the multi-well plates was 
subtracted and the % cell adhesion relative to C6-WT cell line was calculated 
(% adhesion = average absorbance of the C6-WT cells /average absorbance 
of C6-STX cells in the same condition x 100). 
4.2.6. Flow cytometry (Annexin V apoptosis detection assay) 
 
4.2.6.1. Cell line preparation 
 
C6-WT, C6-STX cells were seeded at a cell density of 4 x 105 in T75 flasks. 
Two flasks for each cell line were seeded, one of which was incubated under 
normoxic conditions (5% CO2 and 95% air) while the other was incubated 
under hypoxic conditions (5% CO2, 0.1% O2 and 95% nitrogen gas) at 37°C 
for 96 hours. 
4.2.6.2. Annexin V staining 
 
After 96 hours incubation at normoxic/hypoxic conditions, media from each 
flask was collected and cells were trypsinised. Trypsinised cells along with 
the collected media, containing floating dead cells, were placed in a 20 ml 
tube and centrifuged for 5 minutes at 10000 g. After centrifugation, media 
was discarded and cell pellets were re-suspended in 1 ml of HEPES buffer. 
Cells were centrifuged again for five minutes at 1500 g. 
Cell pellets were re-suspended in propidium iodide / Annexin V mix (1:5) 
(100 µl). After 15 minutes incubation, the solution was transferred to falcon 
round bottom tubes (FACS tubes) and Annexin-binding buffer was added 
(0.5 ml). Samples were analysed by flow cytometry. 
4.2.6.3. Data Analysis 
 
Samples were analysed by flow cytometry, (annexin V and propidium iodide 
fluorescence excitation/emission are 494/518 nm and 535/617 nm 
respectively). The cell population was separated into three groups: live cells, 
which show only a low level of fluorescence; apoptotic cells, which show 
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green fluorescence and dead cells, which show both red and green 
fluorescence, as summarised in figure 4.67. 
 
 
 
 
 
 
 
 
Figure 4.67 Schematic representation of the results obtained by flow cytometry. 
 
4.2.7. Trypan blue exclusion assay for cell viability 
 
Cell lines were prepared as previously described for the Annexin V apoptosis 
assay (section 4.2.6). Cells were trypsinised and the cell density of each cell 
line suspension was determined using a haemocytometer. A 0.4% solution of 
trypan blue was prepared in PBS solution (pH 7.2 to 7.3) and 0.1 mL of 
trypan blue stock solution was added to 1 mL of cells. Each haemocytometer 
chamber was loaded with 10 µl of the solution and examined immediately 
under a microscope at low magnification. The number of blue-stained cells 
and the number of total cells was counted. Cell viability (%) was calculated 
as follows: 
% Viable cells = [1.00 – (Number of blue cells ÷ Number of total cells)] × 100 
4.2.8. Western blot analysis 
 
Western blot assay was performed as previously described in chapter 2. For 
the experiment carried out in this chapter 12% resolving gel was used. The 
resolving gel was made up of tris base (0.37 M, pH 8.8), 12% acrylamide 
mix, 0.1% SDS, 0.1% ammonium persulfate and 0.04% TEMED. 
Propodium Iodide 
Annexin V 
Annexin –/PI + 
(Cell debris) 
Annexin -/PI- 
(Live cells) 
Annexin +/PI+ 
(Late apoptotic) 
Annexin +/PI – 
(Early apoptotic) 
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4.2.8.1. Sample preparation 
 
C6-STX and C6-WT cells were seeded at the density of 2 x 105 cell/well in a 
six-well plate and incubated for 24 hours at 37°C in a 5% CO2 humidified 
atmosphere to allow cells to adhere. After 24 hours, medium was removed 
and fresh medium containing different concentrations of CoCl2 was added. 
Two wells were used as a control where no CoCl2 was added. After 16 hours 
cells were collected. 
4.2.8.2. Protein extraction 
 
After trypsinisation cells were centrifuged and cell pellet was washed with 
PBS and re-suspended in 200 µl of lysis buffer consists of 10 µl 1X 
phosphatase inhibitor (P5726, Sigma, UK), 50 µl of 1X protease inhibitors 
cocktail (S8830, Sigma, UK) and 940 µl of RIPA buffer (NaCl (150 mM), %1 
IGEPAL CA-630, 0.5% sodium deoxycholate, 0.1% SDS (GE Healthcare) 
and Tris (50 mM, pH 8)) in a microcentrifuge tube, maintaining constant 
agitation for 30 min at 4°C. The lysate was then sonicated three times (3 
cycles, 10 seconds each, %10 amplitude) with one minute rest on ice 
between each ten-second pulse. The lysate was centrifuged at 13,000 x g for 
5 minutes at 4°C and the supernatant was collected into new microtubes. 
4.2.8.3. Quantification of protein concentration (Bradford assay) 
 
Bradford reagent (GE Healthcare, UK) was diluted with distilled water (4:1). 
A set of bovine serum albumin (BSA) standards with known concentrations 
were prepared (0-1mg/ml). Standard and cell lysate samples were added in 
triplicate into 96 well plate (10 µl per well). Diluted Bradford reagent was 
added to each well (200 µl), and incubated for 5 minutes. The absorbance of 
the samples was examined using plate reader (Thermo Scientific multiskan 
spectrum, Thermo Scientific, UK) (595 nm) and standard curve between the 
concentration of the standards and its absorbance was created from which 
the concentration of the samples was calculated. 
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4.2.9. Statistics  
 
All experiments were repeated three times independently unless otherwise 
specified. Statistical analyses were performed using Excel software. 
Differences between two groups were evaluated with Student's t test (Two 
tailed) where the P value significance is: P value (P) >0.05 was deemed not 
significant, P < 0.05 * was statistically significant, P < 0.01 ** and P < 
0.001*** were statistically highly significant. 
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4.3. Results and discussion 
 
4.3.1. Investigation of possible additive anti-migratory effect of 
using selected SPIs in combination with polyST inhibitor   
 
In order to investigate the possible additive anti-migratory effect of using 
polyST inhibitors in combination with selected SPIs, the effect of a number of 
signalling pathway inhibitors (SU5402, axitinib, crizotinib, PF-573228, 5-FU 
and GNF-5837) on polySia-expressing neuroblastoma cell line (SH-SY5Y) 
migration was investigated in presence/absence of ICT-3176. The 
expression of these signalling pathways in SH-SY5Y cell line was confirmed 
by parallel work performed by Dr. Virginie Viprey (Data not shown). 
Non-toxic concentrations of the SU5402, axitinib, crizotinib, PF-573228 and 
GNF-5837, as pre-determined by MTT assay, (10, 2.5, 2, 3 and 2 µM 
respectively) were used for this analysis; the non-toxic concentrations were 
chosen to ensure that the reduction in the cell migration is not caused by loss 
of cell viability. SH-SY5Y cells were treated with SU-5402, crizotinib, PF-
573228, axitinib or GNF-5837. Each signalling pathway inhibitor was added 
to two wells, to one of them 250 µM of ICT-3176 was also added. To one 
well ICT-3176 only was added. The migration of the cells within all the wells 
was calculated and compared with control (untreated) wells.  
Of the combinations evaluated, only crizotinib in combination with ICT-3176 
resulted in an additive inhibitory effect on the migration of SH-SY5Y cells (P 
value = 0.02) (Figure 4.68). Crizotinib alone produced a non-significant 
reduction in cell migration. ICT-3176 caused a 35% reduction in cell 
migration (P value = 0.01). Together, crizotinib and ICT-3176 led to a 60% 
reduction in SH-SY5Y migration (P value = 0.01). 
Axitinib, SU-5402, GNF-5837 and PF-573228 combinations did not show any 
inhibition compared with ICT-3176 alone at the concentrations tested.  
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The results obtained from this experiment suggest that there is possibly a 
cross-talk between polySia-NCAM and c-MET/ALK signalling pathway that is 
modulating cancer cell migration. These results come in agreement with a 
number of previous studies which suggested that inhibition of N-linked 
glycosylation impairs c-MET activity and ALK phosphorylation, resulting in 
disruption of downstream signalling 32,186.  
 
Figure 4.68 Effect of the combination of polyST inhibitor ICT-3176 and different signalling 
pathway inhibitors on SH-SY5Y cell migration. Concentrations determined previously by MTT 
assay. , * refers to P < 0.05. Results represent the mean of three independent experiments. 
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The effect of polySia expression on cancer cell behaviour under 
hypoxic conditions 
4.3.2. Evaluation of the effect of hypoxia on polySia expression  
 
Our first goal was to investigate whether hypoxia has any effect on the level 
of polySia expression on tumour cells. C6-STX cells (and C6-WT cells, used 
as a control to eliminate any false-positive results caused by presence of 
sialic acid in the medium at which the cells are grown) were incubated at 37 
°C at either 0.1% oxygen, 5% carbon dioxide and 95% nitrogen (hypoxia) or 
5% Carbon dioxide and 95% air (normoxia). After 30 and 48 hours cells were 
harvested and ST8SiaII expression was confirmed using RT-PCR (Data not 
shown). polySia expression was quantified using the cell-based 
chromatographic assay described in chapter 2. 
Interestingly, a comparison of the polySia expression of C6-STX cells under 
hypoxia and normoxia demonstrated a difference. C6-STX cells exhibited a 
significant reduction (40 ± 6.9 %) in the expression of polySia under hypoxia 
compared to normoxia. No significant differences in polySia expression were 
detected between the 30 h and 48 h measurements (Figure 4.69). C6-WT 
cell were used as negative control where no expression of polySia was 
detected under both conditions. The cell-based polySia quantification was 
carried out using both methods, i.e. both Endo-N and mild acidic hydrolysis 
for the removal of polySia from the cell surface. Similar results were obtained 
from both experiments (SD ± 15%).  
These data strongly indicate that polySia expression in cancer cells is down 
regulated under hypoxic conditions. To-date, there are no studies that have 
pointed out the effect of hypoxia on the expression of polySia, however these 
results are consistent with previous studies that has suggested that acute 
hypoxia produces a degree of glycocalyx degradation (a 0.2 – 1 μm thick 
negatively charged anti-adhesive and anti-coagulant carbohydrate-rich layer) 
231. 
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Figure 4.69 Effect of hypoxia (48 hours, 0.1% O2) on polySia expression in C6-STX cells. Cell-
based HPLC analysis was used to detect polySia in C6-STX cells under normoxic (upper curve) 
and hypoxic conditions (lower curve, after 48 hours of hypoxia) Y-axis represents % 
abundance while x-axis represents time (A). The graph represents the mean ± SD (n = 3) of the 
relative integrated signal (B). 
  
4.3.3. Effect of polySia-expression on cancer cell migration under 
hypoxic conditions 
 
Many reports have revealed that hypoxia promotes cancer cell migration 
227,232,233. Since polySia expression is linked to high migratory potential in 
cancer cells under normoxic conditions 234, we decided to evaluate 
whether the reduction in polySia observed under hypoxic conditions 
translated into a modulation of tumour cell migration. 
 
As previously, the scratch assay was used to study these effects. In addition 
to the C6-STX and C6-WT cells, the study was expanded to also include SH-
SY5Y and DLD-1 cells. Once again, migration under hypoxic and normoxic 
conditions was compared.  
The results demonstrated that for the two polySia-expressing cell lines (C6-
STX and SH-SY5Y), no difference in cell migration was observed between 
the hypoxic and normoxic conditions. This is despite our finding that the level 
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of polySia expression is reduced in C6-STX cells under hypoxia (Figure 
4.70). Interestingly, the control cells (C6-WT and DLD-1), which do not 
express polySia, showed a significant and marked reduction in cell migration 
under hypoxia (Figure 4.70).  
(A) 
 C6-STX C6-WT SH-SY5Y DLD-1 
T0 
    
T 
(16/2
4/41) 
    
 
(B) 
 
Figure 4.70 Effect of hypoxia on the relative migration of polySia positive/negative cell lines. A) 
SH-SY5Y, C6-STX cells expressing polySia and negative cell lines C6-WT and DLD-1 were 
scratch wounded with a micropipette tip and filmed after 16, 24 and 41 hours using time-lapse 
video-microscopy under hypoxic conditions. Images at t = 0, 16, 24 and 41 hours after 
scratching illustrate wound closure. B) The graph represents wound closure calculated by 
measuring the reduction of the wound area over time using Image J software: the percentage of 
the wound closure under hypoxic conditions is presented relative to that observed under 
normoxic conditions for each cell line. Results represent the mean of three independent 
experiments.  
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We next decided to evaluate the effect of a polyST inhibitor (ICT-3176 at 250 
µM) on cell migration under hypoxic conditions. Cell migration was compared 
with non-treated cells. It was found that treatment of the cells with ICT-3176 
resulted in significant inhibition in C6-STX cell migration (22.4 ± 2.5%) 
(Figure 4.71). This compares to the migration assay of ICT-3176 carried out 
previously in-house, which showed that ICT-3176 resulted in 30% inhibition 
of C6-STX cell migration at a concentration of 500 µM under normoxic 
conditions. Here it was found that at concentration of 250 µM ICT-3176 
results in 22.4 ± 2.5% inhibition in C6-STX cell migration under hypoxic 
conditions. The effect of ICT-3176 is suspected to be greater under hypoxic 
conditions since less polySia is expressed, as shown earlier (Section 4.3.3). 
This might be explained by the suggestion that polySia might be affecting cell 
migration by interacting with different signalling pathways which are over-
expressed under hypoxia such as c-MET signalling pathway. Taken together, 
these results demonstrate that polySia potentially plays an important role in 
hypoxia-induced cancer cell migration. 
 
Figure 4.71 Effect of ICT-3176 on the migration of C6-STX cells under hypoxia. A) C6-STX cells 
were treated with polyST inhibitor ICT-3176 under hypoxic conditions and were scratch 
wounded with a micropipette tip and filmed after 16 hours using time-lapse video-microscopy 
under hypoxic conditions. Images at T0 and T16 after scratching illustrate wound closure. B) 
The graph represents the quantification of the polyST inhibition effect on the wound closure 
calculated by measuring the reduction of the wound area over time using Image J software; the 
percentage of the wound closure after treatment with ICT-3176 is presented relative to that 
observed with the control untreated cells. Results represent the mean of three independent 
experiments.  
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4.3.4. Effect of hypoxia on polySia-driven cancer cell-matrix 
adhesion 
 
As discussed earlier it was previously reported that polySia inhibits cancer 
cell adhesion through modulation of NCAM-NCAM interactions and NCAM 
interaction with other molecules in addition to exerting a repulsion force 
created by the negative charge on the polySia chains (Chapter 1, section 
1.4.2). Besides, evidence has been presented suggesting that polySia and 
hypoxia modulate the c-MET signalling pathway (Section 4.1.2), which have 
a significant role on cancer cell adhesion 235. In order to investigate the effect 
of hypoxia on polySia-mediated adhesiveness of cancer cells, C6-STX and 
C6-WT were incubated under either normoxic or hypoxic conditions. After 48 
hours, cells were harvested and the adhesion assay was performed as 
described in the materials and methods section.  
After 48 hours of incubation under hypoxic conditions, C6-STX cells were 
less able to adhere to Matrigel©. Adhesion capacity was reduced to 83.7 ± 
2.9% of control C6-WT cells adhesiveness (P value= 0.01). This is consistent 
with previously published studies which suggest that polysialylation of NCAM 
have an inhibitory effect on cell-adhesion 175. There was no difference in the 
reduction of cell adhesiveness between normoxic and hypoxic conditions, 
however (Figure 4.72). These results suggest that unlike migration, hypoxia 
does not affect polySia-mediated cell-matrix adhesion. The difference in cell 
adhesion of C6-STX compared with C6-WT cells was expected to be lower 
under hypoxic conditions compared with normoxic conditions since less 
polySia is expressed in C6-STX cells under hypoxic conditions compared to 
normoxia. One possibility might be that polySia modulates cell adhesion by 
interacting with different signalling pathways under hypoxic conditions, such 
as c-MET which is over expressed in hypoxic conditions 183,236. This warrants 
further exploration. 
Future studies should include other extracellular matrix substrates. It has 
been previously shown that high levels of polySia have different effects on 
cell adhesion to different ECM components, such as fibrinocitin, laminin, 
heparin and Matrigel 98.  
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Figure 4.72 Effect of hypoxia on the polySia-mediated adhesiveness of cancer cells, showing a 
reduction in cell adhesion to Matrigel
© 
in C6-STX compared to C6-WT cells under both 
normoxic and hypoxic conditions. Results represent the mean of three independent 
experiments.  
4.3.5. Effect of polySia expression on cancer cell survival under 
hypoxic conditions 
 
In order to determine the effect of polySia expression on the survival of 
cancer cells under hypoxia, C6-STX and C6-WT cells were subjected to 
hypoxic conditions for 96 hours while control flasks of the cells were 
incubated for the same duration under normoxic conditions. After 96 hours, 
cells were examined under the microscope and then were collected and cell 
count was determined manually using a haemocytometer. Viable and dead 
cell count were also calculated using trypan blue staining (Figure 4.73).  
Interestingly, it was found that polySia-expressing cells were associated with 
higher cancer cell survival under hypoxic conditions compared to polySia 
negative cell lines (Figure 4.73C). C6-WT cells exhibited 56.4 ± 6.2% less 
survival than C6-STX cells (C6-WT survival was calculated as a percentage 
of C6-STX survival). These results were further confirmed with trypan blue 
exclusion assay. C6-WT cells exposed to hypoxia for 96 hours were 
associated with a significant 85.8 ± 5% reduction in viability compared to 
polySia-expressing C6-STX cells (C6-STX cell death was calculated as a 
percentage of C6-WT cell death) (Figure 4.73A, B). 
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(C) 
 
Figure 4.73 Effect of hypoxia on the survival of polySia expressing cells (C6-STX) compared to 
non-expressing cells (C6-WT). A) Subjecting both C6-STX and C6-WT cells to hypoxia for 96 
hours, results in reduction in C6-WT cells survival. Results were confirmed with trypan blue 
exclusion assay where the induction of cell death caused by hypoxia was 85.8% less in C6-STX 
compared to C6-WT (B). In graph A the percentage cell count of C6-WT cells is calculated as a 
percentage of the C6-STX cell count, in graph B, the percentage cell death of C6-STX cells is 
normalised against the C6-WT cell count. Graph C) shows the morphological change in C6-STX 
and C6-WT cells after incubation under hypoxic or normoxic conditions for 96 hours. Results 
represent mean of three independent experiments.  
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In order to provide further supporting evidence for the results, hypoxia-
induced apoptosis was analysed in C6-STX and C6-WT cells using annexin 
V and propidium iodide (PI) staining. Propidium iodide is widely used in 
conjunction with Annexin V to determine if cells are viable, apoptotic, or 
necrotic through differences in plasma membrane integrity and permeability 
237.  
In this assay, cells were subjected to hypoxia or normoxia and after 96 hours 
cells were harvested, labelled with annexin V and propidium iodide mixture 
and analysed using flow cytometry. Cells undergoing apoptosis are Annexin 
V positive and propidium iodide negative. Propidium iodide staining identifies 
dead cells while lack of annexin V staining and propidium iodide uptake is 
observed in live cells (Figure 4.67). The results were compared with control 
cells incubated under normoxic conditions. 
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Figure 4.74 Effect of polySia expression on the survival of cancer cells under hypoxic 
conditions determined by PI/Annexin V apoptosis assay. A) Flow cytometry analysis of C6-STX 
and C6-WT cells apoptosis under hypoxic and normoxic conditions; (1) represents C6-WT cells 
under normoxic conditions, (2) represents C6-WT under hypoxia, (3) represents C6-STX under 
normoxia and (4) represents C6-STX under hypoxia. B) Diagrammatic representations of the 
result of flow cytometry analysis. C) Percentage of annexin V staining of different cell lines 
under each condition. Results represent mean of three independent experiments.  
The ability of PI to enter a cell is dependent upon the permeability of the 
membrane; PI does not stain live or early apoptotic cells due to the presence 
of an intact plasma membrane. In late apoptotic and necrotic cells, the 
integrity of the plasma and nuclear membranes decreases, allowing PI to 
pass through the membranes, intercalate into nucleic acids, and display red 
fluorescence. 
Annexins are a family of calcium-dependent phospholipid-binding proteins, 
which bind to phosphatidylserine (PS) to identify apoptotic cells. In healthy 
cells, PS is predominantly located along the cytosolic side of the plasma 
membrane. Upon initiation of apoptosis, PS loses its asymmetric distribution 
in the phospholipid bilayer and translocate to the extracellular membrane, 
which is detectable with fluorescently labelled Annexin V. In early stages of 
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apoptosis, the plasma membrane excludes viability dyes such as propidium 
iodide (PI), therefore cells which display only Annexin V staining are in early 
stages of apoptosis. During late-stage apoptosis, loss of cell membrane 
integrity allows Annexin V binding to cytosolic PS, as well as cell uptake of PI 
238.  
As shown in figure 4.74, the apoptotic fraction of C6-WT cells was 
significantly higher than C6-STX cells (73.5% less apoptosis in C6-STX cells) 
under hypoxic conditions, while no significant difference in the C6-WT and 
C6-STX cell survival under normoxic conditions was detected. These results 
suggest that polySia expression might have a role in enhancing cancer cell 
survival under hypoxic conditions. As discussed earlier both polySia 
expression and hypoxia have been shown to modulate FGFR expression, 
which has an important role in maintaining cell viability under conditions of 
stress (section 4.1.2). 
These results support the suggestion by Ajit Varki et al., which indicated that 
since cancer is a “microevolutionary” process in which only the fittest cells in 
a genetically heterogeneous population survive, under hypoxic conditions 
many of the glycan biosynthetic pathways change in order to improve the 
survival of cancer cells 239.  
Under the poorly oxygenated conditions found in locally advanced tumours, 
hypoxia-resistant cancer cells survive by the principle of natural selection, 
acquiring hypoxia tolerability through a transcription factor HIF, the nuclear 
translocation of which is facilitated by inactivation of tumour suppressors 
such as VHL and p53. Recently, HIF was shown to induce transcription of 
several genes for glycan synthesis, leading to the significant alteration of 
glycan profiles in order to promote cell survival under hypoxic conditions 239. 
4.3.6. Effect of polySia expression on the proliferation of cells 
under hypoxic conditions  
 
In order to investigate the effect of polySia expression on the proliferation of 
cells under hypoxic conditions, growth curves of both C6-STX and C6-WT 
211 
 
cell lines were generated as described in the materials and methods section. 
It was found that hypoxia significantly reduced cell proliferation regardless of 
polySia expression status (Figure 4.75A). The results were confirmed by 
performing the MTT assay on C6-STX and C6-WT cell lines under hypoxic 
and normoxic conditions (Figure 4.75B).  
The reduction in cancer cells proliferation under hypoxic conditions comes in 
agreement with previous published studies. It was previously reported that 
cells exposed to hypoxia are generally arrested at the G1/S-phase boundary; 
O2 partial pressures of 0.2–1 mmHg disproportionately lengthen the G1 
phase or arrest cells in the G1 phase, resulting in the reduction of cancer 
cells rate of proliferation 213,240. 
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(B)  
 
 
 
 
 
 
 
 
 
 
Figure 4.75 Effect of polySia expression on cell proliferation under both hypoxic and normoxic 
conditions measured by performing growth curve (A) and MTT assay (B). Results represent the 
mean of three independent experiments.  
4.3.7. Initial investigation into the role of hypoxia-inducible factor-
1 (HIF-1) in the altered behaviour of polySia-expressing tumour 
cells under hypoxic conditions 
 
A critical mediator of the hypoxic response is the transcription factor hypoxia-
inducible factor 1 (HIF-1) that up regulates expression of proteins that 
promote angiogenesis, anaerobic metabolism, metastasis and many other 
survival pathways 241. HIF-1 is a transcription factor for dozens of target 
genes, HIF-1α serves as a testimony to the central role of HIF-1; HIF-1 
activity in tumours depends on the availability of the HIF-1α subunit, the 
levels of which increase under hypoxic conditions and through the activation 
of oncogenes and/or inactivation of tumour suppressor genes 225,242. In order 
to investigate whether HIF-1α expression modulates the altered polySia-
mediated cancer cell behaviour under hypoxic conditions, cobalt chloride 
(CoCl2), a known chemical inducer of HIF-1α, which stabilize HIF-1α by 
blocking HIF-1α posttranslational modification by prolyl hydroxylase was 
used 243,244. 
In the next few experiments, the effect of HIF-1α induction, using cobalt 
chloride, on the key polySia-induced behavioural changes of cancer cells 
under hypoxia were examined.  
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4.3.7.1. Determination of cytotoxicity of cobalt chloride on C6 cells 
(determination of IC50) 
 
In order to determine the suitable concentrations for studying the effect of 
HIF-1α induction on both migration and survival of C6 cell lines using cobalt 
chloride, an MTT viability assay was performed. In this experiment, the 
viability of C6-STX and C6-WT cells was examined after incubation with 
different concentrations of CoCl2 and the IC50 value was calculated. 257.48 ± 
9.6 µM and 289.13 ± 11.95 µM were the IC50 values of CoCl2 using C6-STX 
and C6-WT cells respectively. No significant difference in the IC50 values of 
both cell lines was detected (Figure 4.76). 
 
 
 
 
 
 
 
 
 
Figure 4.76 Determination of the cytotoxicity (IC50 value) of cobalt chloride using C6-STX and 
C6-WT cell lines after 24 hours of exposure. Results represent mean of three independent 
experiments.  
For the migration assay, concentration of CoCl2 that caused less than 20% 
loss in the viability of both cell lines were used (100 and 130 µM, as 
determined from figure 4.77). Non-toxic concentrations were chosen to 
ensure that the reduction in the migration is not caused by loss of cell 
viability. On the other hand, a concentration of CoCl2 that induces reduction 
in cell viability, more than 20%, (200 µM) was used in order to examine cell 
survival under stress conditions. 
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In order to confirm the induction of HIF-1α expression using the selected 
CoCl2 concentrations, a western blot analysis of HIF-1α expression, of both 
C6-STX and C6-WT cells after treatment with CoCl2 have been performed 
using monoclonal rat HIF‑1α antibody (R&D systems, UK). It was found that 
using this antibody no bands were detectable in any of the samples. This 
could be explained by the low sensitivity of the antibody, in addition to the 
fact that HIF-1α detection is difficult due to its low abundance and short life 
time (t½: approx. 5 min) 
245-247. 
Lactate dehydrogenase A (LDHA) is an enzyme that catalyses the 
conversion of pyruvate and NADH to lactate and NAD+ and is one of several 
target genes that is induced by HIF-1α 248,249. Here we have detected the 
level of LDHA expression as an indicator for the possible expression of HIF-
1α in cells treated with CoCl2. The expression of LDHA in both C6-WT and 
C6-STX CoCl2-treated cells was significantly higher than control untreated 
cells, which is an indicator of the induction of HIF-1α expression (Figure 
4.77). 
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Figure 4.77 Expression of LDHA after treatment of C6-STX and C6-WT cells with different 
concentrations of CoCl2. (A) Lane 1 represent control untreated cells, lane 2 represents 100 µM 
CoCl2 and lane 3 represents 200 µM CoCl2. (B) Quantification of LDHA expression after CoCl2 
treatment. Results were normalized against actin expression and represent two independent 
experiments. 
4.3.7.2. Effect of HIF-1α induction on polySia-triggered cancer cell 
migration 
 
In order to investigate whether HIF-1α expression modulates the altered 
polySia-mediated migration of cancer cells under hypoxic conditions, the 
migration of C6-STX and C6-WT cells was examined after treatment with 
100 and 130 µM cobalt chloride respectively. Two concentrations were used 
since it was observed that using 130 µM of cobalt chloride, while not causing 
significant loss of viability of C6 cells as examined by MTT assay, resulted in 
a change in the morphology of the cells. So, in order to ensure that the effect 
on cell migration was not caused by any effect on the phenotype of the cells, 
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a lower concentration (100 µM) was also used that did not cause any change 
in the cell morphology. 
Cells were seeded in 0.5 x 106 cell/well density in six-well plates. After 24 
hours, the attached cell monolayer was scratch wounded with a micropipette 
tip and fresh medium containing different concentrations of CoCl2 was 
added. Plates were incubated for 16 hours at 37°C, filmed after 16 hours 
using Lumascope microscopy (Table 4.28) and the percentage wound 
healing was calculated and the results were compared with control untreated 
cells.  
It was found that treatment of the cells with CoCl2 caused significant 
inhibition in the migration of both C6-STX and C6-WT cell lines compared to 
the untreated cells. However, the relative percentage of migration inhibition 
in cobalt chloride treated C6-WT cells was significantly higher compared to 
C6-STX cells; CoCl2 treatment resulted in significantly higher migration 
inhibition in C6-WT cells compared to C6-STX cells (difference in the 
percentage of inhibition is 21.1 ± 9.5% with 100 µM CoCl2, P value= 0.03 and 
34.57 ± 15.3% with 130 µM CoCl2, P value= 0.02) (Figure 4.78). Combining 
these results with the results of the migration assay of different cell lines 
under hypoxic conditions that showed that cell lines which do not express 
polySia showed a significant and marked reduction in cell migration under 
hypoxia (Figure 4.70), these results suggest that the polySia-enhanced 
migration of cancer cells under hypoxic condition might be modulated by 
HIF-1α induction. 
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Figure 4.78 Quantification of the effect of CoCl2 on the migration of C6-WT and C6-STX 
calculated by measuring the reduction of the wound area over time using Image J software. The 
percentage of C6-WT wound closure after cobalt chloride treatment is calculated as a 
percentage of the C6-STX wound closure. Results represent the mean of three independent 
experiments.  
 
 
 
 
 
 
 
 
 
 
 
0
20
40
60
80
100
120
C6-STX C6-WT
%
 m
ig
ra
ti
o
n
 r
e
la
ti
v
e
 t
o
 C
6
-S
T
X
 c
e
ll 
lin
e
 
Effect of Cocl2 (100µM) treatment on the 
migration of C6-STX, C6-WT cell lines  
* 
0
20
40
60
80
100
120
C6- STX C6- WT
%
 M
ig
ra
ti
o
n
 r
e
la
ti
v
e
 t
o
 C
6
-S
T
X
 c
e
ll 
lin
e
s
 
Effect of CoCl2 (130 µM)  treatment on the 
migration of C6-STX, C6-WT cell lines  
* 
218 
 
Table 4.28 Effect of CoCl2 on the migration of C6-WT and C6-STX. Wound size at t = 0 and 16 
hours after scratching C6-STX and C6-WT cells with/without 100 µM cobalt chloride treatment. 
Results represent three independent experiments.  
 
 T0 T16 
C6-STX, 
Control 
 
  
C6-STX, 
CoCl2, 100 
µM 
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4.3.7.3. Effect of HIF-1α induction by CoCl2 on polySia-expressing 
cancer cell survival 
 
The effect of HIF-1α induction on the apparently enhanced cell survival 
observed in polySia-expressing cells was investigated. In this experiment, 
the percentage cell survival of C6-STX and C6-WT cells was calculated after 
incubation with 200 µM CoCl2. It was found that there was no significant 
reduction in the cell survival recorded with C6-WT cells compared to the C6-
STX cells (P value = 0.26). Results were confirmed using trypan blue 
exclusion assay (Figure 4.79).  
This suggested that the enhancement of cell survival associated with polySia 
expression under hypoxic conditions is not linked to HIF-1α up regulation. 
 
 
 
 
 
 
 
 
Figure 4.79 Effect of HIF-1α induction on the survival of C6-STX and C6-WT cells. Results 
represent mean of three independent experiments  
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4.4. Conclusion 
 
In this chapter, two aspects of the mechanism by which polySia exerts its 
effects have been explored: the possible additive anti-migratory effect of 
using selected signalling pathway inhibitors that have been previously 
suggested to be modulated by polySia expression in combination with a 
polyST inhibitor and the effect of polySia expression on cancer cell behaviour 
under hypoxic conditions.  
In order to study the possible additive anti-migratory effects of using polyST 
inhibition in combination with the selected SPIs, the anti-migratory effect of 
ICT-3176 in combination with the aforementioned SPIs was assessed. It was 
found that significant reduction in the migration of the SH-SY5Y cells is 
induced using a combination of ICT-3176 and crizotinib (c-Met/ALK inhibitor) 
compared to the inhibition in the migration caused by ICT-3176 or crizotinib 
treatment alone. This suggests that there is possibly a cross-talk between 
polySia-NCAM and c-MET/ALK signalling pathway that is modulating cancer 
cell migration. 
Crizotinib is an FDA-approved drug used to treat adults with non-small cell 
lung cancer, a disease that in a subset of patients is caused by 
translocations of the ALK gene 250. ALK is also a frequent target of genetic 
alteration in advanced neuroblastoma 251. However, certain ALK mutations 
result in de novo crizotinib resistance, and a phase I trial of crizotinib showed 
a lack of response in patients harbouring those ALK mutations 252. Different 
combinations have been examined in order to enhance the patient’s 
response such as crizotinib combination with topotecan and 
cyclophosphamide 252. Here we have shown that combining crizotinib with 
polyST inhibitor results in enhancing its anti-migratory effect which starts a 
new potential area of study in order to investigate whether combining polyST 
inhibitor with crizotinib would result in synergistic effects on proliferation, 
signalling, and cell death of neuroblastoma cells as well, and whether this 
would translate into a positive effect on the patient response to the treatment. 
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The second part of this chapter investigated the effect of polySia expression 
on cancer cell behaviour under hypoxic conditions. Changes in the 
composition of the extracellular matrix reflect on its biological properties, 
these changes result in significant alterations in tumour and stromal cell 
properties such as migration, proliferation and survival. Recent studies have 
established a direct link between hypoxia and the composition and 
organisation of the extracellular matrix. In a study performed by Glikes et al., 
it was shown that hypoxia promotes extracellular matrix remodelling to 
facilitate metastasis 222. 
Here it was found that expression of polySia reduces cell adhesion and 
enhances both migration and survival under hypoxic conditions. It is 
suggested that the polySia-enhanced migration of cancer cells under hypoxic 
condition might be modulated by HIF-1α induction; it was found that 
induction of HIF-1α, using cobalt chloride, results in significantly higher 
migration inhibition C6-WT compared to C6-STX cells. On the other hand, 
the pro-survival effect of polySia under hypoxic conditions was suggested to 
be independent of HIF-1α expression. 
To sum up, here we have initially investigated certain aspects of the 
mechanism of polySia activity. It is suggested that polySia-enhanced cell 
migration might be modulated by c-MET/ALK activity. Besides, polySia 
expression is suggested to play a role in reducing cancer cell adhesion and 
enhancing migration and survival under hypoxic conditions. Further studies 
are needed in order to further confirm the results obtained in this study, 
which will be discussed in chapter 5.  
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Chapter 5. General discussion and future perspective 
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5.1. General discussion 
 
Cancer is among the leading causes of mortality worldwide. In 2012, there 
were 14 million new cases and 8.2 million cancer-related mortality worldwide 
26. Despite the tremendous work done in this field, today cancer still accounts 
for about one in every seven deaths worldwide 26. Metastasis is the most 
deadly aspect of cancer and results from several interconnected processes 
including cell proliferation, angiogenesis, cell adhesion, migration, and 
invasion into the surrounding tissue. Metastasis is still the principal cause of 
death in cancer patients despite decades of research aimed at restricting 
tumour growth 26,253. 
Although some types of metastatic cancer can be cured with current 
treatments, most cannot 254. Metastatic cancer may be treated with systemic 
therapy (chemotherapy, biological therapy, targeted therapy, hormonal 
therapy), local therapy (surgery, radiation therapy), or a combination of these 
treatments. The choice of treatment generally depends on the type of 
primary cancer; the size, location, and number of metastatic tumours; the 
patient’s age and general health; and the types of treatment the patient has 
had in the past 255. 
Researchers are studying new ways to stop the growth and migration of 
primary cancer cells and metastatic cancer cells, including new ways to 
boost the strength of immune responses against tumours. In addition, 
researchers are trying to find ways to disrupt individual steps in the 
metastatic process 254. The primary goal of these studies was to provide an 
understanding of the nature of cancer cells so they can be more effectively 
treated and eradicated with the main aim of understanding the basic controls 
of both normal and cancer cells which allows cancer cells to create an 
identity. This was achieved by studying the mechanism of action of cancer 
cell growth, proliferation, metastasis and interaction with local environment 
and other cells 26. 
Although over 90 percent of cancer mortality today are due to metastasis, 
there is no effective anti-metastatic drug on the market 256,257. Currently most 
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FDA licensed or internationally available anti-metastatic drugs have been 
categorized as anti-vascular (angiogenesis) and matrix metalloproteinase 
(MMPs) inhibitors with more than 500 related-agents of different chemical 
formulae having been reported. However, due to indiscriminate molecular 
inhibitiors and generally low survival benefits for patients, these drugs are far 
from satisfactory in the clinic 258. 
The concept of the work described in this thesis is the development of a 
novel anti-metastatic drug that depends on inhibiting the migration of cancer 
cells by inhibiting the synthesis of polySia, a carbohydrate which is re-
expressed during progression of a number of malignant human tumours and 
correlates with increased metastatic potential, tumour progression and poor 
prognosis 37. 
Carbohydrates play a key role in cellular interactions. Until recent years, little 
attention has been given to these molecules, primarily because they are so 
diverse and so much more difficult to study than, for example, proteins that 
are directly encoded by genes. It is only fairly recently that carbohydrates 
have been given more attention because of overwhelming evidence that they 
are extensively involved in human health and disease and because of 
advances that have been made in their synthesis, analysis and manipulation 
259,260. 
Various carbohydrate-based drugs and diagnostics are currently in use. 
Zanamivir and Oseltamivir are a monosaccharide-based drug that is used for 
treating influenza 261. Heparin, consisting of a mixture of polysaccharides, 
has been used for decades as an anti-clotting agent 262. Acarbose is a 
glycosidase inhibitor that is used to treat type-2-diabetes by regulating 
carbohydrate digestion, intestinal absorption and carbohydrate metabolism 
259,263.  
For decades, it has been established by many glycobiologists that the 
structures of glycans, which decorate all eukaryotic cell surfaces, changes 
with the progression of cancer, a phenomenon which was first described by 
Meezan et al. in 1969 37. Consequently, glycosylation pattern of a cell can be 
225 
 
considered as a code for cellular physiology. A number of studies have been 
performed in order to understand this code at both molecular and functional 
levels. Although glycobiologists are still at the early stages of interpreting this 
code, their studies have already inspired novel methods to detect glycans 
characteristic of disease conditions, to prevent disease glycan formation and 
to destroy cells that display them. However, as mentioned earlier, progress in 
understanding glycobiology of cancer has been slow relative to studies that 
target understanding the role of different proteins and nucleic acids in cancer 
progression. 
Many factors contribute to this slow progress, for example, the biosynthesis 
of glycans, unlike other biopolymers, is not template-driven 264. Additionally, 
the link between different carbohydrates expression and malignant function 
is not fully understood. A range of hypothesis have been suggested ranging 
from protection of tumour cells from immune surveillance by their glycan coat 
to promotion of tumour-cell metastasis by glycan-mediated adhesion to 
distant sites 264,265.  
PolySia, as discussed earlier in the introduction, has a significant role in 
promoting cancer cell migration. It contributes to the metastasis of various 
types of cancer and therefore, it is a promising drug target in a large 
population of cancer patients 100. In this study two general aims were 
addressed; first, the development and validation of ST8SiaII small molecule 
inhibitor and second initially investigating the mechanisms by which polySia 
exerts its effects. 
In order to develop and validate a small molecule ST8SiaII inhibitor, a cell-
free high throughput chromatographic assay was developed. Using this 
assay allowed the analysis of an inhibitor every six minutes, giving results 
that are quantitative, reliable and specific. This is the first high throughput 
quantitative assay for the analysis of human ST8SiaII enzyme activity that 
provides sufficient resolution to characterise individual product lengths; i.e. 
can be used to study the way the enzyme affects polySia chain length to be 
reported. The development of this assay paves the way for the development 
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of an effective ST8SiaII inhibitor. Using the results obtained from this assay 
will allow building a structure activity relationship library for the ST8SiaII 
enzyme that can be used for the development of more potent inhibitors.    
The next step for the development of ST8SiaII inhibitor was to design a cell-
based assay that allows the examination of the effect of inhibitors on polySia 
synthesis in the complex conditions of the tumour environment. The assay 
was further optimized to allow the analysis of polySia expression in different 
cell lines for further examination of these compounds on different types of 
cancer. The expression of polySia in head and neck cancer has been 
examined here for the first time. This suggests a new field of research about 
the effect of ST8SiaII inhibition on the progression of the disease. 
Although many cell-based assays for the analysis of ST8SiaII activity have 
been previously reported, the developed cell-based chromatographic assay 
reported in this study is the first assay that allows understanding of the 
mechanism of action of the inhibitors by providing molecular weight 
information about the monomers released from the polySia synthesized in 
the presence of these inhibitors. Using this assay to analyse the effect of 
treating neuroblastoma cells with mannosamine compounds has solved the 
long debate in the literature about the mechanism of action of these 
compounds. Here we have proven that ManNprop is incorporated in the 
polySia chains giving modified polySia. 
The final step for validation of the design inhibitors was achieved by 
examining the effect of inhibitors on the migration of cancer cells that 
express polySia. This not only allowed the investigation of the effect of 
ST8SiaII inhibition on migration of cancer cells, but also gave some data 
about the selectivity of the designed inhibitors, helping to further ‘’sieve’’ 
them to choose the most potent, selective inhibitors. 
As discussed earlier in the introduction, so far polySia has been efficiently 
modulated only by genetic manipulations or by enzymatic digestion. Here, 
novel, selective and potent ST8SiaII inhibitors that significantly reduce 
polySia expression and inhibit the migration of the polySia-expressing 
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neuroblastoma cells have been reported for the first time. Although the 
inhibitors examined in this thesis are not yet potent enough to start in vivo 
studies, more potent inhibitors are being developed and analysed using the 
developed assay. Compound SAR is also being established using the novel 
cell-free assay as will be discussed in the future perspective section. 
The second part of this study involved initial investigation of different aspects 
of polySia activity. This has been achieved by two parallel studies; studying 
the additive anti-migratory effect of combining a polyST inhibitor with 
compounds involved in different cancer pathways and studying the impact of 
polySia expression on the behaviour of cancer cells under hypoxic 
conditions. From these studies I was able to demonstrate the possible 
beneficial effects of combining crizotinib (an FDA-approved c-MET/ALK 
inhibitor drug used for treatment of patients with NSCLC) and ST8SiaII 
inhibitor (ICT-3176) for inhibiting the migration of neuroblastoma cells.  
The other study involved investigating the role of polySia expression on 
cancer cell behaviour under hypoxic conditions. It was found that polySia 
expression resulted in more aggressive behaviour of cancer cells presented 
as increased survival and migration potential and inhibition of adhesion to 
extracellular matrix. 
5.2. Future perspective  
 
A number of open investigations must be solved to allow the development of 
a potent, selective and druggable ST8SiaII inhibitor. These investigations 
suggest a variety of research directions that need to be pursued to make 
such an inhibitor feasible. 
Here the future experiments that could be done in the short, medium and 
long term are described. 
5.2.1. Short-term objectives 
 
The developed cell-free chromatographic assay is an efficient tool for 
building a structure activity relationship library for ST8SiaII inhibitors. 
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However, more small molecule inhibitors have to be analysed to allow this. 
Such experiments will allow understanding the chemical groups that are 
responsible for the inhibitor molecule binding with the ST8SiaII enzyme and 
blocking its activity. This allows modification of the selectivity and the 
potency of the inhibitor by changing its chemical structure. 
In this study the effect of promising inhibitors was examined by a 2D 
migration assay. Although it have its advantages, as described earlier in 
chapter 3, studying the effect of the inhibitor using 3D migration assay and/or 
tumour spheroid-based migration assay would give more understanding of 
the effect of the inhibitor in a situation that more closely matches the 
structure and biochemical environment of native tissue to predict in vivo 
activity. 
Another aspect that should be studied is examining the expression of 
ST8SiaII enzyme within the layers of neuroblastoma multicellular tumour 
spheroids to validate the results obtained earlier with the 2D cell-based 
chromatographic assay. In this thesis, the effect of hypoxia on the expression 
of polySia was examined in a 2D system at which all the cells were exposed 
to the same level of oxygen, however in vivo different layers of tumour are 
subjected to different oxygen levels. In order to understand the effect of this 
oxygen level gradient on polySia expression a 3D model which utilises 
neuroblastoma spheroids could be used. This will give more detailed 
understanding of the effect of hypoxia on polySia expression.  
This should be followed by studying the effect of inhibiting ST8SiaII, using 
lead inhibitor and knock down, on the invasion of neuroblastoma multicellular 
tumour spheroids. Multicellular tumour spheroids (MCTS) mimic the 
organisation of a tumour and are considered as an invaluable model to study 
cancer cell biology and to evaluate new drugs 266. It was shown earlier in this 
study that ST8SiaII inhibition results in reduction of tumour migration under 
both hypoxic and normoxic conditions. Using a spheroid model would help to 
profile the cellular response to ST8SiaII inhibition under the heterogenic 
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hypoxic/normoxic conditions within the tumour, which closely mimic the in 
vivo situation. 
Detailed assessment of enzyme binding kinetics and druggability of the hit 
inhibitors have to be investigated. Characterizing the relationship between 
the pharmacokinetics (PK, concentration vs. time) and pharmacodynamics 
(PD, effect vs. time) is an important tool in the discovery and development of 
new drugs 267. It is recommended that PK/PD strategies be implemented in 
early research phases of drug discovery projects to enable successful 
transition to drug development 267. Druggability is a concept that refers to the 
properties of the active pharmaceutical ingredient relative to the required 
properties of the agent to be developed. This includes the physicochemical 
properties of the agent such as the ability to compress it into a tablet or 
formulate it for oral administration. As well as its pharmacokinetic properties 
that reveals dosing requirement and possible drug interaction potential and 
the possibility of food effect 268.  
In the case of an anti-metastatic drug that is aimed for neuroblastoma 
patients, the ideal pharmaceutical formulation would be an oral liquid 
formulation to be suitable for the administration to infants and children on a 
long-term basis.  
5.2.2. Medium-term objectives 
 
Designing a model for in vivo analysis of anti-metastatic drug would be the 
next milestone for the design of ST8SiaII inhibitor. This model should be 
used to study the lead inhibitor selected by using the SAR library and 3D 
invasion and migration models. Using the in vivo model would allow studying 
the possible side effects of the drug and also the possible beneficial effect of 
combination therapy. Examining the effect of the selected inhibitor on 
subcutaneous xenograft in mice would be the first step. This would allow 
studying the pharmacokinetics of the drug such as its tissue distribution and 
cellular uptake. This should be followed by the design of metastatic model 
such as using orthotopic injection transplantation, which more closely 
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resembles human cancers including tumour histology, vascularity, gene 
expression, responsiveness to chemotherapy and metastatic biology 269.  
Orthotopic metastatic models for studying neuroblastoma have been 
previously reported. An example of an orthotopic is reported by Khanna C. et 
al., in this model tumours were established following adrenal injection of 
different neuroblastoma cell lines in SCID mice where it was found to be 
more biologically relevant, including angiogenic phenotype, and enhanced 
spontaneous distant metastasis compared to subcutaneous (heterotopic) 
injection 270,271. 
 5.2.3. Long-term objectives 
 
Finally, the long-term objectives would be to start a phase I clinical trial, by 
first selection of the suitable patients whom might benefit from the treatment 
(PolySia positive) such as neuroblastoma patients, this can be achieved by 
examining the tumour biopsy for  biomarkers such as ST8SiaII gene 
expression, and initiate the trial for dosing, safety and early efficacy 
information,  considering that clinical trials of anti-metastatic drug molecules 
that prevent cancer dissemination are likely to be required for use right after 
diagnosis, not after failure of standard-of-care therapies.  
A parallel phase I/II clinical trial design for combination therapies could be 
beneficial for studying of the effect of combining ST8SiaII inhibition with 
different neuroblastoma treatment protocols 272 such as anti-GD2 
immunotherapy (Unituxin), which has recently been approved by the FDA 
and EMA specifically for neuroblastoma (in combination with GM-CSF, 
Interleukin-2).  
5.3. Conclusion 
 
In conclusion, the work presented in this thesis has described the 
development of two novel assays for the analysis of ST8SiaII inhibition in 
both cell-free and cell-based settings. In addition, a set of ST8SiaII inhibitors 
designed and synthesised in house were evaluated for their ability to reduce 
polySia expression and to modulate cell migration in vitro. Potent ST8SiaII 
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inhibitors have been reported for the first time. The possible additive anti-
migratory effect of combining polyST inhibition with the inhibition of certain 
signalling pathways has been investigated. Finally, the effect of polySia 
expression on cancer cell behaviour under hypoxic conditions was 
examined, where it was found that polySia expression enhanced cell 
migration and survival and inhibits cell adhesion. 
To sum up, greater attention should be paid towards the development of an 
effective anti-metastatic drug. A successful drug targeting metastasis could 
therefore make a big impact on patient survival. 
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